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ABBREVIATIONS AND DEFINITIONS
The abbreviations recommended by the Biochemical Journal in its 
instructions to Authors [Biochem J (1981) 193, 4-27] have been used 
throughout the thesis with the following additions:
BHK cells Baby hamster kidney fibroblasts
c.p.m. counts per minute
DATD Diallytartardiamide
EBV Epstein-Barr virus
FPLC Fast protein liquid chromatography
Hepes [4-(2-hydroxyethyl)-1-piperazine-ethane-sulphonic acid]
HSV-1 (G or F) Herpes simplex virus type-1 Strain 17 Glasgow or Strain F
HSV-2 Herpes simplex virus type-2
HSV-1 PK Herpes simplex type-1 protein kinase
HPLC High performance liquid chromatography
HCMV Human cytomegalovirus
kbp kilobase pair
Mr apparent relative molecular mass
m.u. map units
PBS Phosphate-buffered saline
p.f.u. plaque-forming unit
PRV Pseudorabies virus
PRV PK Pseudorabies protein kinase
rpm revolutions per min
SDS Sodium dodecyl sulphate
TEMED NNN'N'-tetramethylethylene-diamine
TK Thymidine kinase
US3 The third open reading frame of the unique short (Ug)
region of the HSV-1 genome 
VZV Varicella zoster virus
Vero cells African green monkey kidney cells
ViPK Virus-induced protein kinase
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DEFINITION OF UNITS
IA260 unit is the quantity of material contained in 1ml of solution which 
has an absorbance of 1 at 260 nm, when measured in a cell with 1 cm light 
path.
1 unit of protein kinase activity is defined as the amount of enzyme that 
catalyses the incorporation of 1 nmol phosphate per min into protein 
substrate under standard assay conditions.
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SUMMARY
The subject of this thesis is a protein kinase that had previously been 
detected in cellular cytoplasmic extracts of cells infected with the 
a-herpesvirus, pseudorabies (PRV). The object of the work undertaken 
here was to purify the enzyme to allow its proper characterisation, and to 
determine its genetic origin.
The enzyme induced by infection of hamster fibroblasts with PRV was 
purified to apparent homogeneity by a combination of DEAE-cellulose, high- 
performance hydrophobic, threonine-sepharose, protamine-agarose and high- 
performance gel-exclusion chromatography. This purification resulted in an 
enzyme with a specific activity in excess of 1,000 nmol units/mg, a figure 
comparable with other homogeneous protein kinases. Polyacrylamide gel 
electrophoresis of the purified enzyme under denaturing conditions revealed 
a single stained band at a position of migration corresponding to an 
apparent molecular weight of 38,000. Polyacrylamide gel electrophoresis of 
the purified enzyme after incubation with [y^P]ATP in the absence of 
added substrate resulted in incorporation of ^ P  into this protein band, 
consistent with the 38,000 molecular weight protein being a protein kinase 
with a capacity for autophosphorylation. The isoelectric point of the 
phosphorylated form of the enzyme was approximately 4.9. The molecular 
weight of the native enzyme was determined by gel-exclusion chromatography 
and found to be approximately 70,000. It is therefore likely that the 
protein kinase is homodimeric.
When hamster fibroblasts or Vero cells were infected with Herpes simplex 
type-1 (HSV-1) a new protein kinase activity was also detected. The 
protein kinases from cells infected with HSV-1 and PRV had similar
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catalytic properties. Both catalysed the transfer of phosphate from ATP 
(but not GTP) to basic (but not acidic) proteins, protamine being the 
preferred substrate in vitro, and they appear to be independent of known 
regulatory molecules. These protein kinases were also active at 1M KC1, a 
particularly striking characteristic.
The protein kinase activity from cells infected with HSV-1 was partially 
purified using the methods used for the enzyme from cells infected with 
PRV. The final purified preparation contained two major species of 
apparent molecular weights 68,000 and 61,000 when analysed by 
polyacrylamide gel electrophoresis under denaturing conditions. In 
addition, when incubated with [y^P]ATP, the purified enzyme 
preparation phosphorylated a protein species of molecular weight 68,000 and 
isoelectric point 5.6. It is probable that this represents 
autophosphorylation of the HSV-1 protein kinase, which may be one of the 
two major species observed in the purified preparation. The molecular 
weight of the native enzyme was investigated by gel-exclusion chromatography 
and was found to be in the range of 150,000 - 200,000. This suggested 
that the enzyme may be a homodimer like the PRV protein kinase.
Synthetic peptides were used to investigate the substrate-specificity of 
the protein kinases. The enzyme from cells infected with PRV had similar 
substrate preferences to the enzyme from cells infected with HSV-1, but 
these were distinct from those of other known protein kinases. Both could 
catalyse the phosphorylation of both seryl and threonyl residues in 
peptides containing several arginyl residues on the amino terminal side of 
the target residue. At least two basic N-terminal residues were required 
and the best substrates contained four to six such residues. Other amino 
acids on both the N-terminal and C-terminal sides of the phosphate acceptor 
could exert a modulating influence on substrates for the viral kinases. 
There were indications that hydrophobic amino acids immediately adjacent to
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the target residue on its N-terminal side caused a decrease in 
phosphorylation of the target residue by the viral kinases. The amino 
acid, proline, exerted a marked effect when adjacent to the target residue, 
depending on whether it was N or C-terminal. If it was positioned on the 
N-terminal side, phosphorylation was enhanced, but if present on the 
C-terminal side, phosphorylation of the synthetic peptide substrate was 
decreased. Acidic residues positioned on the C-terminal side of the target 
residue appeared capable of negative modulation of the phosphorylation of 
peptides by the viral kinases. The basic residues, lysine or ornithine, 
were much inferior to arginine as positive determinants for substrates of 
the viral protein kinases.
The amino acid sequences of proteins predicted to be viral phosphoproteins 
in HSV and VZV were examined for conserved phosphorylation sites suitable 
for the viral protein kinases. The only one that was identified was an 
immediate-early protein which from other considerations is unlikely to be 
the physiological substrate for this enzyme. It is therefore possible that 
the physiological substrate for the viral protein kinase is cellular.
Initial indirect experiments were consistent with the protein kinases being 
encoded by the viral genome. The enzyme activities obtained from cells 
infected with each virus differed in their chromatographic properties on 
anion-exchange and gel-permeation resins. The kinetics of induction of 
these enzymes were similar to the viral early protein, DNA polymerase. The 
amount of enzyme detected depended on the multiplicity of infection, and no 
enzyme was detected in cells infected with virus which had been irradiated 
with ultra-violet light. When cells were infected with HSV-1 strain tsK, 
which has a temperature-sensitive mutation in the gene for the immediate- 
early protein required for transition to early protein synthesis, enzyme 
was induced at the permissive but not the restrictive temperature.
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Direct evidence that the protein kinase detected in cells infected with 
HSV-1 was encoded by the viral genome was obtained from exploring the 
relationship of this protein kinase to the protein predicted to be encoded 
by gene US3, as the latter contained motifs found in known protein kinases. 
Hamster fibroblasts and Vero cell lines were infected with a mutant of 
HSV-1 with a genetically engineered deletion in the US3 open reading frame. 
The protein kinase was not present in cells infected with the deletion 
mutant but was detected when cells were infected with a recombinant in 
which the US3 open reading frame had been rescued.
Confirmation that the protein kinase was the product of the US3 gene was 
obtained using an antiserum to a synthetic oligopeptide corresponding to 
the carboxy-terminal eight amino acids of the predicted US3 protein.
This antiserum reacted weakly with a polypeptide of 68,000 molecular weight 
in extracts of cells infected with HSV-1, and with increasing intensity 
with fractions of increasing specific activity from the enzyme • 
purification. The immunoreactive species in the purified preparation 
corresponded in electrophoretic mobility to the phosphorylated protein 
species of 68,000 molecular weight obtained by incubation with 
[Y32P]ATP in the absence of exogenous substrate.
This demonstration that the a-herpesviruses encode a protein kinase 
provides the first example of an authentic protein kinase encoded by a 
eukaryotic virus (the protein kinases of certain acute transforming 
retroviruses being properly regarded as the products of transduced cellular 
genes). Although the experiments with the deletion mutant indicate that 
the protein kinase is not essential for growth of the virus in tissue 
culture cells, the conservation of this function between human and pig 
a-herpesviruses implies that it confers a selective advantage for the 
virus, even though the nature of this is unknown at present.
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INTRODUCTION
I PROTEIN KINASES AND PROTEIN PHOSPHORYLATION
Protein phosphorylation is of central importance in the response of 
cells to various internal and external signals. Many cellular 
enzymes involved in the control of metabolic pathways can exist in 
either a phosphorylated or a dephosphorylated form, and their 
activity is regulated by this reversible phosphorylation. An example 
of this is the control of phosphorylase kinase activity by cyclic AMP 
- dependent protein kinase (Cohen, 1985; Krebs, 1985). Proteins other 
than enzymes are also regulated by phosphorylation. Examples include 
the phosphorylation of histone H1 in the nucleus, which is thought to 
control chromosome condensation (Matthews, 1980), and muscle myosin 
light chain, the degree of phosphorylation of which has been 
implicated in the control of muscle contraction (England, 1980).
More recently it has been shown that the lamins, proteins of the 
nuclear envelope, are also phosphorylated, and it is thought that 
this may control the breakdown of the nuclear envelope during mitosis 
(Fisher, 1987).
The phosphorylation and dephosphorylation reactions are catalysed by 
two different types of enzymes, and it is the differential modulation 
of the activity of these enzymes that determines the extent of 
phosphorylation and hence regulates the function of a particular 
protein. The enzymes which catalyse the phosphorylation event are 
the protein kinases, and those responsible for dephosphorylation are 
the phosphoprotein phosphatases.
There are many more protein kinases than phosphatases known, and this 
seems to reflect a greater substrate-specificity in the former class 
of enzyme. Each protein kinase can catalyse the phosphorylation of
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either a single protein or a restricted range of different proteins, 
although sometimes one protein serves as a substrate for more than 
one kinase. In contrast most phosphoprotein phosphatases have a much 
wider substrate range, although some more specific ones have been 
reported (Ingebritsen and Cohen, 1983).
From these considerations it would be expected that the control of 
the phosphorylation reactions is primarily through the control of 
protein kinases, and this indeed appears to be the case. Protein 
kinases catalyse the transfer of phosphoryl groups from ATP, or ATP 
and GTP, to seryl, threonyl or, in some instances, tyrosyl residues 
positioned in characteristic recognition sequences within the protein 
substrate. The protein kinases may be classified in relation to this 
acceptor amino acid residue as serine/threonine protein kinases or 
tyrosine protein kinases. A variety of effectors can regulate the 
activity of different protein kinases. These effectors can be 
hormones or growth factors (in the case of membrane receptor 
kinases), second messengers (cyclic AMP, cyclic GMP, diacylglycerol) 
or small intracellular molecules (e.g. Ca haemin, double-stranded 
RNA, acetyl CoA). Many protein kinases have the ability to transfer 
phosphoryl groups from ATP to their own hydroxyl residues in an 
intramolecular reaction; and this phenomenon, which may be a 
fundamental general feature of these enzymes, is termed 
autophosphorylation.
The various different aspects of protein kinases, which are discussed 
in more detail below, can be used to classify these enzymes; and one 
such classification is shown in Table 11.
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1.1 Regulation
The effectors that regulate protein kinase activity may arise from 
extracellular signals, either directly via first messengers or 
indirectly via second messengers; or they may be intracellular, 
either small non-enzymic molecules or other protein kinases. Many 
protein kinases do not appear to be regulated by any effector 
molecules, although for other protein kinases there may well be 
effectors, as yet unknown, governing their activity.
Protein kinases regulated by first messengers are the hormone or 
growth factor receptor kinases. Examples of these are the receptors 
for insulin (Ullrich et_al., 1985), epidermal growth factor (Cohen 
et_al., 1982; Hunter et al;., 1984; Staros et_al., 1985), platelet- 
derived growth factor (Cooper et al., 1982, Yarden et al., 1986) and 
insulin-like growth factor (Ullrich et al., 1986). The binding of 
the ligand appears to activate the intrinsic tyrosine protein kinase 
activity of the receptor, which is manifest experimentally as 
autophosphorylation of the receptor. It is at present uncertain 
whether the chain of intracellular events elicited by the hormone is 
a consequence of a conformational change in the receptor resulting 
from this autophosphorylation, or whether it results from the 
phosphorylation of an extrinsic substrate, the identity of which is 
still unknown.
Other protein kinases are regulated by a relatively small number of 
chemical mediators or second messengers, which can alter the 
phosphorylation states of many intracellular proteins in concert. 
Cyclic AMP regulates the activity of the cyclic AMP-dependent protein 
kinases. These enzymes exist in isoenzymic forms designated as 
type I and type II (Reimann et al., 1971) consisting of two catalytic
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subunits and two regulatory subunits which bind the effector. In the 
absence of cyclic AMP the regulatory (R) and catalytic (C) subunits 
have a high affinity for each other, but on binding the nucleotide 
this affinity is decreased by a factor of 10^ . The holoenzyme (R2C2) 
is inactive because a part of the regulatory subunit directly impedes 
the active site of the catalytic subunit. It has been proposed that 
cyclic AMP binds to the R subunit of R2C2 forming an intermediate 
ternary complex: cyclic AMP. R2C2* A conformation change then occurs 
in the R subunits, and they dissociate from the C subunits. [R2 
(cyclic AMP)i| + 2C] (Hoppe, 1985). Cyclic GMP can also regulate 
protein kinase activity. The cyclic GMP-dependent protein kinase • 
consists of two identical subunits, and upon binding of cyclic GMP 
activation of the enzyme occurs without physical dissociation of the 
subunits:
inactive E2 + 2 cyclic GMP E2 - cyclic GMP2 active
Intracellular regulation of protein kinases can be achieved by small 
non-enzymic effectors. Ca^+ ions activate many protein kinases, 
either alone or in association with calmodulin, a Ca^+ - binding 
protein. Indeed one of the subunits of phosphorylase kinase (Jesse - 
chan et_al., 1982), is itself calmodulin (Cohen et al., 1978). This 
enzyme can be activated by the binding of Ca^+ to its calmodulin 
subunit (§), and the subsequent initiation of a change in the 
conformation of the enzyme. Two types of myosin light-chain kinase 
(Stull et al., 1985) and a less specific Ca^+/calmodulin-dependent 
protein kinase, designated as the multifunctional protein kinase by 
many investigators (McGuiness et al., 1983; 1985; Woodgett et al.,
1984), are all activated by Ca^+ ions. Another Ca^+ ion-dependent
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serine protein kinase, but one that does not utilise calmodulin, is 
protein kinase C, discovered by Nishizuka and co-workers (Ioune 
et al., 1977; Takai et al., 1977; Nishizuka, 1983). The principal 
effector controlling the activity of protein kinase C in vivo is 
thought to be diacylglycerol (Nishizuka, 1984). Phorbol esters have 
been shown to mimic diacylglycerol in this respect (Castagna et al., 
1982).
There are other protein kinases regulated by small molecules, 
including double-stranded RNA, haemin, and metabolites involved in 
the pyruvate dehydrogenase reaction. These latter protein kinases 
are examples of the enzymes with the narrowest substrate specificity.
Protein kinases themselves may act as catalytic effectors for other 
protein kinases, as exemplified by phosphorylase kinase. This latter 
enzyme is not only regulated by Ca^+ ions but also by phosphorylation 
- dephosphorylation, the effector kinase responsible for this being 
the cyclic AMP-dependent protein kinase. Not only phosphorylation by 
other protein kinases, but also autophosphorylation has been 
implicated in the regulation of activity of certain protein kinases. 
An example of this is protein kinase C, where autophosphorylation 
increases the activity of the enzyme by decreasing (at least with the 
artificial substrate, histone H1) the Km for its substrate in vitro 
(Mochly-Rosen and Koshland, 1987). The potential biological 
importance of autophosphorylation has also been investigated by 
site-specific mutagenesis of potential autophosphorylation sites in 
the protein kinase product of the cell-cycle control gene, cdc 2, of
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the fission yeast, Schizosaccharomyces pombe (Booher and Beach,
1986). It was reported that mutations within a region which may be 
the site of phosphorylation resulted in a loss of cdc 2 protein 
kinase activity. In the case of pp60 v~s— , the tyrosyl protein 
kinase product of the v-src gene of Rous sarcoma virus (Collett and 
Erikson, 1978), the N-terminal region of this protein may regulate 
its catalytic activity since autophosphorylation of pp60 v~sr- in 
this locale is correlated with elevated protein kinase activity 
(Collett et al., 1984; Brown and Gordon, 1984). In addition, 
proteolytic removal of the entire N-terminal half of pp60 
resulted in increased activity (Levinson et al., 1981; Brugge and 
Darrow, 1984). It is becoming apparent that almost all cellular 
tyrosine protein kinases are subject to tight negative regulation by 
their non-catalytic domains, and these enzymes can be converted into 
transforming proteins by the removal of such negative regulatory 
elements. Similarly, a point mutation that changes Tyr 527 to Phe in 
the c-src gene-product can have this consequence (Hunter, 1987).
Finally there is a fairly large group of protein kinases for which no 
regulatory agents are known. These are termed independent protein 
kinases, examples of these being listed in Table 11. Included are the 
so-called casein kinases (casein is certainly not their physiological 
substrate), which are abundant and ubiquitous enzymes that do not 
appear to have any regulatory effectors; and the protein kinases 
encoded by several oncogenes, the effectors for which (for it is 
reasonable to assume there must be such) are as yet unknown.
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1.2 Site-specificity
Of the factors responsible for the specificity of protein kinases, 
the primary structure around the phosphorylation site of the 
substrate plays an important role (Nimmo and Cohen, 1977; Pinna 
et_al., 1979; Gould, 1985; Glass et al., 1986; Pinna et al., 1986; 
Michnoff et al., 1986; Ferrari et al., 1987). Table 12 illustrates 
this in summarising the results of experiments using synthetic 
peptides modelled on phosphorylation sites of proteins phosphorylated 
in vivo or in vitro by the particular protein kinase. Using these 
peptides it is possible to define the minimum primary structural 
requirements of the protein kinase for the particular substrate.
The substrate-specificity of cyclic AMP-dependent protein kinase has 
been particularly well defined: the enzyme requires -two basic
residues on the N-terminal side of the target residue and a 
hydrophobic residue immediately adjacent to the target residue is 
also required (eg RRAS). Serine residues are also preferred to 
threonine as targets by these enzymes, although phosphorylation of 
the latter does occur. Protein kinase C will phosphorylate peptides 
with blocks of basic residues on the C-terminal and N-terminal sides 
of the target. Other types of protein kinases, for example casein 
kinases I and II, do not have this preference for basic residues but 
phosphorylate substrates with large blocks of acidic residues 
clustered on the N-terminal side of the target, in the case of casein 
kinase I, or on the C-terminal side for casein kinase II (Marin 
et al., 1986; Pinna et al., 1986). Although the use of these 
synthetic peptides has provided information regarding primary
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structure determinants of protein kinases, it should be pointed out 
that the substrate specificity of protein kinases is also determined 
by secondary, tertiary and quaternary structures of the protein. 
Examples of this are phosphorylase kinase and glycogen synthase 
kinase-3, the substrate specificities of which must rather be 
considered in terms of particular three-dimensional domains (Pinna 
et al., 1986).
Although some protein kinases (for example cyclic AMP-dependent 
protein kinase and casein kinase II) have quite broad specificities, 
it can be seen that they nevertheless are relatively easy to 
distinguish using artificial protein substrates of different amino 
acid compositions, or more precisely, using synthetic model peptides 
(Engstrom et al., 1984).
Table 12 does not include the most highly specific protein kinases 
such as those that phosphorylate eIF-2. Although the site 
phosphorylated in vivo is known in this (Kudlicki et al., 1987) and 
other similar cases, little work has been done to define which 
features of the environment of the target are the major determinants 
of specificity, and indeed, whether it is primary or higher-order 
structure that is involved.
1.3 Structure
Protein kinases have a wide variety of structures, as can be seen 
from Table 13: some are monomeric, eg. kinase C and casein kinase I,
whereas others are multimeric. The simplest of these latter are 
homodimeric, for example the cyclic GMP-dependent protein kinases, 
whereas phosphorylase kinase, which has four different types of 
subunit all of different apparent molecular weights, is an example of
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a more complex quaternary structure. Although protein kinases have a 
wide range of molecular weights and subunit structures, it is 
possible to identify within the primary structures of most protein 
kinases a regulatory domain or subunit, which is responsible for 
binding the effector, and a second domain (kinase domain) or subunit 
responsible for the catalysis (Fig 12).
(i) Conserved domains in protein kinases
The amino acid sequences of all eukaryotic protein kinases so 
far examined share a number of highly conserved motifs that are 
unique to, and diagnostic of, the catalytic domain of this 
class of enzyme (Barker and Dayhoff, 1982; Takio et al.,
1984a). Examples of these motifs are shown in Fig 11.A. Within 
this overall homology certain subsidiary features even allow 
one to distinguish those protein kinases that phosphorylate 
tyrosyl residues from those that phosphorylate seryl and 
threonyl residues (Hunter and Cooper, 1985). This is clear on 
examination of the C-terminal domain (Fig 11B): certain amino
acids are conserved in both nature and position in these 
kinases and the serine/threonine protein kinases do not share 
this homology.
In the context of the explosion in the availability of 
nucleotide sequence information and, with it, of predicted 
amino acid sequences, the recognition of the conserved motifs 
of the catalytic domain has provided an alternative route to 
the identification of additional members of the protein kinase 
family. This predictive approach has been exploited
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successfully in the study of the oncogenic retroviruses (Sefton 
and Hunter, 1984; Hunter and Cooper, 1986), circumventing the 
often laborious protein purification procedures usually 
required in identification of protein kinases. In yeast 
several genes identified by mutant phenotypes in growth or 
progression through the cell cycle have recently been predicted 
to encode protein kinases on the basis of such sequence 
comparisons. (Lorincz and Reed, 1984; Patterson et al.,
1986; Simon et al., 1986; Teague et_al., 1986; Celenza and 
Carlson, 1986). In the case of CDC 28 (Reed et al., 1985) and 
SNF 1 (Celenza and Carlson, 1986) this prediction has been 
confirmed by subsequent characterisation of the gene-product.
(ii) Divergent domains in protein kinases
As well as conserved areas in their structure, protein kinases 
also display divergent structural domains. In some protein 
kinases it has been clearly demonstrated that the binding site 
for the effector is on a separate subunit to that containing 
the catalytic function. This is illustrated by cyclic. 
AMP-dependent protein kinase, with its regulatory subunit, and 
phosphorylase kinase, with its Ca^+ - binding calmodulin 
subunit. The structure of the domain or subunit involved in 
binding the effector is highly specific and depends on the 
nature of the particular effector molecule. For instance 
protein kinases regulated by cyclic nucleotides, cyclic 
AMP-dependent protein kinases and cyclic GMP-dependent protein 
kinases, have characteristic nucleotide binding sites (Fig 12)
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which have also been shown to share homology with the otherwise 
unrelated cyclic AMP binding protein (CAP) of E.Coli (Titani 
et al., 1984; Takio et al., 1984(a) and (b); Weber et al., 
1982).
In other cases the evidence that the divergent domain binds the 
effector is more indirect. Thus, partial proteolysis of 
protein kinase C generates a fragment lacking the N-terminal 
divergent domain but still maintaining catalytic activity.
This latter, however, is now constitutive, being independent of 
the effectors, Ca^+ and phospholipid (Parker et al., 1986). 
Perhaps surprisingly, examination of the primary structure of 
the C-terminal domain of protein kinase C revealed no 
similarity to that of the other well characterised Ca^+ - 
binding protein, calmodulin. However a possible similarity to 
the Ca^+ and phospholipid-dependent protein, phospholipase A2, 
has been pointed out (Maragonore, 1987).
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TABLE 1.2
THE SUBSTRATE-SPECIFICITY OF PROTEIN KINASES DEFINED BY SYNTHETIC PEPTIDES 
(Data from Pinna et al., 1986)
Protein kinases
Examples of 
suitable peptide 
substrates
Suggested minimum 
primary structure 
requirement
Cyclic AMP-dependent PK RRASVA R(K)RXS(T)XX
Cyclic GMP-dependent PK RKRSRKE R___S(T)R
Myosin light chain kinase KKRPERATSNVFA R(X)2-3RXXS(T)XXX
Multifunctional 
calmodulin-dependent 
protein kinase
PLSRTLSVSS RXXS
Phosphorylase kinase KRKQISVRGL SXR
LSYRGYSL (higher structure 
required)
H4 Protein kinase 
(protease activated) VKRISGL KRXS___
Physiological casein kinase 
(Mammary gland)
STXEDSP
Multifunctional/casein 
kinase I EQLSPTSPEENSKKTVDM Acidic Cluster-SXX
Multifunctional/casein 
kinase II
SEEEEE
P
S(T)X(o_2)~(EDS )n
SAAEEEEEE
RREEETEEE n = 3
(continued) 
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TABLE 1.2 (CONTINUED)
Protein kinases
Examples of 
suitable peptide 
substrates
Suggested minimum 
primary Structure 
requirement
Pyruvate dehydrogenase 
kinase YHGHSMSDPGVSYR ___SXXD___
Glycogen synthase 
kinase-3
Inactive on short 
peptides
Integrity of large 
domain
Tyrosine protein kinases KLIEDNEYTAR
DRVYIHPF
EXnY
Protein kinase C GKGRGLSLSRFSWGA
GSRRRRRRY (R)n.•.S or T..,(R)n
RRLSSLRA 9
- denotes residues that are phosphorylated. 
P denotes phosphoamino acid.
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TABLE 1.3. STRUCTURAL CHARACTERISTICS OF PROTEIN KINASES
Protein kinase
Monomer
molecular
weights
Subunit
structure
Autophosphorylated
subunits
Cyclic AMP- 
dependent 
protein kinases 
Type I and Type II
45.000 R
40.000 C
r2c2
C only Type I 
CR Type II
Cyclic GMP-dependent 
protein kinase
74-81,000 E E2 E
Phosphorylase
kinase
a 118-145,000 
8 108-128,000 
Y 40,000 
6 17,000
(calmodulin)
a484Y454
a and 8
Myosin light- 
chain kinase 
(skeletal muscle)
70,000 monomer +
Multi-functional 
protein kinase
isoform I 50,000 
II 58-60,000
monomer +
Protein kinase C 77-87,000 monomer +
eIF-2 kinase 80-95,000 monomer +
Casein kinase I 32-42,000 monomer +
Casein kinase II 42-44,000a 
38-40,000a' 
24-26,000$
aa’ 82 8
pp60v“src/pp50c-src 60,000 monomer +
EGF Receptor 
(A341 cells)
170,000 monomer +
Insulin Receptor 
(adipocyte)
a 130,000 
8 95,000 
(glycoproteins)
<*282 01282
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Fig. 11 A.
Highly conserved motifs in the catalytic 
domain of eukaryotic protein kinases
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II THE GENETIC REPERTOIRE OF HERPESVIRUSES
The particular aspect of protein phosphorylation and protein kinases
dealt with in this thesis relates to cells infected with certain
a-herpesviruses. This section deals with some of the general
characteristics of these viruses. Herpesviruses may be defined as
viruses of eukaryotes, having single, large, linear, double-stranded
DNA genomes, which are replicated and packaged into icosahedral
nucleocapsids within the nuclei of infected cells. These then are
enclosed in protein teguments and glycoprotein and lipid envelopes to
give their infectious extracellular forms (Roizman, 1982). The
participation of essential virus-coded gene products in the
replication of virus DNA, the formation of concatameric replicative
intermediates and their maturation into progeny genomes by
site-specific recombination cleavage reactions should also be
considered as characteristic features in the definition of
DNAs
herpesviruses. The sizes of the herpesvirus, jvary from Varicella 
zoster virus (VZV), of 125 kbp; Pseudorabies virus (PRV), of 150 kbp, 
Herpes simplex viruses type 1 and type 2 (HSV-1/2), of 155-158 kbp; 
Epstein Barr virus (EBV), of 179 kbp, to Cytomegalovirus (CMV), of 
240 kbp.
Despite the similarity in the morphology of the capsid and envelope 
of different herpesviruses, the typical presence of nuclear inclusion 
bodies in infected cells, and the propensity of the viruses to 
establish latent and recurrent infections, the genomes of these 
viruses have undergone sequence and structural divergence among the 
different mammalian subgroups. The herpesvirus family is divided 
into three main subgroups: a, represented by HSV, PRV and VZV;
8, CMV; and y» EBV an<^  herpes saimiri viruses. This
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classification is based primarily on the size of the genome, other 
structure considerations, and (more recently) DNA homology. However 
it is equally valid from a biological standpoint; for example these 
groups show differences in host range, growth rate and cytopathology 
of infections. The best characterised herpesviruses belong to the 
a subgroup.
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1 g-HERPESVIRUSES
The a-herpesviruses are exemplified by the intensively studied 
herpes simplex viruses associated with common oral (HSV-1) and 
genital (HSV-2) infections of man, and by the causative agent of 
human chicken pox and shingles (VZV). Considerable work has also 
been performed on pseudorabies virus (PRV), an a-herpesvirus of 
swine, also known as Suid herpesvirus 1, and the causative agent of 
Aujeszky’s disease.
(i) Genome organisation
The genomes of HSV-1 and HSV-2 consist of two components, long 
(L) and short (S), comprising 72% and 18% of the total genome, 
respectively. Both L and S can invert relative to one another 
such that viral DNA extracted from infected cells or virions 
consists of 4 isomers: an arbitrarily designated prototype
(P), inversion of the S component (Is), inversion of the L 
component (II), and inversion of both components (Is l )
(Hayward, 1975; Roizman, 1979). Each component consists of 
unique sequences (Ul or Us) flanked by inverted repeats 
(Fig 13). The inverted repeats of the L component were 
designated as ab and b’a', whereas those of the S component 
were designated a'c' and ca (Wadsworth et al., 1975). In 
addition to the inverted repeats, HSV DNA contains a direct 
terminal redundant sequence of approximately 400 bp. This 
portion is also present within the internal inverted repeats 
and is referred to as the sequence 'a* (Davison and Wilkie, 
1981). The 'a' sequence has been shown to contain a cis-acting 
site for the inversion of L and S components relative to one 
another (Mocarski et al., 1980; Mocarski and Roizman, 1981.
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Chou and Roizman, 1985), this site being involved in the 
cleavage of concatemeric DNA and packaging of unit-length 
genomes into capsids (Vlazny et al., 1982). The 'b' sequence 
of the inverted repeats of the L component also contains 
cis-acting sites for the inversion of HSV DNA sequences 
(Longnecker and Roizman, 1986). The structure of the genome of 
PRV and VZV is very similar to that of HSV-1 and HSV-2 except 
that L is not bounded by inverted repeats and does not invert, 
consequently virion DNA populations contain only two types of 
molecule (Stevely, 1977; Henry et al., 1981; Straus et al., 
1982).
The HSV-1 genome contains approximately 80 genes (Honess and 
Roizman, 1973; McGeoch et al., 1985). These genes form 
several groups: a (immediate-early), 81 and 82
(early) and y^  and Y2 (late).
The expression of these is coordinately regulated and 
sequentially ordered in a cascade fashion (Honess and Roizman 
1974; 1975). The 5 a genes (see Table 14 for nomenclature) 
are the first genes to be expressed after infection and are 
transcribed by the host RNA polymerase II in the absence of 
viral protein synthesis de novo. A functional a4 gene 
product is required for the transition from a to 8 gene 
expression (Knipe et al., 1979; Dixon and Schaffer, 1980; 
Preston, 1981). Genes a27 and a22 play a role in late 
gene expression (Sacks et al., 1985; Sears et al., 1985) but 
the functions of a0 and a47 are unknown. Whereas HSV-1 
has five a genes (Fig 14), PRV has only one, which is in a 
corresponding genomic location (in the R$ region) and shares
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sequence homology with a4 of HSV-1 (Ben-Porat et al., 1983; 
Davison and Wilkie, 1983). The PRV immediate-early protein (IE 
63, Mr 180,000), like a4 of HSV-1, is known to be required 
to initiate the early and late phases of viral gene expression 
(Ihara et al., 1983), but unlike a4 it does not appear to 
be required for multiple reinitiation events from early genes 
(Ahlers and Feldman, 1987).
(ii) Comparison of the organisation of the genes in the unique long 
region of a-herpesviruses
In recent years DNA sequence analysis has allowed precise 
comparisons between some corresponding regions in the genes of 
HSV-1, HSV-2, VZV and PRV. The genome of PRV is for the most 
part colinear with the 1^ arrangement of the genome of HSV-1; 
however an inversion or translocation of sequences mapping on 
the PRV genome between 0.07 and 0.39 map units was observed and 
a comparison of the map positions of 5 genes with known 
functions confirmed these findings. The genes coding for the 
major immediate-early protein, the major capsid protein and the 
thymidine kinase occupy similar positions on the genome of PRV 
and on the genome of HSV-1 in the II arrangement. However the 
genes for DNA polymerase and for the major DNA binding protein 
appear to be inverted relative to one another on the genomes of 
the two viruses (Ben-Porat et al♦, 1983).
The complete sequence of VZV has been published and the genes 
are numbered from 1-71 (left to right) starting from the 
extreme end of the L region (Davison and Scott, 1986). In the 
genome of VZV the DNA polymerase (gene 28) and. the major DNA 
binding protein (gene 29) are in the same order as in the PRV
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genome. However the major capsid protein has been displaced 
from the position it occupies in PRV and HSV-1 relative to 
these two genes, so that it is VZV gene 40. The two regions of 
difference between the VZV and HSV-1 genomes are present at the 
ends of the L-segment, which have been sequenced in HSV-1.
HSV-1 appears not to contain homologues to VZV gene 1, gene 2 
and gene 61. Also the inverted repeats flanking Ul are much 
larger in HSV-1, at approximately 9000 bp, than they are in VZV 
(88.5 bp), and the single gene thus far identified from the 
HSV-1 sequence of this region specifies a spliced 
immediate-early mRNA encoding a0. At the present stage of 
analysis no homologue for this gene has been detected in VZV. 
Thus the differences in gene arrangement between VZV and HSV-1 
in the S segment and at the ends of the L segment r'esult in VZV 
apparently lacking homologues to two of five HSV-1 immediate- 
early genes; those encoding a47 and a0. There is only 
one other region for which sufficient HSV-1 data are available 
to indicate a difference in gene layout between VZV and HSV-1. 
It is almost certain that HSV-1 lacks a homologue to VZV gene 
13, which encodes a protein with thymidilate synthetase 
activity (Thompson et al., 1987).
(iii) Comparison of the organisation of the genes in the unique short 
region of a-herpesviruses
At present the largest published HSV-1 sequence is the short 
region of 26,000 bp (McGeoch et al., 1985; 1986 a), comprising
the short unique sequence together with the two flanking short 
repeat sequences. The Ug region of HSV-1 is almost 13,000 bp 
and contains 12 open reading frames. The genes are transcribed
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as 13 mRNAs, one gene being transcribed from two different 
initiation sites (McGeoch et al., 1985). None of these mRNA's 
are spliced, the splicing of mRNAs already mentioned for 
aO, being a distinct rarity in a-herpesviruses. A 
region of the Us portion of HSV-2 has been partially sequenced 
(Rixon and McGeoch, 1985; McGeoch et al., 1987). This region 
contains six genes (termed US2 to US7 and a part of another, 
US8). The HSV-1 and HSV-2 sequences were found to be colinear 
and related in predicted amino acid sequence, except for the 
US4 genes.
In PRV a section of the Us region has also been sequenced which 
contains genes from positions corresponding to US4 to US8 of 
HSV-1 and HSV-2, except that there is no homologue of gene US5. 
The gene in the position corresponding to US4 has a predicted 
protein product homologous to that of the corresponding gene in 
HSV-2 and not to that of HSV-1 (see Fig 15).
In the case of VZV there are greater differences from the S 
segment of HSV, which in HSV-1 contains 13 unique genes and in 
VZV only seven. Each VZV gene has a homologue in HSV-1 but the 
remaining 6 HSV-1 genes have no counterparts in VZV. The 
missing genes include US12 (the immediate-early gene, which 
encodes a47) and US6 (the gene which encodes glycoprotein 
D). These regions of the two genomes differ substantially in 
layout (c.f. Table I6), but they are clearly related.
(iv) The open reading frame US3 of HSV-1
Several of the open reading frames that became apparent from 
sequencing the Us region of HSV-1 did not correspond to known 
viral proteins. Examination of the predicted amino acid
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sequences allowed some general conclusions (eg membrane- 
association, likely glycoprotein nature), but more precise 
prediction of function required comparison with the sequences 
of proteins of known function. It was found (McGeoch and 
Davison, 1986) that the amino acid sequence of the 53 kDa 
predicted product of the US3 gene of HSV-1 contained most of 
the sequence motifs characteristic of protein kinases already 
mentioned in section 1.1 (Fig 11.A). Subsequently the 
corresponding region in the genome of HSV-2 was analysed and it 
was predicted to encode a protein of identical size, exhibiting 
15% amino acid sequence identity to the predicted HSV-1 US3 
gene product. The predicted product of the US3 gene of HSV-1 
was also homologous with the 44 kDa predicted product of gene 
US2 (gene 66) of VZV (Davison, 1983; Davison and McGeoch,
1986). The predicted VZV protein kinase differs completely 
from that of HSV-1 in the N-terminal region, but in the 
C-terminal catalytic domain the two predicted protein kinases 
show 45$ identity (Fig 16). The relationship of these 
predicted proteins to the conserved motifs of the known protein 
kinases is shown in Fig 17. Because the sequence of the entire 
genome of VZV is known it is possible to state with certainty 
that US2 is the only VZV gene predicted to encode a protein 
kinase. As regards HSV-1 it can only be said that no open 
reading frame yet sequenced, other than US3, has been predicted 
to encode a protein with homology to protein kinases. It 
should be stressed that at the time of their proposal as 
protein kinases, none of these predicted gene products has been 
recognised as a protein species in infected cells.
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2 COMPARISON OF GENE ORGANISATION OF a-HERPESVIRUSES WITH 8-AND
HERPESVIRUSES
The extensive accumulation of nucleotide sequences has allowed direct 
genetic comparisons, not only within the herpesvirus subfamilies, 
but also between the different subfamilies. Baer et al. (1984) 
reported the first complete sequence of a herpesvirus genome, that of 
Epstein-Barr virus (EBV), a human pathogen belonging to the 
Y-herpesvirinae. Comparison with the sequences which became 
available for genes from HSV-1 and HSV-2 gave the first clear 
evidence of genetic similarity between members of different 
subfamilies. Of the HSV genes which have been sequenced to date many 
have identifiable counterparts in EBV, and these are illustrated in 
Table 15 and 16. Thus there is compelling evidence that HSV and EBV 
arose from a common progenitor.
Computer comparisons of the amino acid sequences of proteins 
predicted from the published complete VZV and EBV DNA sequences 
allowed the identification of EBV counterparts to 29 of 67 unique VZV 
genes. Conserved genes were detected only in the Ul component of 
each genome, and were located in three major regions. Within each of 
these regions the conserved genes are generally colinear (Davison and 
Taylor, 1987), but the three regions are arranged differently with 
respect to one another in the two genomes. No conserved genes were 
detected in the Us region, in the repeated regions or in sequences 
near the ends of the Ul . This is not particularly surprising as 
these regions are also among the most distantly related in the two 
a-herpesviruses, VZV and HSV-1.
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The 20,349 bp sequence of the human cytomegalovirus (HCMV) Hind III F 
fragment of the Ul segment (approximately 60-80 kb of 235 kb total 
genome size) has revealed 8 open reading frames with homology to HSV 
and/or EBV. With respect to EBV, these homologous genes can be 
divided into two blocks: one block contains three genes, including
the DNA polymerase and glycoprotein B, and the other block contains 
five genes of unknown function. Although the relative organisation 
of genes within each block is identical in HCMV and EBV, the relative 
position of each block within the two genomes differs. In HCMV the 
two blocks are present directly adjacent to each other, whereas in 
EBV they are found 92 kb apart (Kouzarides et_al., 1987). The Ug 
region of HCMV has also been determined (Weston and Barrell, 1986), 
but it is completely unrelated to that of EBV, consistent with the 
pattern already seen in other comparisons between a-herpesviruses 
from different subgroups.
The difference between the S regions of a-, 8- and y-herpesviruses 
could mean that genes from this region in a-herpesviruses have 
counterparts in the L region of the 8- and y-herpesviruses.
However, this is not the case with HSV-1 and EBV, and in particular 
it should be stressed that there is no predicted protein kinase in 
EBV. One cannot yet be sure of the situation in 8-herpesviruses, 
but it may be that a protein kinase gene is a feature unique to 
a-herpesviruses.
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TABLE 1.4 THE NOMENCLATURE OF HSV-1 IMMEDIATE-EARLY PROTEINS
IE number a number Vmw number
IE1 aO Vmw 110
IE2 a27 Vmw 63
IE3 a4 Vmw 175
IE4 a22 Vmw 68
IE5 a47 Vmw 12
The table correlates the different nomenclatures applied to the five 
immediate-early proteins (IE 1-5) of HSV-1. The a-numbering system 
relates to the new proteins of infected cells (ICP) observed on SDS gel 
electrophoresis and numbered in order of decreasing size (Wilcox et al, 
1980). The Vmw system numbers the proteins by their apparent Mr (x10“ )^ as 
deduced from similar SDS gel electrophoresis. (Haarrand Marsden, 1981).
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3 PHOSPHORYLATION IN CELLS INFECTED WITH HERPESVIRUSES
The fact that the US3 gene of HSV-1 is homologous to known protein 
kinases makes it necessary to consider what is known regarding 
phosphorylation in cells infected with herpesviruses. In other 
viruses phosphorylation of proteins has been implicated in their 
replicative cycles: for example, in the interaction of structural
virion proteins with the RNA of murine retroviruses (Sen, 1977), and 
in the control of the activity of the RNA polymerases of vesicular 
stomatitis virus (Kingsford and Emerson, 1980), and influenza virus 
(Kamata and Watanabe, 1977). Although there are only a small number 
of examples of viral protein phosphorylations for which specific 
functions have been assigned, there are very many phosphorylated 
regulatory and structural proteins in animal viruses for which the 
phosphorylation may turn out to be functionally important (Jeng 
et al., 1977; Russell and Blair, 1977; Clinton et al., 1979;
Wilcox et al., 1980).
During the lytic infection of cells by herpesviruses the 
phosphorylation of many viral proteins occurs (Pereira et al., 1977; 
Marsden et al., 1978; Wilcox et al., 1980; Faber and Wilcox, 1986; 
Perry et al., 1986). Examples of the known HSV-1 phosphoproteins are 
shown in Table 17. Some cellular proteins are also phosphorylated 
(Fenwick and Walker 1979), one of which has been identified as being 
the ribosomal protein S6 (Kennedy et_al., 1981).
Important to the understanding of the significance of these different 
phosphorylations is the identification of the protein kinases 
responsible for catalysing them. Such protein kinases might be of 
cellular origin or be specified by the particular virus itself. As
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already mentioned in the Introduction (Section I), the cellular 
protein kinases constitute a large and diverse family of enzymes, 
differing in their substrate specificities, regulatory control and 
the amino acids that they phosphorylate. Cellular enzymes are 
thought to be responsible for several of the protein phosphorylations 
that occur in infected cells. The protein kinase activity 
responsible for the phosphorylation of the major phosphorylated 
species of the virions of PRV and HSV-1 is indistinguishable from 
host casein kinase II (Stevely et al.t 1985), and the kinase 
responsible for the increased phosphorylation of ribosomal protein S6 
during infection of BHK cells with PRV is almost certainly the 
specific cellular S6 kinase, which is also activated by growth 
stimuli (Jakubowicz and Leader, 1987 (a) and (c)).
As regards virally-coded protein kinases in general, it is 
well-established that the tyrosine protein kinase, pp60 v~sr--, is the 
product of the src gene of Rous Sarcoma Virus (Collett and Erikson, 
1978; Levinson et al., 1978). Such highly oncogenic retroviruses as 
Rous sarcoma virus represent a distinct group in the retrovirus 
family with respect to the organisation of their genomes, and their 
ability to cause acute diseases with a short latent period (Cooper 
and Hunter, 1983). These genomes are chimeric, with both termini 
being derived from a non-defective weakly-oncogenic retrovirus but 
the central part of the genome containing sequences originating from 
a transduced cellular gene or genes. This part of the genome, which 
is responsible for transformation, is termed the viral oncogene.
Many of the viral oncogenes encode tyrosine-specific protein kinases 
(Sefton, 1985), although other viral oncogenes such as v-mos and
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v-raf encode proteins that are serine/threonine protein kinases. 
However these retroviral protein kinases cannot be regarded as normal 
viral proteins. The genes which code for them originate from host 
cells, and in most cases have actually inactivated or replaced a 
retroviral gene, so that a "helper" virus is required for infection. 
Although it can be argued that viral enzymes such as thymidine kinase 
were probably also originally aquired from the host genome, the 
situation with the oncogenic retroviral protein kinases is clearly 
different. What is important here is not a single enzymic function 
but an ability to induce cellular transformation, as exemplified by 
the fact that other viral oncogene products such as those of ras and 
fos are not protein kinases at all.
Until the identification of the open reading frame US3 in the genome 
of herpesviruses there was no convincing evidence for a protein 
kinase encoded by a eukaryotic virus as an inherently viral protein. 
Attempts had previously however been made to identify protein kinases 
that might be encoded by herpesviruses, and these employed three 
main approaches, which will be considered in turn in relation to 
possible candidates for the product of the US3 gene.
One approach has been to examine the phosphorylating ability of 
immune-precipitated viral antigens, the substrate being either the 
putative kinase itself ("autophosphorylation reaction"), the 
immunoglobulin, or added exogenous protein. Although this approach 
was originally applied successfully to the v-src kinase (Collett and 
Erikson, 1978), its main drawback has been the possible contamination 
of the antigen with minute amounts of catalytically active cellular 
protein kinase(s). This is illustrated with human cytomegalovirus,
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where the 68 kDa viral tegument protein of the virus was identified 
by immunoprecipitation of extracts of infected cells with a 
monoclonal antibody (Michelson et al., 1984). The immunoprecipitates 
of this protein had an associated protein kinase activity which was 
found almost exclusively in the nuclear fraction of the infected 
cells. This protein kinase phosphorylated casein, used GTP as well 
as ATP and was inhibited by heparin, although at ten times higher 
concentrations than cytoplasmic casein kinase II for which these 
properties are otherwise diagnostic (Michelson et al., 1985). This 
requirement for a higher concentration of heparin to inhibit protein 
kinase activity is also a property of a cellularly-specified nuclear 
casein kinase II (Baydoun et al., 1986). Thus there are clear 
grounds for suspecting that the immunopreciptate is contaminated with 
nuclear casein kinase II. Further evidence supporting the suspicion 
that this enzyme activity is not intrinsic to the virally-coded 
tegument protein came from analysis of the gene specifying it. This 
gene was predicted to encode a protein with an amino acid sequence 
bearing no relationship to the protein kinase family (Davis and Huang, 
1985).
It is worth mentioning that with other viruses there have been 
similar experiences. The large transforming (T) antigen of Simian 
Virus 40 which was phosphorylated in vivo, was originally thought to 
have intrinsic seryl protein kinase activity. However the activity 
has now been separated from the antigen, indicating that the antigen 
is not itself a protein kinase (Walser and Deppert, 1986). Similarly 
immunoprecipitates of the transforming protein (middle T antigen) of 
Polyoma Virus contain a tyrosine protein kinase activity. However
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this activity can be attributed to pp60c~src (Courtneidge and Smith, 
1983) which exists in a stable complex with the middle T antigen.
As regards a-herpesviruses it has been reported that an 
immunoprecipitated antigen of VZV has protein kinase activity. This 
was a protein of Mr 50,000 designated p50 which could phosphorylate 
glycoprotein I (gl) (which is also phosphorylated in vivo) in vitro, 
but not other VZV glycoproteins, for example gll and gill (Montalvo 
and Grose, 1986). Protein p50 could not be detected in purified 
virion preparations or in uninfected cells. Using the monoclonal 
antibody, indirect immunofluorescence microscopy revealed that the 
p50 protein was located on the outer-membrane surface of infected 
cells. It was postulated that the p50 with kinase activity was 
either a virally coded non-structural protein, or a cellular product 
the synthesis of which was activated by viral infection. However the 
positioning of the protein on the outer-membrane surface would be 
most unusual for a seryl/threonyl protein kinase, all previous 
examples of which are intracellular. Thus p50 may not be a protein 
kinase but the immunoprecipitates of this protein may be contaminated 
with a small amount of a cellular protein kinase.
Another approach to identifying possible protein kinases encoded by 
herpesviruses (and other viruses) has been to examine purified 
virions. The rationale here was that certain virion proteins were 
found to be phosphorylated in vivo, and it was thought that the 
enzymes responsible might be viral and specifically localised in the 
virion. Such protein kinases were envisaged as being important for 
the phosphorylation and regulation of the functions of virion
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proteins. Indeed in HSV-1 (Lemaster and Roizman, 1980) and later in 
PRV (Stevely et al.t 1985) protein kinase activity was found in 
association with the virion and could catalyse the phosphorylation of 
virus proteins in vitro. However this, in itself, did not prove the 
protein kinase activites in question to be virally coded. The chance 
incorporation of cellular protein kinases into virions is also a 
possibility. Indeed fractionation of soluble extracts of purified 
virions showed that they contained protein kinase activities with 
properties similar to cellular casein kinase II (Stevely et al., 
1985). This phenomenon is not unique to herpesviruses, for cellular 
protein kinases have been found in the virions of vesicular 
stomatitis virus (Harmon et al.t 1983) and Rous sarcoma virus (Weis 
and Faras, 1983).
A third approach has been to screen extracts of infected cells for 
new protein kinase activity, using artificial substrates such as 
histones, protamine, casein and phosvitin. Adoption of this 
technique lead to the identification of two possible candidates for 
an a-herpesvirus protein kinase in addition to the previously 
mentioned p50 of VZV. A new phosvitin/casein kinase activity was 
reported to be present in HeLa cells infected with HSV-1 (Blue and 
Stobbs, 1981), and a new protamine kinase activity was detected in 
BHK cells infected by PRV (Katan et al., 1985).
The kinase activity reported by Blue and Stobbs was specific for 
acidic rather than basic substrates. This activity was very 
different from the protein kinase reported by Katan et al. (1985), 
which could phosphorylate basic proteins but was incapable of using 
acidic proteins such as casein and phosvitin as artificial
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substrates. The two enzymes also differed in size and time of 
appearance. The appearance of the activity described by Blue and 
Stobbs (1981) appeared to be balanced by the disappearance of a 
pre-existing cellular kinase activity, suggesting that it may be a 
derivative of a pre-existing cellular protein kinase such as a casein 
kinase.
As previously mentioned, the location of the VZV p50 protein on the 
surface of the cell membrane would seem to make this an unlikely 
candidate for the viral protein kinase.
The most likely candidate for the protein kinase encoded by 
a-herpesviruses seemed to be that designated "virus-induced 
protein kinase" (ViPK) by Katan et al. (1985), as this was shown to 
be unrelated to a range of known cellular protein kinases.
The objective of this work was to purify, characterise, determine the 
substrate-specificity and genomic origin for this protein kinase.
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TABLE 1.7. HSV-1 PHOSPHOPROTEINS
Name/Description Class Genomic Location
ICP 0 111K a IE1 0.02-0.04 (TLL) 
0.95-1
ICP 27 63K a IE2 0.74-0.75
ICP 4 175K
(transcriptional activator)
a IE3 0.82-0.86 (IRs) 
0.96-1 (TRs)
ICP 22 68K a IE4 0.86-0.87 (US1)
ICP 6 148K
(Ribonucleotide reductase)
8 0.57-0.6
ICP 8 127
(major DNA binding protein)
8 0.386-0.411
ICP 19 (18?) 82K 
(Alkaline Exonuclease)
8 0.16-0.175
ICP 150K
(DNA polymerase)
8 0.41-0.43
ICP 31/VP 16 65K Y 0.669-0.685
ICP 39.3 38K 
(VP23)
0.66-0.76
US9 10K
(Virion tegument protein)
(US9)
references: Frame et al. (1986)
Lemaster and Roizman (1980)
Marsden et al. (1978)
McGeoch et al. (1985; 1986a; 1986b) 
Pereira et al. (1977)
Preston (1979a; 1979b)
Quinn and McGeoch (1986)
Stevely et al. (1985)
Swain and Galloway (1985)
Watson et al. (1979)
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MATERIALS
1 BIOLOGICAL
1.1 Cells
BHK 21/C13 cells are an established line of Hamster Kidney 
fibroblasts (MacPherson and Stoker, 1962). These cells contained an 
intact thymidine kinase gene. Cell stocks were obtained from the MRC 
Virology Unit, Institute of Virology, University of Glasgow. They 
were thus termed BHK (TK+) (Glasgow cells).
The following cell lines were gifts from Prof. B. Roizman,
Marjorie B. Kovler Viral Oncology Laboratories, University of 
Chicago, Chicago, Illinois, U.S.A.
BHK (TK~) cells
Vero (TK~) cells: African green monkey kidney cells 
Rabbit Skin cells: Originally obtained from J. McLaren, were used for 
transfection of cells with viral DNA (Longnecker and Roizman, 1986). 
Human 143 (TK~) cells were used for selection of TK+ and TK” 
recombinant viruses. (Longnecker and Roizman, 1986).
1.2 Viruses
Pseudorabies virus (PRV), a member of the Alpha-Herpesvirus group, 
was originally obtained from Kaplan and Vatter (1959), via 
Dr. W.S. Stevely.
Herpes simplex virus type 1 (HSV-1) Glasgow Strain 17 was provided by 
Dr. J. MacNab, MRC Virology Unit, Institute of Virology, University 
of Glasgow, Glasgow. It was termed HSV-1(G).
Herpes simplex virus type 1 (HSV-1)F strain (Ejercito and Kieff, 
1968), was provided by Prof. B. Roizman (University of Chicago). It 
was termed HSV-1(F).
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1.3 Viral Mutants
tsK mutant of HSV-1(G) (Marsden et al., 1976) was a gift from 
Dr. J. MacNab.
Recombinant viruses of HSV-1(F), R7035, R7041, R7050, R7051 were 
gifts from Dr. R. Longnecker and Prof. B. Roizman, University of 
Chicago.
HSV-1(F) A305(TK") (Post et al., 1981, Post and Roizman., 1981) 
was provided by Prof. B. Roizman.
1.4 Plasmids
These were used during the construction of HSV-1(F) recombinant 
viruses.
pRB103 - Plasmid containing the Bam HI Q fragment of HSV-1(F). 
pRB3446 - 4.89 kp fragment of HSV-1(F) Sac I fragment cloned in 
vector pUC19-
pRB425 - 4.47 kbp fragment of HSV-1(F) Hind III - Sac I fragment 
cloned in vector pUC19. 
pRB3635 - 4.89 kbp Sac I fragment from plasmid pRB3446 with a27-TK 
chimeric gene inserted in place of a small Nco I fragment 
within the US3 gene. 
pRB3696 - The US3 gene sequence of HSV-1(F) is deleted in this
plasmid. The deletion is in the 4.47 kbp Hind III - Sac I 
fragment (cloned as pRB425). The deletion extends from a 
Pst I site located 69 amino acids from the 5' end of US3 to 
a Bam HI site located at amino acid 357 or US3.
The plasmids described above were constructed by Dr. R. Longnecker 
and were gifts from him and Prof. B. Roizman.
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2 CHEMICAL
2.1 General
General laboratory chemicals were of analytical grade, where 
appropriate and obtained from standard commercial suppliers unless a 
particular source is specified.
2.2 Radiochemicals
[3^S]methionine, [^ 2^I]NaI and 3^[P]orthophosphate were purchased 
from Amersham International Ltd., England.
[Y32P]ATP was either from Amersham International or synthesised 
according to Maxam and Gilbert (1980).
[^ 2-*I]NaI was used to prepare radiolabelled protein-A.
2.3 Enzymes, Other Proteins, Amino Acids and Additional Compounds 
Protein kinase C, homogeneous preparation isolated from bovine brain 
according to Parker et al. (1984) was a gift from Dr. P.J. Parker, 
ICRF, London.
Protein kinase C, partially pure preparation, was purified from BHK 
cells according to the method of Kikkawa et al. (1986). Cyclic 
AMP-dependent protein kinase was from rabbit muscle and was purchased 
from Sigma Chemical Co., U.S.A.
Casein Kinase II was a gift from Dr. 0-G. Issinger Department of 
Human Genetics, University of the Saarland.
DNase (prepared according to Banks et al., 1985) was a gift from 
Dr. K.L. Powell, University of Leeds.
Protamine sulphate, casein and mixed histones type II-A, lysine rich 
histones III—S, histone type V-S, VI-S and VII-S were from Sigma 
Chemical Co., U.S.A.
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Low molecular weight protein standards were from Pharmacia, Sweden. 
High molecular weight protein calibration kit was from Boehringer 
Mannheim GMBH, West Germany. L-threonine, O-phosphoserine,
0-phosphothreonine and O-phosphotyrosine were from Sigma Chemical 
Co., U.S.A.
Cycloheximide, 1, ethyl-3-(3-dimethylaminopiopyl)-carbodiimide 
hydrochloride, phenyl methyl sulphonyl fluoride, Lubrol-PX, 
^-glycerophosphate and EGTA were obtained from Sigma Chemical 
Co., U.S.A. Aquacide (Type II) was from Calbiochem Behring 
Corporation, U.S.A. Puromycin was obtained from Boehringer Mannheim, 
West Germany.
2.4 Nucleic Acids and Nucleotides
ATP was from P-L Biochemicals Inc., U.S.A. Cyclic AMP was from 
Boehringer Mannheim, West Germany.
2.5 Peptides
Synthetic peptides for determination of substrate specificity were 
synthesised according to Marchiori et al. (1979; 1982), Meggio et al,
(1981) and Chessa et al. (1983).
All were gifts from Prof. F. Marchiori and Prof. L.A. Pinna of the 
Organic Chemistry and Biochemistry Departments, respectively, of 
Padua University, Padua, Italy.
A synthetic peptide of the eight C-terminal amino acids of the 
predicted product of the US3 gene of HSV-1 (with an additional 
tyrosine amino acid at the N-terminal side) was synthesised by 
Cambridge Research Biochemicals, Cambridge, England.
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2.6 Antibodies
Monoclonal, polyclonal and peptide antibodies to protein kinase C 
were gifts from Dr. P.J. Parker, ICRF, London.
A Synthetic oligo-peptide antiserum to the predicted product of the 
US3 gene (anti-US3 serum) was provided by Dr. M. Frame and Prof. J. 
Subak-Sharpe of the MRC Virology Unit, Institute of Virology, 
University of Glasgow, Glasgow.
Monoclonal antibody H1163 to HSV-1(F) glycoprotein B was a gift from 
Dr. L. Pereira, Rickettsial Disease Laboratory, California, 
Department of Public Health, Berkeley, California, 94704, U.S.A.
2.7 Chromatographic Material
DEAE-cellulose (DE-52) was from Whatman Biochemicals Ltd., England. 
DEAE-Sephacel, Phenyl-Sepharose, Sephacryl S-200, AH-Sepharose 4B, 
Mono Q HR 5/5 column (5mm x 50mm), Superose 6 (10 x 300mm), and 
Superose 12 (10 x 300mm), were all from Pharmacia, Sweden.
Protamine-agarose was from Sigma Chemical Co., U.S.A. 
Threonine-sepharose was synthesised according to Kikkawa et al. 
(1986). Sepharose is a registered trademark of Pharmacia AB.
The TSK phenyl-5PW column was a product of Toyo Soda Manufacturing 
Co., (Japan) and obtained through Anachem, Luton, England.
2.8 Reagents for electrophoresis
Acrylamide, N-methylene-bis-acrylamide, diallytartardiamide and 
ammonium persulphate were from Biorad Laboratories, U.S.A.
Urea was of Aristar grade, from British Drug House Ltd., England.
Ampholines pH 4-6 were from LKB, Sweden.
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Agarose (type VI) and, Coomassie Brilliant Blue R250 and G250 were 
from Sigma Chemical Co., U.S.A.
NNN"N''tetraethylmethylethylenediamine (TEMED) and Bromophenol 
Blue were from Eastman Kodak Co., U.S.A.
Pyronine Y was from G.T. Gurr Ltd., England.
2.9 Reagents for Immunology
Nitrocellulose (BA or BA85) was from Schleicher and Shuell; Anderman 
and Co., Ltd., Surrey, England. Tween 20 was from Sigma Chemical Co., 
U.S.A.
The electrotrans-blot apparatus was from Biorad Laboratories, U.S.A.
Horseradish peroxidase-coupled rabbit anti-mouse immunoglobulin G was 
from Miles Laboratories Inc., Elkhart, Ind., U.S.A.
Ortho-dianisidine dihydrochloride and hydrogen peroxide were from 
Sigma Chemical Co., U.S.A.
2.10 Reagents and Tissue Culture
Eagle's minimum essential medium (MEM) Glasgow Modification (G-MEM) 
(Eagle, 1959, as modified by MacPherson and Stocker, 1962), MEM 
vitamins, MEM amino acids, MEM amino acids minus methionine, newborn 
calf serum, sodium bicarbonate, L-glutamine and trypsin were from 
Gibco Bio-Cult, Scotland. Dulbecco modified Eagle minimum essential 
medium, maintenance medium 199, foetal calf serum were from Gibco 
Bio-Cult, U.S.A.
Trypsin and PPLO agar were from Difco Laboratories, U.S.A. Blood 
agar, brain and heart infusion broth, tryptose phosphate broth were 
from Oxiod Ltd., England. Penicillin and streptomycin were from Glaxo 
Pharmaceuticals Ltd., England.
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Bromouracil deoxyribose and methotrexate were from Gibco, U.S.A.
Phenol red and Giemsa stain were from BDH Chemicals, England.
Dimethylsulphoxide (DMSO) and L-glutamine were from Sigma Chemical 
Co., U.S.A.
Plastic ware was from Nunc, England and U.S.A.
2.11 Photographic Materials and Reagents
DX10 photographic developer, FX40 photographic fixer, X-ray (screen) 
film (X-Omat XAR5), X-ray (screen) film (X-Omat S) were from Eastman 
Kodak Co., U.S.A.
Cronex intensifying screens and cassettes were from du Pont de 
Nemours and Co. Inc., U.S.A.
2.12 Scintillation Reagents
2,5-diphenyloxazole (PPO), p-bis-[2-5 phenyloxazole] - benzene 
(POPOP) were from New England Nuclear, U.S.A.
Ecoscint was from National Diagnostics, New Jersey, U.S.A.
2.13 DNA Cloning Reagents
Restriction endonucleases were purchased from New England Biolabs, 
Beverly, Mass., U.S.A. T4 DNA ligase was obtained from Boehringer 
Mannheim Biochemicals, Indianapolis, Ind., U.S.A.
Agarose, low and high melting point, was from Sea Kerm Me agarose 
(FMC Corp., Marine Colloids Div., Rockland, Maine, U.S.A.).
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3 COMPOSITION OF STANDARD SOLUTIONS
3.1 Phosphate-Buffered Saline (PBS)
This buffer was prepared essentially according to Dulbecco and Vogt 
( 1954) and contained 0.17M NaCl, 3.4mM KC1, 10mM NaHPCty, 2.4mM 
KH2PO4, 0.49mM MgCl2 and 0.68mM CaCl2 at a pH of 7.5.
3.2 Scintillation Fluid
A. 66% (v/v) toluene, 33% (v/v)2-methoxyethanol,
0.4% (w/v) 2,5 - diphenyloxazole,
X
0.01% (w/v) p-bis-[2-(5-phenyloxazoyl)]-benzene.
B. ECOSCINT
3.3 Cell Culture Media
A. ETC - Glasgow modified Eagles medium containing tryptose 
phosphate and bovine calf serum.
300ml sterile distilled water 
40ml Eagles minimum essential medium, Glasgow modification 
(G.MEM)(X10)
40ml tryptose phosphate
14ml sodium bicarbonate (7.5% ; 200mM)
4ml penicillin/streptomycin (10,000 units)
4ml L-glutamine (200mM)
This medium was supplemented with 1%(v/v), 5%(v/v) or 10%(v/v)
newborn calf serum as indicated.
B. DME
Dulbecco modified minimum essential medium was supplemented with 
5%(v/v) or 10%(v/v) foetal calf serum and antibiotics. To make 
5 litres of this growth media, one 5 litre packet of Hazleton DME 
was added to 4 litres of sterile distilled water and mixed for
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20 min. 7.5g of NaHC03 was added till the colour changed from 
orange to red. A further litre of distilled water was added and 
the media was mixed for 1 to 2h.
For transportation of cells, flasks of confluent Vero cells were 
filled to capacity with DME supplemented with 10% (v/v) foetal 
calf serum and 4.5g of glucose. For BHK cells the flasks were 
filled with ETC containing 10% (v/v) newborn calf serum.
C. 199 Media for Propagation and titration of Viruses 
199V Medium
400ml sterile distilled water 
50ml concentrated 199 medium
(Hank's BSS 10X) ^
0.5ml penicillin/streptomycin 
(10,000 units)
5ml inactivated foetal calf serum*
5-6ml NaHC03 (7.5% ; 200mM)**
1-5ml glutamine (200mM)***
* Inactivated by heating the serum for 30 min. at 56°C.
** NaHC03 was added till the colour of the medium turned cherry red. 
*** The 199 (10X concentrate) obtained from commercial sources,
contained glutamine. However the glutamine only remains stable 
for 8-12 weeks. - During this time, and after, it was necessary to 
supplement the medium with the amino acid. For each month after 
the arrival of 199 from the supplier 1ml of 1% (w/v) glutamine 
was added to the medium.
199V medium minus specific amino acids was prepared as described 
above, except that, dialysed, inactivated foetal calf serum was 
used.
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1990 Medium
This medium was used for the titration of HSV-1(F) and R7035, 
R7041, R7050 and R7051 recombinant viruses on Vero cells. It 
consisted of 500ml of 199V medium with an additional 0.5ml of 
pooled human Y-globiilin (0.5-1mg).
D. Pre-Freeze Medium (PFM)
The formulation used depended on the cell type.
Vero cells
BHK TK" cells (USA) BHK TK' cells (Glasgow)
360ml sterile distilled water 
40ml 199 medium x 10 
100ml inactivated foetal 
calf serum
The pH of each solution was adjusted till the medium became a 
bright tomato red colour by the addition of sterile 6M NaOH 
dropwise.
E. Freeze Medium
The appropriate pre-freeze medium (PFM) was used with 
Dimethylsulphoxide (DMS0) in a ratio of 4 parts PFM : 1 part 
DMS0.
F. Tryptose Phosphate Broth
For 5 litres of broth, 147.5g of Tryptose phosphate broth (Difco 
bacto) was added to 5 litres of distilled water. The mixture was 
divided into 40ml aliquots and sterilized by autoclaving at 
15 lbs/sq in pressure for 15 min.
360ml sterile distilled water 
40ml G-MEM * IO 
100ml newborn calf serum
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G. Versene
Versene (EDTA, disodium salt) was prepared in PBS. The total 
solution contained, in 1 litre : 0.14M NaCl, 2.7mM KC1, 10mM
NaHPOlj, 2.4mM KH2PO4, 2mM EDTA, 0.015% phenol red. The versene 
mixture was aliquoted and autoclaved and stored at room 
temperature.
Trypsin/Versene
Just before use a trypsin/versene mixture was prepared containing 
1 volume of trypsin (0.25% (w/v)) and 4 volumes of versene.
H. Giemsa Stain
To stain infected monolayers Giemsa stain was prepared as 
follows:
30g of Giemsa was added to 1,980ml of glycerol and heated at 56° 
for 90 to 120 min, after which 1,980ml of methanol was added and 
the solution was mixed well. The stain was allowed to stand at 
room temperature for 7 days and then filtered through Green's
904.5 filter paper. The stain was bottled and diluted 1 in 10 
with distilled water before use.
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METHODS
1 TISSUE CULTURE METHODS
1.1 Growth of Cells
A. BHK 21/C13 TK+ (Glasgow) or TK" (USA) Cells.
These were grown as monolayers in rotating 2.5 litre roller 
bottles (glass or plastic) in 150ml of pre-warmed ETC 
supplemented with 10% newborn calf serum or, in the case of the 
BHK TK" (USA) cells, DME supplemented with 10% foetal calf serum. 
Cultures were seeded at 2-3 x 10^  cells per roller bottle and 
"gassed" with 100ml of 5% (v/v) CO2 in dLir to maintain 
buffering capacity. The bottles were rotated at 37°C for three 
days, by which time the cells had generally just reached 
confluence.
B. Vero Cells, TK" (African green monkey kidney cells).
p
These were transferred from 500ml (150cm ) plastic flasks to 2.5 
litre roller bottles in 150ml of pre-warmed DME supplemented with
n
10% foetal calf serum. The cultures were seeded at 5-6 x 10' 
cells per roller bottle and "gassed" as described in 1.1 A. The 
cells were confluent within two to three days at 37°C. Vero 
cells were also grown in small screw-topped plaque dishes. The 
cultures were seeded at 2-3 x 10 cells per dish and the cells 
were grown in 10ml of DME supplemented with 10% foetal calf serum 
and gassed with 10mls of 5% CO2 in dir, The cells reached 
confluence within 12-24h at 37°C.
C. Rabbit Skin Cells
These were grown under similar conditions to the Vero cells in
o
plaque dishes or 150cm plastic flasks.
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D. Cell Density
The number of cells obtained from confluent monolayers from the 
various flasks were:
c
plastic screw-topped plaque dish; 4-5 x 10
plastic 500ml flask (150cm^); 5 x 10^
roller bottle 2.51; 2.5 x 108
E. Passaging Cells
When cells had become confluent they were removed from the 
plastic or glass vessel by trypsinization. Firstly the medium 
was discarded and the cells were rinsed with approximately 
10-20ml of a trypsin/versene mixture (1 part trypsin (0.05%),
4 parts versene), prepared as described in Materials, Section 
3.3G, and pre-warmed to 37°C. After 2 min this mixture was 
discarded and another 10-20ml of the trypsin/versene mixture was 
added. The cells were rinsed again for 2 min and this mixture 
was then poured off, leaving 2-5ml of the trypsin/versene mixture 
in the flask. The flask was then rotated at 37°C until the cells 
were clearly seen detaching from the walls. This usually took 
5-10 min. Approximately 20ml of the appropriate pre-heated 
medium was then added to the flask of cells and the cells were 
suspended in this medium using an automatic pipette aid and a 
10ml sterile glass pipette. The cells were transferred to a 
sterile vessel and either seeded immediately, or kept at 4°C for 
up to 24h before seeding.
F. Freezing and Storage of Cells
a. Small Scale
Cell cultures were grown and harvested by trypsinization when 
they were between 80-90% confluent. They were resuspended in
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the appropriate grown medium, (this was determined by the 
particular cell type) and the suspension was centrifuged at 
2000 rpm (500g) for 5 min. The cells were resuspended at 
4-12 x 108 per 1ml of the appropriate pre-freeze medium (PFM) 
described in Methods (Section 3.3D). This suspension was 
left on ice for 30 min and was mixed at 10 min intervals.
Then an equal volume of cold PFM-DMS0 mixture (Methods, 
Section 3.3E) was added slowly. The cell suspension was 
again left on ice for 30 min and mixed at 10 min intervals.
r  £
Aliquots of approximately 1ml containing 2 x lO3 - 5 x 10 
cells were placed in sterile screw-topped vials and frozen at 
-80°C or in liquid nitrogen.
,b. Large Scale
BHK TK+ (Glasgow) cells from one roller bottle were harvested 
by trypsinization when 90% confluent. They were resuspended 
in ETC supplemented with 10% newborn calf serum. The 
suspension (approximately 5 x 10^  - 1 x 10^  cells/ml) was 
centrifuged at 2000 rpm (500g) in a Beckman bench centrifuge, 
to sediment the cells. The medium was removed and 20ml of 
freeze medium were added to the cells. The cells were then 
cooled to 4°C and 5 x 108 - 1 x 10^  cells in 10-20ml of cold 
ETC freeze medium were dispensed in 20ml screw-topped sterile 
Universal Bottles. These were then frozen directly at -80°C. 
Cells stored in this way remained viable for 6 months to 1 
year.
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G. Recovery of Cells After Freezing
a. Small Scale:
Each vial of cells was quickly thawed to 37°C in a water bath 
and diluted by adding 10ml of pre-warmed growth medium.
The cells were then placed in a small screw-topped plaque 
dish. Cells from 1 vial became confluent within 1h. 
Alternatively, cells from 1 vial were sometimes diluted with 
50ml of pre-warmed growth medium and transferred to a single
p
150cm (500ml) plastic flask, generally reaching confluence
within 24h.
b. Large Scale:
Each Universal Bottle of cells was quickly thawed to 37°C in
p
a water bath; the cells were transferred to a 150cm flask 
and, when they were confluent, trypsinized and placed in a 
2.51 roller bottle containing 150ml of the appropriate growth 
medium (as described in Methods, Section 1.1 A).
1.2 Infection of BHK Cells with Pseudorabies Virus
BHK TK+ (Glasgow) cells were grown to confluence in roller bottles 
for 3 days at 37°C. Each bottle was infected with PRV at a 
multiplicity of approximately 20 p.f.u./cell in 20ml of the original 
medium or fresh medium with the calf serum reduced to 1%. The virus 
was allowed to adsorb onto the cells for 1h at 37°C. After this 
adsorption period the medium was removed and replaced with 50ml of 
the original medium or fresh ETC medium containing 1% calf serum, and 
the infection allowed to continue at 37°C until harvesting. This was 
usually 8h after infection, when 95% - 100% of the cells were rounded 
up but still remained on the surface of the roller bottle or flask.
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1.3 Infection of BHK Cells and Vero Cells with Herpes Simplex Virus 
Type 1
BHK cells were infected when confluent with 10 p.f.u./cell of 
HSV-1(G) in 20ml of ETC/roller bottle, with the calf serum reduced to 
1%. The virus was allowed to adsorb onto the cells for 1h at 37°C. 
After this time the medium was discarded and 50ml of ETC containing 
1% calf serum was added. The infection was allowed to continue at 
37°C until harvesting 17—18h after infection. BHK TK” (USA) and Vero 
cells were grown to confluence at 37°C. They were infected at 
10 p.f.u./cell with HSV-1(F), R7035, R7041 or R7050 in 25ml per 
roller bottle of 199V growth medium. The particular virus was 
discarded and 50ml of 199V was added, and infection continued for 
17—18h, when the cells were harvested.
1.4 Growth of Pseudorabies Virus
PRV for subsequent bulk preparation of protein kinase was prepared as 
follows: BHK cells were grown to confluence in 2.5 litre roller
bottles. Then they were infected at 1 p.f.u./200 cell with PRV in 
20ml of ETC medium containing 1% calf serum per roller bottle. After 
an adsorption period of 1h at 37°C the cells were overlayed with 
100ml of ETC containing 1% calf serum. The infection was allowed to 
continue at 37°C until the cytopathic effect was complete (36-48h). 
The roller bottles were shaken gently and the virus and cell debris 
were aliquoted in 250-300ml quantities and stored frozen at -80°C. 
This virus was used to infect cells for the preparation of the 
protein kinase. PRV stocks were produced as described above but once 
the cytopathic effect was complete the bottles were shaken gently to 
detach the remaining cells from the glass surface, and the cell 
debris removed by centrifugation at 2000 rpm (500g) for 10 min. The
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virus was sedimented by centrifugation at 10,000 rpm (20,000g) for 
90 min in an MSE-18 centrifuge. The sedimented virus was resuspended 
in growth medium containing 1% calf serum, titred and stored in 
aliquots over liquid nitrogen.
1.5 Growth of Herpes Simplex-1(G)
Virus for bulk preparation of protein kinase was prepared essentially 
according to the method described above for PRV (Methods,
Section 1.4) but with the following amendments. Infection was at 
1 p.f.u. per 100 cells with an original stock of HSV-1 of titre 
5 x 10^  p.f.u./ml. A complete cytopathic effect was achieved in 
48-72h under these conditions. Supernatant viral stocks were also 
prepared as for PRV, however the majority of HSV-1 virus remains 
associated with the cell pellet after the first centrifugation. This 
pellet was therefore resuspended in approximately 6ml of ETC (1% calf 
serum) and sonicated. The virus was titred and shock-frozen in 2ml 
aliquots at -80°C.
1.6 Growth of the Temperature Sensitive Mutant of HSV-1(G): tsK
Approximately 7 roller bottles of confluent BHK cells were infected 
at a multiplicity of 1 p.f.u./300 cells. The titre of the stock of 
tsK was 1.3 x 10? p.f.u./ml and 0.4ml was added to 350ml of ETC 
containing 5% calf serum which had been prewarmed to 31°C. 50ml of 
this was added to each roller bottle of cells. The cells were 
transferred to 31°C and after 3 days a complete cytopathic effect was 
observed. The bottles were shaken gently and the cells were 
sedimented by centrifugation for 5 min at 2000 rpm (500g). The cell 
pellet was resuspended in 6ml of ETC and sonicated to release the 
virus still associated with the cells. The supernatant was 
centrifugated at 10,000 rpm (20,000g) for 90 min in a MSE-18
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centrifuge. The pellet of virus was resuspended in approximately 
10ml of ETC and titred before use.
1.7 Infection of Cells with tsK
p
Plastic flasks (150cm ) of confluent BHK cells were infected at a 
multiplicity of 10 p.f.u./cell with tsK in ETC medium containing 1 % 
calf serum. The flasks of cells, medium, pipettes and virus were all 
pre-warmed to the appropriate temperatures: 31°C, the permissive
temperature, or 38.5°C, the restrictive temperature. The virus was 
allowed to adsorb onto the cells in 5ml of ETC (1% calf serum) for 
1h. The medium was then removed and 20ml of ETC (1% calf serum) was 
added. The infections were then allowed to continue for I8h at the 
appropriate temperatures in carefully monitored incubators to prevent 
any escape of the mutant into 0 protein synthesis, which could 
occur if the temperature fell below 38.5°C. The cells were rounded 
up by I8h after infection and were harvested at this time.
1.8 Growth of HSV-1(F) and Recombinant Viruses (R7035, R7041, R7050 
and R7051)
Ten plastic roller bottles of confluent Vero cells were used 
routinely to make stocks of each virus. Each roller bottle of cells 
was infected at a multiplicity of 1 p.f.u./100 cells with the 
appropriate virus in 25ml of pre-warmed 199V. The virus was allowed 
to adsorb for 1h at 37°C. The cells were then overlayed with a 
further 50ml of pre-warmed 199V. The virus was allowed to grow for 
approximately 48-72h at 34°C, by which time a good cytopathic effect 
was observed. The bottles were shaken gently to dislodge any cells 
and virus from the plastic surface. The virus and cells were then 
poured into sterile screw-capped bottles and sedimented at 5000 rpm 
(10,000g) for 10 min. The supernatants were discarded and the
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pellets were resuspended in a final volume of approximately 10ml of 
199V. The suspension was then sonicated to release the majority of 
the virus associated with the cell. Each virus preparation was 
aliquoted into 2ml fractions and stored at -80°C. A portion of each 
was used for immediate titration. The stocks of virus used for the 
original innoculation were prepared from a mother stock as follows:
Screw-topped plaque dishes each containing 4 x 10° Vero cells were 
infected at 1 p.f.u./100 cells with an aliquot of the mother seed 
stock in 1ml of 199V medium. After 1h the cells were overlayed with 
5ml of 199V and infection was allowed to continue for 36-48h, when a 
complete cytopathic effect was observed. The dishes were shaken 
gently and frozen at -80°C. An aliquot of these seed stocks was 
titred.
1.9 Titration of Viruses
A. PRV
Serial logarithmic dilutions of PRV were prepared in ETC (1% calf
serum). Screw-topped plaque dishes were seeded with 2-3 x 10^
BHK cells in 5ml of ETC (10% calf serum) and the cells were 
allowed to grow to confluence in a CO2 incubator at 37°C. Three 
to four dishes were used per dilution. After the cells had grown 
for 12-24h the medium was aspirated off the cells. The cell 
monolayers were infected with 0.1ml of the various virus 
dilutions: routinely 10“  ^-10”^  were used. After adsorption of
the virus onto the cells for 1h, 5ml of ETC (1% calf serum) was 
added and the incubation continued for a further 2h. Then
approximately 250]ig of heparin was added to each dish to 
prevent the virus spreading and the cultures returned to the 37°C 
incubator for a further 24-30h. After this time the medium was
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removed and the infected monolayers fixed with 4% formal saline 
for 10-20 min. After fixing, the monolayers were stained with 
Giemsa stain for 20 min and then washed with distilled water.
The plaques were clearly visible by eye but were viewed also with 
a plate microscope and counted. Plates containing 10-50 and 
100-200 plaques were chosen and the average number taken over the 
4 dishes was used to calculate the titre of the virus.
B. HSV-1(G) and tsK
HSV-1(G) was titred essentially as already described for PRV. 
Serial dilutions of HSV-1(G) were prepared in ETC (1 % calf 
serum). Plaque dishes with approximately 3 x 10 cells were set 
up and grown for 12h at 37°C. The monolayers were then examined 
to ensure an even cell layer was achieved. HSV-1(G) was titred 
at 37°C and 31°C, the titres obtained at 31°C being routinely a
factor of 10 lower than that obtained at 37°C. tsK was titred at
31°C and 37°C also. To each plaque dish 0.1ml of the
appropriately diluted virus (10“  ^-10“^  range) was added. The
virus was allowed to adsorb onto the cells for 1h, and then 
overlayed with 5ml of ETC (1% calf serum) and left for 48-72h in 
an incubator maintained at the appropriate temperature. The 
medium was then removed and the infected monolayers were fixed 
and stained as before.
C. HSV-1(F), R7035, R7041, R7050 and R7051
Vero cells were used for the preparation of these viral stocks
and also for the titration of these viruses. Screw-topped plaque 
dishes with confluent Vero cells (approximately 4 x 10 ) were 
used. Serial logarithmic dilutions of each virus were prepared 
in 199V. (Care was taken to mix each dilution thoroughly and new
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pipettes were used throughout.) The medium was aspirated off the 
cells and the cell monolayers were infected with 0.1ml of the 
various dilutions of virus (routinely 10“8 -10 ~^), each 
condition being performed in triplicate. The virus was allowed 
to adsorb onto the cells for 1h at 37°C. The cells were then 
overlayed with 5ml of 199V medium and the cells returned to 37°C 
for 36-48h. When the monolayers were sufficiently infected, the 
plaques were clearly visible even before staining. The medium 
was removed from each dish and 2-5ml of methanol was added.
After 10 min, this was removed and the infected monolayers were 
stained with Giemsa stain for 30 min.
The monolayers were then washed with distilled water. The 
plaques were clearly visible as clear holes in the cell sheet. 
They were counted and the average values used to calculate the 
concentrations of HSV-1(F), R7035, R7041 and R7050 viral stocks. 
As a control, viruses of known titre were re-titred in every 
viral titration.
D. Titres
The typical titres obtained routinely for the various viral 
stocks were:
PRV 1 X 109 - 5 X 109 p.f.u./ml
HSV-1(G) 1 X 108 - 5 X 108 p.f.u./ml
tsK 1 X 108 P f.u./ml
HSV-1(F) 2 X 109 - 5 X 109 p.f.u./ml
R7035 1 X 108 - 1 X 109 p.f.u./ml
R7041 1 X 108 - 1 X 109 p.f.u./ml
R7050 1 X 108 - 1 X 109 p.f.u./ml
R7051 1 X 109 P f.u./ml
Page 71
1.10 Labelling of BHK and Vero Cells with [^ 2P]Orthophosphate
c
Screw-topped plaque dishes containing 4 x 10 Vero or BHK cells were 
labelled with ^2P during infection with HSV-1(F), R7041 or during 
mock infection. The cells were infected as described in Methods, 
Sections 1.3 and 1.14. One hour before the chosen time for 
labelling, the medium was removed from the cells and 1ml of growth 
medium in which the phosphate had been decreased to one tenth (0.09mM) 
of its normal concentration and from which tryptose phosphate broth 
had been excluded was added. After the 1h incubation period, 
200-500pCi of [82P]orthophosphate was added to the cells. The 
cells were either harvested after short intervals or they were rinsed 
with 199V medium (with the phosphate concentration decreased to 10% 
of its normal concentration) and then overlayed with 2ml of this 
medium. The labelled cultures were then further incubated for 2-4h 
and then harvested.
1.11 Labelling of BHK and Vero Cells with [^S]Methionine
4 x 108 cells in screw-topped plaque dishes were labelled with 
[ 3 8 S ] m e t h i o n i n e  during viral infection. After infection for 3h the 
cells were washed with medium lacking methionine, and 30 min later 
200-500yCi of [ ^ S ] m e t h i o n i n e  was added to the cells in 2ml of 
methionine-free medium diluted with 199V in a ratio of 9:1. After 1h 
a further 200-500|iCi of [^8S]methionine was added, and after 1h 
the cells were harvested.
1.12 Inactivation of PRV and HSV-1(G) by Ultra-Violet Radiation
Irradiation of each virus by ultra-violet light was as follows:
Stock virus was diluted tenfold with phosphate-buffered saline
p
containing 1% (w/v) glucose. Aliquots (2.5ml) received 5kJ/m of 
radiation in 50mM petri dishes under a UVSL-58 Mineralight
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(Ultra-Violet Products, San Gabriel, CA., U.S.A.). Dosage was 
calculated from the distance between source and sample and the time 
of irradiation.
1.13 Assay of DNA Polymerase
This was performed according to Weissbach et al. (1973).
1.14 Mock Infection
This was performed under the same conditions as the particular viral 
infection, except that no virus was added. The appropriate reduced 
volume of medium was added to the cells and 1h later this was removed 
and new medium added. The volume of this medium was again the same 
volume used in viral infection. The cells were harvested at the same 
time as the particular virally infected cells.
1.15 Preparation of Plasmids
Plasmids pRB3446, pRB3447, pRB425, pRB3696 were prepared according to 
a modification of the methods of Birnboim and Doly (1979) and Maniatis 
et al. (1982). A single bacterial colony was inoculated into 1 litre 
of sterile L-broth (20g/litre) containing glucose (1g/litre) and 
ampicillin in a 2.5 litre flask, and shaken overnight at 37°C. The 
bacteria were centrifuged in a Sorval centrifuge at 8000 rpm (7000g) 
for 30 min at room temperature. Material from 1 litre of original 
culture was resuspended in 20ml of a solution containing 25mM 
Tris-HCl (pH8), 50mM EDTA (di-sodium salt), 1% (w/v) glucose and 
5mg/ml lysozyme, and then left at room temperature for 5 min. A 
wide-bore pipette was used to add 40ml of a solution containing 
0.2M NaOH and 1% SDS, and the mixture was mixed and left on ice for 
10 min. Again using a wide-bore pipette, 45ml of a cold solution of 
3M potassium acetate (pH4.8) was added. The mixture was left on ice 
for 5 min and then centrifuged at 10,000 rpm (20,000g) for 30 min.
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The supernatant was transferred to a new tube by straining it through 
Kleenex tissues. Then 0.6 vol of isopropanol was added and the 
solution mixed and left at room temperature for 15 min. The mixture 
was then centrifuged at 8000 rpm (7000g) in a Sorval centrifuge for 
10 min at room temperature. The precipitated DNA was resuspended in 
a solution of 10mM Tris-HCl (pH7.6) and 1mM EDTA or glass-distilled 
water. Plasmid DNA was separated from chromosomal DNA by caesium 
chloride density gradient centrifugation. Each gradient contained 
24ml CsCl (175% w/v) 12ml of DNA solution and 1ml of ethidium 
bromide (5mg/ml). The tubes were topped up with extra CsCl and 
water in the same ratio as CsCl to DNA solution. The tubes were 
centrifuged at 45,000 rpm for 15-18h at 23°C in the VTi75 rotor of a 
Beckman ultracentrifuge. The centrifuge was allowed to stop without 
use of the break and the DNA visualised using ultra-violet light.
The lower of the two bands observed was carefully removed using a 
10ml syringe and needle.
The ethidium bromide was then removed from the DNA by three to four 
successive washings with isopropanol. The top phase was aspirated 
off after each wash. The DNA was then dialysed against a solution 
containing 10mM Tris-HCl (pH7.6-8) and 1mM EDTA for 12h with several 
changes of buffer. The concentration of the DNA was then determined 
using the relationship that 50yg/ml DNA has an A260 value of 1 
when measured in a cell with a 1 cm light path. Yields of 1.8-2mg of 
DNA were obtained. The DNA was divided into aliquots and stored at 
-20°C.
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1.16 Transfection of BHK TK“ Cells with Plasmid DNA (for Transient 
Expression)
Plasmid DNA (40-80yg) was transfected into cells which had been 
grown until they were 90% confluent in (150cm2) flasks. The DNA was 
diluted to 2.25ml in Tris-HCl (pH8) and 1mM EDTA. 2.25ml of a 2 X 
concentrated solution of saline buffered with Hepes was then added. 
This contained 8g NaCl, 0.37g KC1, 1g glucose, 0.125g Na2HP0i|.2H2O,
5g HEPES (free-acid) dissolved in 250ml of distilled water and the pH 
adjusted to 7.05 with NaOH. The final volume was adjusted to 500ml 
and the solution was autoclaved or filtered. The DNA mixture was 
- then thoroughly mixed and approximately 0.25ml of 2.2M CaCl2 was 
added causing the DNA to precipitate. This mixture was allowed to 
remain at room temperature for no longer than 10 min. The medium was 
aspirated off the cells and the cells were washed once with fresh DME 
containing 10% foetal calf serum (Materials, Section 3.3B). 
Approximately 4.5ml of the CaCl2/DNA suspension was added to each 
flask of cells, and the cells were incubated at room temperature for 
10-15 min, 45ml of DME (10% foetal calf serum) was added to the cells 
and they were incubated at 37°C for 4h. After this time the DNA and 
medium was aspirated off the cells and they were washed with DME 
containing no serum, care being taken that the cells were not lost at 
this time.
Approximately 10ml of DME with no serum but containing 15-20% (v/v) 
glycerol was next added to the cells and they were incubated for
1-1.5 min. All the glycerol medium was then removed and the cells 
were washed once with DME containing no serum. Again care was taken 
not to lose the cells at this stage. 65ml of DME supplemented with
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10% foetal calf serum was added to each flask of cells and they were 
incubated at 37°C for 40-48h. To aid recovery of the cells after the 
shock, the medium was changed about every 4h.
1.17 Preparation of Viral DNA
p
(1) Small Scale : For the preparation of viral DNA from a 150cm 
flask of infected cells
Cells were harvested by scraping into PBS when the cytopathic 
effect was 100%. The cells were centrifuged at 2000 rpm (500g) 
for 5 min and the supernatant was then removed. Approximately 
2ml of 0.5% (v/v) NP40 in 10mM Tris-HCl (pH8) and 1mM EDTA was 
added to the sedimented cells. This mixture was vortexed and 
kept on ice for 5-10 min. 10yl of RNase (10mg/ml) was 
added. The mixture was centrifuged at 2000 rpm for 5 min in an 
Eppendorf centrifuge to sediment the nuclei. The supernatant 
was removed and 50yl of 20% (w/v) SDS and 50yl of 
proteinase K (10mg/ml) was added. This mixture was then 
incubated for 30 min to 2h, extracted with phenol and then 
ether, and the DNA precipitated by addition of 1/20 vol of 4.5M 
sodium acetate and 5 vols of ethanol. The yield of DNA was 
usually sufficient for approximately 10 restriction 
endonuclease digestions.
(2) Large Scale : For the preparation of viral DNA from 1-5 roller 
bottles of infected cells
The cells were harvested when the cytopathic effect was 
complete, and centrifuged for 10 mins at 2000 rpm (500g).
They were resuspended in 12ml of a solution containing 10mM 
Tris-HCl (pH8) and 1mM EDTA. 0.3ml of 20% (v/v) NP40 was then
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added and the mixture was vortexed and kept on ice for 10 min. 
The nuclei were removed by centrifugation of this mixture for 
10 min at 2000 rpm. 0.5ml of 5M EDTA, 0.5ml of 20% (w/v) SDS 
and 0.1ml of Proteinase K (10mg/ml) were added to the 
supernatant. This mixture was incubated at 37°C for 2-12h, 
before being subjected to Nal density gradient centrifugation 
essentially according to Walboomers and Ter Schegget (1976). 
Approximately 1.5ml of Nal which had been saturated at room 
temperature was added for. each ml of supernatant, and this 
should give a solution with a refractive index of 1.434-1.435. 
The centrifuge tube was then filled to capacity with extra Nal 
at the correct refractive, index after 0.5ml of EtBr (5mg/ml) had 
been added to the mixture. The tubes were centrifuged at 45,000 
rpm for 18—36h in the VTi50 rotor of a Beckman ultracentrifuge. 
After centrifugation the lower band in the gradient which was 
visualised by ultra-violet light was collected in a.syringe.
This was subjected to extraction with phenol and ether before 
being dialysed against 10mM Tris-HCl (pH8) and 1mM EDTA.
1.18 DNA Co-transfections
These were performed as described by Graham and Vander Eb (1973) as 
modified by Kousoulas et al. (1984). Essentially rabbit skin cells 
were treated with 0.2mg of DEAE-dextran per ml in PBS for 5 min and 
washed with 10mM Tris HC1 (pH7.5) containing 1mM EDTA and 150mM NaCl 
immediately before adding the precipitated DNA. DNA in 0.5ml of 
N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid buffer was 
precipitated onto rabbit skin cells by the addition of 30yl of 
2.2M CaClp and incubation at room temperature for 30 min. Growth 
medium (DME containing 10% foetal calf serum: Materials,
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Section 3.3B) was added 10 min after the addition of the 
CaCl2-precipitated DNA to the rabbit skin cells. After incubation 
for 6-1 Oh the medium was replaced and the cells were further 
incubated.
1.19 Selection of Recombinant Viruses
TK" progeny was selected on 143 TK“ cells maintained in medium 
containing a mixture of 199V supplemented with 3$ foetal calf serum 
and bromouracil deoxyribose (40|ig/ml). TK+ progeny was selected 
on 143 TK“ cells maintained in medium consisting of a mixture of DME 
supplemented with 10$ foetal calf serum, hypoxanthine aminopterin and 
thymidine (HAT).
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2 PREPARATION OF CELLULAR FRACTIONS
All the following manipulations were conducted at 0-4°C.
2.1 Total Extracts from Infected BHK and Vero Cells
Infected monolayers were washed once with PBS, harvested and 
sedimented by centrifugation at 2000 rpm (500g) for 5 min. The cells 
were solubilised in a disruption buffer containing: 7.5mM MgCl2, 10mM
2-mercaptoethanol, 10mM EGTA, 40]ig/ml PMSF, 40mM
3-glycerophosphate (pH7.4), 8.5$ (w/v) sucrose, 2$ (w/v) SDS and 
then sonicated.
2.2 Nuclear Extracts from Infected BHK and Vero Cells
Infected cells were washed twice with PBS, scraped off and sedimented 
by centrifugation at 2000 rpm (500g) for 5 min. The cells were 
disrupted by addition of the following buffer: 40mM
3-glycerophosphate (pH7.4), 7.5mM MgCl2, 10mM 2-mercaptoethanol,
10mM EGTA and 40pg/ml PMSF. The nuclear and membrane fractions 
were separated from the cytoplasmic extract by subsequent 
centrifugation in a micro-centrifuge for 10 min. The sediment 
containing the nuclei was then solubilised in the disruption buffer 
described above.
2.3 Cellular Cytoplasmic Extracts (Post-Ribosomal Supernatant)
BHK or Vero cells (either infected or mock-infected) were scraped 
into PBS, washed twice with PBS, and then resuspended in an equal 
volume of a solution containing 10mM KC1, 1.5mM magnesium acetate, 
10mM Tris-HCl (pH7.6), 1mM EGTA and 40pg/ml PMSF, and then 
allowed to stand on ice for 10 min. The cells were then broken open
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by 20 strokes of a Teflon-glass homogenizer and the ionic composition 
adjusted to 125mM KC1, 5mM magnesium acetate, 5mM 2-mercaptoethanol 
and 25mM Tris-HCl (pH7.5). The homogenate was sedimented by 
centrifugation at 10,000 rpm (30,000g) for 30 min, and the 
supernatant subjected to ultracentrifugation at 50,000 rpm (I65,000g) 
for 2.5h in the Ti50 or Ti75 rotor of a Beckman ultracentrifuge.
This removes mitochondria and ribosomes. The supernatant 
(approximately 4-5mg protein per ml) was dialysed overnight against 
Buffer A (20mM Tris-HCl pH7.6, 1mM EDTA, 1mM EGTA, 10mM 
2-mercaptoethanol, 40pg/ml PMSF, 10$ glycerol) and either 
subjected to immediate anion-exchange chromatography or shock-frozen 
and stored at -80°C.
2.4 Ribosomes from BHK Cells
A modified version of the methods described by Ascione and Arlinghaus 
(1970) and Thomas et al. (1977) was used. Sedimented cells were 
resuspended in an ice-cold buffer containing 20mM Tris-HCl (pH7.5), 
50mM KC1, 5mM MgCl2 and 5mM CaCl2, and kept on ice for 10 min. An 
equal volume of a buffer containing 0.5M Sucrose, 0.55M KC1, 10mM 
MgCl2, 5mM CaCl2, 1mM EDTA, 40mM Tris-HCl (pH7.5), 1$ Triton X-100 
was then added and cells left on ice for another 5 min. The cells 
were homogenized with 6 strokes of a Teflon-glass homogenizer. The 
homogenate was sedimented by centrifugation at 2000 rpm (500g) for 
10 min. Sodium deoxycholate was then added to the supernatant to 
give a final concentration of 0.5$ (w/v). The supernatant was 
layered over a step gradient of 8ml of a buffer containing 0.7M 
sucrose in 20mM Tris-HCl (pH7.6), 100mM KC1, 5mM MgCl2, 1mM 
2-mercaptoethanol. The gradients were centrifuged at 27,000 rpm 
(96,OOOg) for I6h at 4°C in the SW27 rotor. Any light material was
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washed off the pellet and, if not used immediately, ribosomes were 
stored at -80°C.
2.5 Ribosomal Subunits
Ribosomal subunits were prepared by dissociation at high ionic 
strength using a modification of the method of Leader and Wool 
(1972). Ribosomes were suspended at 4°C in 10mM Tris-HCl (pH7.5), 
80mM KC1 and 5mM MgCl2. The concentration of KC1 was adjusted to 
500mM and the supernatant clarified by centrifugation at 2000 rpm 
(500g) for 5 min. To promote separation of the subunits the 
clarified suspension was incubated at 37°C for 15 min with 0.1mM 
puromycin and 20mM 2-mercaptoethanol. Aliquots containing approx 
8OA26O units of ribosomes were then layered directly onto 37ml of 
linear 10-30$ (w/v) sucrose gradient containing 10mM Tris-HCl 
(pH7.6), 300mM KC1, 5mM MgCl2 and 20mM 2-mercaptoethanol. After 
centrifugation at 27,000 rpm (96,OOOg) for 4h at 28°C in a Beckman 
SW27 (or SW28) rotor, the gradients were pumped through a Gilford 
flow-cell (Gilford model 240) and the absorbance at 260nm was 
monitored. The subunit fractions were collected and the total 40S 
and 60S subunits obtained from 6-12 were separately pooled and 
sedimented at 177,000g for I6h at 4°C in a Beckman Ti60 rotor. The 
sedimented ribosomes were resuspended in a buffer containing 20mM 
Tris-HCl (pH7.6), 100mM KC1, 4mM magnesium acetate, 7mM 
2-mercaptoethanol and 250mM sucrose, so that the final concentration 
of 40S or 60S subunits was IOOA260 units per ml. Aliquots (0.1ml) 
were stored at -80°C.
Page 81
SEPARATION OF PROTEINS BY CHROMATOGRAPHY
DEAE-Cellulose (DE-52) and DEAE-Sephacel Anion-Exchange Column 
Chromatography.
A. Analytical I
This was used for analytical studies of protein kinases. 
Chromatography was on DEAE-Sephacel packed in a column of
2.5 x 1cm (height x diameter) and equilibrated with Buffer A (20mM 
Tris-HCl pH7.6, 1mM EDTA, 1mM EGTA, 40pg/ml PMSF, 10mM 
2-mercaptoethanol, 10$ glycerol). Cellular cytoplasmic extract 
(prepared as described in Methods, Section 2.3) containing 4-15mg 
protein was applied, the column washed with 25ml of Buffer A, and 
then eluted with 84ml of a linear gradient of 0-0.4M KC1 in the 
same buffer at a flow rate of 12ml/h, 1ml fractions being 
collected and assayed for protein kinase activity.
B. Analytical II
This was used in studies with mutant viruses derived from 
HSV-1(F). The cellular cytoplasmic extract (prepared according to 
Methods, Section 2.3) from each condition (30mg protein) was 
applied to pre-equilibrated DEAE-cellulose (DE-52) packed in a 5 x 
1.6cm column. The column was washed with 165ml of Buffer A and 
eluted with 500ml of a linear gradient of 0-0.4M KC1 in the same 
buffer at a flow rate of 66ml/h, 5.5ml fractions being collected 
and assayed for protein kinase activity immediately.
C. Preparative
The cellular cytoplasmic extract (prepared according to Methods, 
Section 2.3) from a single preparation (generally 75-100mg 
protein) was applied to pre-equilibrated DEAE-cellulose (DE-52) 
packed in a 6 x 1.6cm column. The column was washed with 150ml
Buffer A and eluted with 500ml of a linear gradient of 0-0.4M KC1 
in the same buffer at a flow rate of 72ml/h, 6ml fractions being 
collected. Fractions containing the viral protein kinase 
activity, eluting at approximately 220mM KC1 were combined, 
shock-frozen, and stored at -80°C until the next stage of 
purification.
High-Performance Hydrophobic Interaction Chromatography: TSK
Phenyl-5PW
10Four or five DEAE-cellulose preparations (derived from 4-5 x 10 
infected cells) were allowed to thaw at 4°C and concentrated 10-15 
times in aquacide II for 36h. The concentrated material was dialysed 
for 12h against several changes of Buffer A lacking glycerol and 
containing 1M ammonium sulphate (Buffer B). The dialysed material 
(35-40ml containing 90-100mg protein) was applied by repeated 
injection to a 7.5 x 0.75cm TSK phenyl-5PW column, pre-equilibrated 
with Buffer B and linked to an HPLC system, and the column washed at 
1ml/min with Buffer B until all unbound protein had eluted. The 
column was eluted with 60ml of a linear gradient of 1.0-0M ammonium 
sulphate in Buffer A lacking glycerol at a flow rate of 1ml/min., and 
then with a further 20ml of Buffer at the final concentration of 0M 
ammonium sulphate. Fractions (1ml) were collected and those 
containing the viral protein kinase were combined and subjected 
immediately (without freezing) to the next stage of purification.
Affinity Chromatography : Threonine-Sepharose
L-Threonine was coupled to AH Sepharose-4B essentially according to 
Kikkawa et al. (1986), care being taken to maintain the pH between 5 
and 6 during the coupling reaction. After extensive washing of the 
gel with distilled water, a 7 x 1cm column of the chromedium was
prepared and equilibrated with Buffer A. The viral protein kinase 
(20-25ml, containing 5-6mg protein) from TSK phenyl-5PW was applied 
directly (i.e. without dialysis) to the column, which was washed with 
25ml of Buffer A at a flow rate of 30ml/h, 5ml fractions being 
collected. The flow rate was then decreased to 15ml/h and the column 
eluted with 50ml of a linear gradient of 0-0.4M KC1 followed by 25ml 
of 0.4M KC1, all in the same buffer. The viral protein kinase was 
then eluted from the column with 50ml of a linear gradient of 
0.4M-1.0M KC1 in Buffer A, 2.5ml fractions being collected. Finally 
the column was washed with 15ml of 1.0M KC1. The fractions 
containing the bulk of enzyme activity eluted at approximately 0.7M 
KC1. They were combined and diluted with an equal volume of Buffer A 
to decrease the ionic strength to a value which would allow immediate 
further chromatography (Methods, Section 3.4A) without prior 
dialysis.
3.4 Affinity Chromatography: Protamine-Agarose
A. The diluted viral protein kinase (25-30ml, containing 0.7-0.8mg 
protein) was applied to a 3 x 1cm column of protamine-agarose, 
pre-equilibrated with Buffer A. After washing with 20ml of Buffer 
A the column was eluted with 12ml steps of 0.5M, 0.8M, 1.0M, 1.3M, 
1.5M and 2.0M KC1 at a flow rate of 12ml/h, 1.2ml fractions being 
collected. The enzyme induced by infection with PRV eluted at 
0.8M KC1, in contrast to the enzyme induced by infection with 
HSV-1, which eluted at the 0.5M KC1 step. Peak fractions of 
enzyme activity were combined and adjusted to 0.05% Lubrol-PX.
The purified enzyme was divided into aliquots, shock-frozen and 
stored at -80°C, where it was stable for several weeks at least.
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B. In some instances after hydrophobic interaction chromatography the 
viral protein kinase was applied directly to the protamine-agarose 
column. The conditions of the chromatography were the same as 
those already described above (Methods, Section 3.4A) for the 
enzyme induced by infection with PRV, however several 
modifications were made for chromatography of the enzyme induced 
by infection with HSV-1. The HSV-1 enzyme was applied directly 
(after the hydrophobic stage) to a 3 x 1cm column of protamine- 
agarose pre-equilibrated with Buffer A. The column was washed with 
30ml of Buffer A at a flow rate of 12ml/h and 1.2ml fractions were 
collected. It was then eluted with a linear gradient of 0.3-0.8M 
KC1 in Buffer A and then with 10ml steps of 1.0M, 1.5M and 2.0M 
KC1. The HSV-1 enzyme eluted at approximately 0.5M KC1. The peak 
fractions of enzyme activity were combined and adjusted to 0.05% 
Lubrol-PX. The partially purified enzyme was then aliquoted, 
shock-frozen and stored at -80°C.
3.5 High-Performance Gel-Exclusion Chromatography
A. Superose 12
The protein kinase induced by infection with PRV was purified (as 
described in Methods, Sections 3.1 - 3.4), concentrated 5-fold, 
and then dialysed for 4h against Buffer A supplemented with 500mM 
KC1 and 0.05% Lubrol-PX, but with glycerol omitted (Buffer C).
The concentrated enzyme preparation (15-20pg protein in 0.2ml) 
was applied to a Superose 12 column equilibrated with Buffer C and 
eluted at a flow rate of 0.5ml/min, 0.5ml fractions being 
collected.
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B. Superose 6
A sample of the protein kinase induced by infection with HSV-1 
from the TSK phenyl-5PW column was concentrated 10-fold by 
aquacide II. The concentrated enzyme preparation (0.5mg in 0.2ml) 
was applied to a Superose 6 column equilibrated with Buffer C and 
eluted at a flow rate of 0.5ml/min, 0.5ml fractions were collected.
3.6 High-Performance Anion-Exchange Chromatography
The viral protein kinases partially purified from BHK cells infected 
with PRV or HSV-1(G) by chromatography of the post-ribosomal 
supernatants on DEAE-Sephacel were concentrated and dialysed against 
a buffer containing 20mM Tris-HCl (pH 7.6), 10mM 2-mercaptoethanol 
and 1mM EDTA. Equal activities of the enzymes were either loaded 
together or separately onto a Mono Q column, pre-equilibrated in the 
above buffer. The column was washed with 10ml of 0.25M NaCl in the 
same buffer and eluted with 30ml of a linear gradient of 0.25-0.8M 
NaCl at a flow rate of 1ml/min, 0.5ml fractions being collected.
3.7 Hydrophobic-Interaction Chromatography : Phenyl-Sepharose CL-4B
This was used initially for the preparation of the viral protein 
kinases and was also employed for the purification of protein kinase 
C from BHK cells. Chromatography was performed on pre-equilibrated 
phenyl-Sepharose CL-4B packed in a 6 x 1.6cm column. Fractions 
containing the appropriate enzyme activity from the DEAE-cellulose 
stage were concentrated approximately 10-fold in aquacide II and 
dialysed against Buffer A containing 1M ammonium sulphate (Buffer D). 
The sample (containing 50-100mg protein) was applied to the column, 
which was then washed with 150ml of Buffer D. Next the column was 
eluted with 500ml of a linear gradient of 1.0M-0M ammonium sulphate 
in Buffer A, at a flow rate of 70ml/h, 6ml fractions being collected.
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Finally the column was washed with a further 60ml of Buffer A. The 
column fractions were assayed for protein kinase activity and the 
peak fractions of activity were pooled, concentrated and either 
subjected to further chromatography or shock-frozen and, in the case 
of the viral enzymes, stored at -80°C. Protein kinase C was 
concentrated and either subjected to immediate chromatography on 
threonine-sepharose (as described in Methods, Section 3-3) or 
dialysed against Buffer A containing 50% glycerol and 0.01% triton 
-X100, and stored in aliquots at -20°C.
3.8 Gel-Permeation Chromatography : Sephacryl S-200
Samples of the viral protein kinases obtained after chromatography 
on DEAE-cellulose were concentrated and dialysed for 12h against 
Buffer A containing 0.5M KC1. The same buffer was used for 
equilibration and elution of the column. A sample containing 
approximately 1mg of protein in 0.5ml was loaded on to a 
pre-equilibrated column (40 x 1cm) of Sephacryl S-200. The elution 
was performed at a flow rate of 0.5ml/min, and 0.5ml fractions were 
collected. Blue Dextran (1mg) was used to determine the void volume 
of the column. The positions of elution of proteins of known 
relative molecular mass were determined. Aldolase (2mg), bovine 
serum albumin (2mg), ovalbumin (2mg) and cytochrome c (2mg) were used 
as protein standards.
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4 SEPARATION OF PROTEINS BY POLYACRYLAMIDE GEL ELECTROPHORESIS
4.1 Separation Methods
A. One-dimensional gel-electrophoresis in the presence of sodium 
dodecyl sulphate
This was performed by the method of Laemm/j ' (1970) on SDS slab 
gels. The dimension of the gel plates was 19 x 16cm to fit a 
BRL-V-16-2 slab apparatus, and the thickness of gels was 1.5mm or 
0.5mm. The separation gels contained 10% (w/v) acrylamide and 
0.27% (w/v) bisacrylamide. When optimal separation of proteins of 
approximately 30kDa was required gels containing 15% (w/v) 
acrylamide, 0.09% (w/v) bisacrylamide were prepared. The 
separation gel also contained 0.375M Tris-HCl (pH8.8), 0.1% (w/v) 
SDS, 0.03% (v/v) TEMED and 0.1% (w/v) ammonium persulphate. The 
upper stacking gels contained 5% (w/v) acrylamide, 0.13% (w/v) 
bisacrylamide, 0.12M Tris-HCl (pH6.8), 0.1% (w/v) SDS, 0.03% (v/v) 
TEMED and 0.2% ammonium persulphate. For better resolution of 
viral infected cell proteins labelled with [^p]orthophosphate or 
[3^S]methionine in vivo electrophoresis conditions were slightly 
different. Essentially the proteins were separated on 9.25% (v/v) 
or 11% (v/v) polyacrylamide gels containing SDS and crosslinked 
with diallytartardiamide as described by Morse et al.(1978).
Samples were mixed with 0.5 volumes of sample buffer containing 0.05M 
Tris-HCl (pH6.8), 4.5% (w/v) SDS, 45% (w/v) glycerol, 10% (w/v)
2-mercaptoethanol or 10mM dithiothreitol and 0.002% (w/v)
Bromophenol Blue or Pyronine Y. The maximum amount of protein in 
samples was 100]ig, and the maximum volume of the sample loaded 
was 120pl. The protein samples were completely reduced and 
denatured by heating at 100°C for 2 min. The electrophoresis
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buffer contained 0.05M Tris base, 0.192M glycine, and 0.1% (w/v) SDS 
at a pH of 8.5. Electrophoresis was towards the anode at 25mA per 
gel for 1h and then 40mA per gel for about 4h, until the dye front 
was about 0.5cm from the bottom of the gel. The gels were then 
processed as described in Methods section 4.2.
B. Two-Dimensional gel electrophoresis
This was performed essentially according to O'Farrell et al.
(1977), with the first (iso-electric focussing) dimension 
containing 1% ampholines in the pH 4-6 range. Samples either 
contained 200pg of protein or were highly radiolabelled after 
reaction with [y^P]ATP. The samples were concentrated by 
acetone precipitation and resuspended in no more than 20pl of 
sample buffer containing 9M urea, 5% (v/v) 2-mercaptoethanol or 
10mM dithiothreitol, 2% Nonidet P40 and 2% (v/v) ampholines 
(pH4-6).
The first-dimension gels were poured to a height of 11cm in glass 
tubes of 2mm inside diameter. The gel mixture was composed of 9.2M 
urea, 2% (v/v) Nonidet P40, 7.3% (w/v) acrylamide, 0.1% (w/v) 
bisacrylamide, 3% (v/v) ampholines and 0.06% (w/v) ammonium 
persulphate. The gels were overlayed with a solution containing 9.2M 
urea and 0.1% (v/v) ampholines. The lower reservoir of the gel tank 
was filled with 2% (v/v) orthophosphoric acid, the tube gels were 
placed in the electrophoresis chamber and the samples were loaded and 
then overlayed with 10pl of the overlay solution. The tubes were 
filled with 4% (v/v) ethanolamine and the upper reservoir was then 
filled with this same solution. Electrophoresis was towards the 
anode at 200V for the first hour, then 300V overnight for at least 
12h. The voltage was adjusted to 400V for the last hour of
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electrophoresis to sharpen the protein bands. At the end of 
electrophoresis the gels were removed from the tubes and equilibrated 
for 1h in a two-dimensional SDS interdimensional soaking buffer 
containing 10% (v/v) glycerol, 10mM dithiothreitol, 3% (w/v) SDS,
0.1% Bromophenol Blue and 0.05M Tris-HCl (pH6.8). After the 
equilibration the gels were subjected immediately to the 
second-dimension electrophoresis. The second dimension was on SDS 
slab gels containing 10% (w/v) acrylamide and 0.27% (w/v) 
bisacrylamide, with a stacker gel containing 5% (w/v) acrylamide, 
0.13% (w/v) bisacrylamide, as described in Methods, Section 4.1A.
The first-dimension gel was placed on the top surface of the stacking 
gel and overlayed with 0.1% (w/v) agarose prepared in the SDS 
interdimensional soaking buffer. Electrophoresis was performed 
according to Methods, Section 4.1 A.
4.2 Processing of Gels
A. Staining of gels with Coomassie Brilliant Blue
Gels were stained for 1-2h at room temperature in 0.1% (w/v) 
Coomassie Brilliant Blue R-250 in 50% (v/v) methanol and 10% (v/v) 
acetic acid. They were then destained for 12-24h at 37°C with 
several changes of the destaining solution which contained 10% 
(v/v) acetic acid and 10% (v/v) methanol.
B. Silver Staining
When Coomassie Blue staining was inadequate for visualisation of 
the proteins, the same gels were re-stained using the Biorad 
silver stain derived from the method of Merril et al. (1981).
This method is 10-50 times more sensitive than staining with 
Coomassie Brilliant Blue R-250. All solutions for silver staining 
were prepared in deionised water (conductivity less than
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Ipmho, and they were all warmed to 25°C before use. Staining 
was performed in a glass container placed in a water bath with a 
shaker platform at 25°C. Gels 0.5mm - 1mm thick were kept in 40% 
(v/v) methanol/10% (v/v) acetic acid for at least 30 min until all 
traces of the Coomassie Brilliant Blue R-250 were removed. Gels 
were then treated with 10% (v/v) ethanol/5% (v/v) acetic acid for 
30 min and then incubated in the presence of oxidiser (containing 
potassium dichromate and nitric acid) for 5 min. The gels were 
then subjected to three 5 min washes in deionised water before 
addition of the silver reagent (containing silver nitrate). After 
20 min the silver reagent was removed and the gels were washed 
quickly in deionised water. The developer (containing sodium 
carbonate and paraformaldehyde) was added for 3-10 min. The 
reaction was stopped by incubation of the gels in 5% (v/v) acetic 
acid for 5 min. The gels were stored in deionised water or 40% 
(v/v) methanol to prevent swelling.
,C. Autoradiography
Destained gels containing [^^P]labelled proteins were incubated in 
destaining solution with 3% (v/v) glycerol for 1h and then dried 
on to Whatman 3MM filter paper under suction from an electric 
vacuum pump. Autoradiography was at -80°C on Kodak X-Omat XAR5 or 
X-Omat S film, using a Cronex intensifying screen. In some 
instances gels were dried immediately after electrophoresis (i.e. 
without staining) on the same Whatman 3MM paper and 
autoradiographed as above.
D. Measurement of pH gradients
Measurement of the pH gradient in the first-dimensional gel in 
two-dimensional gel electrophoresis was as follows. An additional
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first-dimensional gel was prepared in parallel with the gel on 
which the sample was loaded. This gel was removed from the gel 
tube after electrophoresis in the first dimension and it was cut 
into 1cm pieces. Each piece was placed directly into a stoppered 
vial. To each piece of gel 1ml of boiling distilled water was 
added and the vials stoppered securely. After 2h the vials were 
vortexed and the pH of the solution was measured with a thin pH 
electrode.
4.3 Immunological Methods
TRANSFER OF PROTEINS TO NITROCELLULOSE MEMBRANES AND DETECTION OF 
ANTIGENS WITH ANTISERA AND PROTEIN A OR A SECOND ANTIBODY CONJUGATED 
TO HORSERADISH PEROXIDASE.
Proteins separated by one-dimensional electrophoresis were 
transferred to nitrocellulose paper, essentially according to Towbin 
el al. (1979) Bowen et al. (1980) and Renart et al. (1979). 
Nitrocellulose was either placed in a single large sheet over the 
entire gel or it was cut into strips (15cm x 0.6cm) and placed over 
the specific proteins to be transferred. To remove any air bubbles, 
the nitrocellulose filters were soaked in the Blotting Buffer of 
Towbin et al. (1979), which consisted of 25mM Tris-HCl (pH8.3), 192mM 
glycine and 20% methanol. The nitrocellulose was allowed to wet by 
capillary action as abrupt wetting led to entrapment of air bubbles 
in the nitrocellulose matrix. The perspex cassette to hold the gel 
was prepared as follows:
Sponge or filter pads were soaked in buffer and placed in the 
cassette, and a piece of Whatman 3MM paper with dimensions slightly 
larger than the gel was soaked in the same buffer and placed on top 
of the pads. The gel and the nitrocellulose membrane were
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equilibrated in this buffer also. The gel was placed on top of the 
Whatman 3MM paper and then the nitrocellulose was positioned on top 
of the gel. A second piece of wet 3MM paper was placed on top of the 
nitrocellulose along with another soaked sponge. The cassette was 
closed and inserted in an Electroblot transblotter tank filled with 
Blotting Buffer. The proteins were then subjected to electrophoresis 
for 2-4h at 400mA towards the anode at room temperature. After the 
transfer, the nitrocellulose filter was removed and placed face up in 
a glass vessel with a lid. The free protein binding sites on the 
nitrocellulose membrane were blocked using any of the methods 
described in the following procedures.
(i) [125i] protein A detection method
Blocking Buffer was prepared. This was essentially a Wash 
Buffer consisting of 0.9% (w/v) NaCl, 0.1% w/v NaN3, 10mM 
Tris-HCl (pH7.4), which was diluted 10 times with water before 
use and supplemented with any combination of the following: 
0.05% Tween 20, 3% Bovine serum albumin or 3% powdered milk.
The blocking was performed overnight at 4°C or 37°C, or 1h at 
room temperature or 37°C on a mechanical shaker. After 
blocking, the nitrocellulose was washed with more Blocking 
Buffer and the antiserum applied. This was diluted 1:50 in 
Blocking Buffer containing 5% inactivated horse serum (v/v).
The volume was the minimum necessary to cover the paper and 
incubation was for 2h at 37°C. In the case of blotting using 
strips of nitrocellulose and peptide antisera the following 
modifications were made. Apparatus consisting of a perspex 
block with 10 shallow slots (15cm x 0.6cm) was used. The 
nitrocellulose strips were placed in each compartment face up,
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and a clean dry strip of Whatman Number 1 filter paper (15cm x 
0.6cm) was placed on top of the nitrocellulose. 250pl of 
the appropriate antiserum was pipetted on top of the filter 
paper, wetting it along its length. The top of the block of 
strips was covered with a glass plate and placed (in a sealed 
container) at 37°C for 2h. After this time the filter strips 
were removed from the nitrocellulose. (If it was necessary to 
conserve antisera, the filter paper was sealed in plastic and 
stored at -20°C. It could be re-utilized without loss of 
signal with a supplement of only 100pl of antiserum). The 
nitrocellulose was then washed with Blocking Buffer.
For routine blots washing was for 30 min with 5 changes of buffer at 
room temperature. More rigorous washing was used in the case of the 
strip blotting with peptide antisera. Washing was for 2-24h at 37°C 
with several changes of Blocking Buffer. [ ^ -*1 ]Protein A was then 
applied in Wash Buffer (i.e. Blocking Buffer without Tween 20) and 3% 
serum albumin. 5 x 10-* cpm of [^^I]Protein A per strip was used in 
3ml of Wash Buffer, or 1-8 x 10-* cpm/ml of [I^-*]Protein A in Wash 
Buffer was used, to cover a large piece of nitrocellulose and 
incubation was for 2-3h. The nitrocellulose filters were then washed 
briefly in Blocking Buffer for 30 min with 5 changes of buffer, or 
more rigorously. This rigorous procedure involved washing for 2-24h 
at 37°C with several changes of buffer. Finally, two washes were 
performed in Blocking Buffer containing 1M KI for 1h each. Then the 
filters were washed twice in PBS, and dried at room temperature on 
blotting paper. The filters were then subjected to autoradiography.
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(ii) Horseradish peroxidase detection method
After electrophoresis, the polypeptides were transferred 
electrically to a nitrocellulose sheet (as described above) and 
reacted with monoclonal antibodies. Briefly, the 
nitrocellulose sheet was incubated for 1h at 37°C in PBS 
containing 3% (w/v) serum albumin. The monoclonal antibody was 
then applied, (usually diluted 1:50-1:100 in PBS with 1% (w/v) 
serum albumin) and incubation with the antibody was for 2h at 
37°C. The unbound antibodies were then removed by washing with 
PBS containing 1% serum albumin.
At least 3 washes, each with 100-200ml of solution, were performed. 
Then the nitrocellulose sheet was incubated in PBS containing 1% 
serum albumin and 5]il per 3ml of horseradish peroxidase-coupled 
rabbit anti-mouse immunoglobulin G (Miles Laboratories, Inc, Elkhart, 
Ind.) for 1-2h. After washing with PBS, the nitrocellulose sheet was 
transferred to a freshly made substrate solution containing 0.02% 
(w/v) ortho-dianisidine dihydrochloride and 0.06% hydrogen peroxide. 
When the antibody-decorated protein bands were visible at the desired 
intensity the nitrocellulose was washed with PBS and dried on 
blotting paper. The procedure described above was essentially from 
Ackermann et al. (1984).
4.4 Appendix
Labelling of Protein A with ^ 1 .
All reagents were prepared just before use; the key reagents were:
(i) PBS
(ii) Chloramine T (10mg in 20ml PBS)
(iii) Sodium metabisulphite (20mg in 20ml PBS)
(iv) 0.1% bovine serum albumin (0.1g in 100ml PBS)
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(v) Protein A (Sigma P8143). The protein A was reconstituted in 
PBS (1mg in 2ml) and dispensed in 20pl (1Oyg) aliquots.
These were stored in plastic vials at -80°C until required
(vi) ^-*I[NaI] (Amersham IMS 30)
(vii) 1M potassium phosphate (pH7.6)
Approximately lOpl of potassium phosphate buffer was added to 
10]ig of protein A. 200pCi of -^*1 [Nal] and 20iil of 
chloramine T solution were then added. The mixture was incubated at 
room temperature for 20 seconds. 20pl of the sodium 
metabisulphite solution was added and the mixture was incubated 
further for 20 seconds and 1ml of PBS was added. The free ^-*1 [Nal] 
was removed by desalting this mixture on a Sephadex G25 column. The 
column was pre-equilibrated with 25ml of PBS containing 0.1% serum 
albumin. 1ml of the iodonated protein A mixture was loaded and the 
column was eluted with the equilibration solution. Approximately 20 
fractions of 0.5ml were collected. The radioactivity of lOpl of 
each fraction was determined in a gamma counter and the fractions 
containing the most highly labelled protein A were pooled and 
aliquoted.
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5 PHOSPHORYLATION REACTION IN VITRO
5.1 Measurement of Protein Kinase Activity
A. Phosphorylation of protein substrates
o p
Protein kinases were assayed by measuring the incorporation of -) p 
from [y^P]ATP into various protein substrates. The 
procedure followed in principle, the method of Corbin and Reimann 
(1974). The standard assay mixture for protein kinase activity 
contained in a total volume of 0.12ml : 20mM Tris-HCl (pH7.6) 10mM 
MgClp, 10mM 2-mercaptoethanol, 0.1mM ATP containing 0.5-1]iCi 
[y^P]ATP, KC1 in the range 50-150mM and 96pg protamine 
sulphate. Protamine sulphate was routinely used as the substrate, 
however mixed histones (0.8mg/ml) or dephosphorylated casein 
(0.8mg/ml) were also used occasionally, and assays for cyclic 
AMP-dependent protein kinase contained 10pM cyclic AMP. The 
reaction was started by addition of the protein kinase (40]il 
in the case of column fractions, or 80]il in the case of 
experiments performed with the recombinant viruses to increase the 
sensitivity of the assay). Incubation was at 30°C for 30 min, 
except when initial velocities were being determined, in which 
case the reaction was terminated after 10 min. At the end of the 
incubation period, 100pl samples were applied to Whatman 3MM 
filter paper discs or P81 filters (2 x 2.5cm pieces) which were 
washed for 15 min periods, twice in 10% (w/w) trichloroacetic 
acid, and four times in 5% (w/w) trichloroacetic acid, and then 
rinsed in absolute ethanol, dried and their radioactivity measured 
either by scintillation spectrometry or as Cherenkov radiation in 
the ^H channel of a scintillation spectrometer.
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B. Phosphorylation of Synthetic Peptides
The reaction mixture for assay of protein kinase activity 
contained in a total volume of 60pl, 20mM Tris-HCl (pH7.5),
100mM, 500mM or 1M KC1, 10mM MgCl2, 10mM 2-mercaptoethanol and
0.1mM ATP containing 1-2]iCi [y^P]ATP, 0.05 units of viral 
protein kinase (or in some experiments cyclic AMP-dependent 
protein kinase with 0M KC1 and 10]iM cyclic AMP) and peptides 
(at the concentrations indicated in the figure legends of Results, 
Section II, 2). Incubation was for 10min at 30°C, after which 
time the reaction was terminated by addition of 6pl of 20% 
trichloroacetic acid. 60yl of the sample was applied to 
phosphocellulose (P81) paper and washed for 20 min in 0.3% 
orthophosphoric acid and then twice in distilled water for a 
further 40 min. The filters were dried and their radioactivity 
determined by scintillation spectrometry. In control experiments 
the binding to phosphocellulose paper of many of the 
phosphopeptides used here (including one of the least basic ones, 
RPTVA) was checked by comparison with the recovery of 
phosphoserine and phosphothreonine after acid hydrolysis, and 
found to be greater than 90% in all peptides tested. For 
determination of kinetic constants, the concentrations of peptides 
were varied in the appropriate ranges, these being from 2-80pM 
to 0.1-4mM, and values were calculated from double reciprocal 
plots fitted to the Michaelis-Menten Equation.
C. Phosphorylation of Ribosomal 40S Subunits
Ribosomal 40S subunits were prepared as described in Methods, 
Section 2.4 and 2.5, and used as substrates for the viral protein 
kinases. The assay conditions for phosphorylation were as 
described in Methods, Section 5.1 A, but with some modifications.
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The assay volume was reduced to 40pl, O.5A260 units of 
ribosomal 40S subunits in 2-5pl were used instead of 
protamine, and 10pl of enzyme fraction was added. After 
30 min incubation at 30°C the reaction was stopped by adding 
20]il of SDS sample buffer and the products of the 
phosphorylation reaction were analysed by one-dimensional gel 
electrophoresis as described in Methods, Section 4.1,A, employing 
the 15% Acrylamide, 0.02% bisacrylamide system. The gel was then
stained, destained, dried and subjected to autoradiography, all as
described in Methods (Section 4.2A and C).
5.2 Autophosphorylation of Viral Protein Kinases
For assay of autophosphorylation of the purified viral kinases the 
following modifications were made to the standard assay described in 
Methods, Section 5.1 A: Protamine sulphate was omitted, the assay 
volume was decreased to 60]il and the enzyme volume to 20pl, 
the concentration of MgCl2 was 20mM, and the specific radioactivity 
of the ATP was increased by using 0.01mM ATP containing 5]iCi 
[y32P]ATP. The reaction was terminated by the addition of 5
volumes of ice-cold acetone, and maintained at -20°C for 24h to
precipitate the protein, which, after centrifugation (for 10 min in 
an Eppendorf microfuge), was resuspended and concentrated in 
10-20]il of sample buffer in preparation for gel electrophoresis 
under denaturing conditions or isoelectric focussing as described in 
Methods,.Section 4.1 A and B.
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6 EXTRACTION OF PHOSPHORYLATED PEPTIDES FROM P81 PAPER
The phosphorylated peptide was precipitated on P81 filter paper as 
described in Methods Section 5.1B. The phosphopeptide was eluted 
from the paper as follows:
The filter paper was rolled and placed in a thin glass tube within a 
test tube. 300pl of 6M HC1 was added and the tubes were 
centrifuged for 1-2 min in a bench centrifuge. The liquid (HC1 and 
extracted phosphopeptide) was removed from the bottom of the tube and 
transferred to a bulb-shaped glass flask. The procedure was repeated 
5-6 times using 100pl of 6M HC1 each time 2.5ml of 6M HC1 was 
added to the extracted phosphopeptide in the bulb shaped flask. The 
radioactivity of the phosphopeptide was monitored and if sufficient 
radiolabelled phosphopeptide was recovered (at least 10,000cpm 
recorded on a Geiger counter) the phosphopeptide was subjected to 
analysis by high-voltage paper electrophoresis as described in 
Methods, Section 7. Mono- and di-phosphorylated forms of the 
particular peptide could be detected by this method.
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7 ANALYSIS OF PHOSPHOPEPTIDES BY HIGH VOLTAGE PAPER ELECTROPHORESIS
This was performed essentially as described by Donella-Deana et al. 
(1979). Phosphorylated peptides prepared as described in Methods, 
Sections 5.1B and 6 were separated from [y^PjATP in some
instances, their mono- and di-phosphorylated forms resolved by 
high-voltage paper electrophoresis. The sample was dried in a vacuum 
desiccator and the residue resuspended in 0.1ml of electrophoresis 
buffer (2.5% (v/v) formic acid and 7.8% (v/v) acetic acid, pH1.9). 
Aliquots of this sample were applied to Whatman 3MM paper. The paper 
was wetted with buffer and subjected to electrophoresis towards the 
anode at 3000V (150V/cm) for approximately 1-2h.
After electrophoresis, the paper was allowed to dry and analysed.
The radioactivity in the electrophoretogram was sometimes quantified 
with a Packard radiochromatogram scanner, but was routinely subjected tc 
autoradiography using Kodak X-omat XAR5 film and an intensifying 
screen at -80°C. The areas corresponding to the phosphopeptides were 
cut out and their radioactivity was determined by scintillation 
spectrometry, or the phosphopeptide was eluted from the paper as 
described in Methods, Section 6, but using 10% acetic acid so that it 
could be further analysed.
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8 ISOLATION AND ESTIMATION OF LABELLED PHOSPHOAMINO ACIDS
Phosphopeptides prepared as described in Methods, Sections 6 and 7 
were further analysed as follows: Each phosphopeptide was hydrolysed
in approximately 2.5ml of 6M HC1 at 110°C for 4h in sealed flasks.
The reaction was terminated by cooling in ice after the 4h period.
The flask was opened and the solution containing the hydrolysed 
peptide was dried, washed once with 0.5ml of distilled water and 
re-dried in a vacuum desiccator. The dried sample was then 
resuspended in 0.1ml of electrophoresis buffer (described in Methods, 
Section 7). Aliquots of this sample (50|il) were applied to 
Whatman 3MM paper, separately and in a mixture with phosphoamino acid 
standards, o-phosphoserine (20]jg) and o-phosphothreonine 
(20]ig), and 5pCi of ^^Pi was also applied separately to the 
paper. The paper was wetted with buffer and subjected to 
high-voltage paper electrophoresis, as described in Methods, Section 
7, but the duration of the run was increased to 3-4h. After this 
time the electrophoretogram was allowed to dry and analysed. The 
portion of the electrophoretogram containing phosphoamino acid 
markers was stained with a ninihydrin/cadmium acetate solution 
(Dreyer and Bynum, 1967). The portion containing ^^P-labelled 
samples was subjected to autoradiography using Kodak X-omat XAR5 film 
and an intensifying screen at -80°C.
After analysis of the autoradiograph of the electrophoretogram, the 
areas of the electrophoretogram that corresponded to [ ^ P ] s e r i n e  and 
[3^p]threonine were cut out of the paper. The amounts [^P]serine 
and [^^P]threonine were determined by scintillation spectrometry.
The values were corrected for hydrolytic losses of 57% and 18% for 
[ 3 ^ P ] s e r i n e  and [^p]threonine respectively (as determined by Bylung 
and Huang, 1976).
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9 DETERMINATION OF THE CONCENTRATION OF PROTEIN
The concentration of protein was measured by the dye-binding method 
of Bradford (1976) as modified by Spector (1978). Coomassie 
Brilliant Blue G-250 solution (1ml) at a concentration of 0.01% (w/v) 
in 0.95% (v/v) ethanol and 8.5% (w/v) phosphoric acid, was mixed with 
an aliquot of the protein solution (containing up to 20pg of 
protein in Buffer A) and the absorbance at 595nm measured in a 
spectrophotometer. A standard curve was prepared using known 
concentrations of bovine serum albumin.
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10 COMPUTER ANALYSIS
To aid in the identification of possible viral coded substrates for 
the viral protein kinases the whole VZV sequence and the complete Us 
region of HSV-1 and HSV-2 were analysed using the ASTL program (R. 
Eason, University of Glasgow, unpublished). The program allows the 
user to identify in amino acid sequences seryl and threonyl residues 
with either basic or acid environments on their N-terminal or 
C-terminal sides. Visual examination was made of all seryl and 
threonyl residues with at least one basic amino acid residue in the 
five adjacent N-terminal amino acid residues.
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RESULTS
I THE GENETIC ORIGIN OF A NEW PROTEIN KINASE FOUND IN CELLS INFECTED
WITH HERPESVIRUS
The new protein kinase activity detected in cells infected with the 
a-Herpesvirus, PRV, was initially designated ViPK: 
virus-induced protein kinase (Katan et al., 1985). This somewhat 
clumsy name had been deliberately chosen to indicate that the genomic 
origin of the enzyme was unknown. In an attempt to solve the 
question of the genetic origin of the enzyme in the present work 
several indirect approaches were undertaken, and these were 
subsequently followed by more direct genetic and immunochemical 
strategies.
1.1 Characteristics of induction of a new protein kinase in cells 
infected with herpesviruses
As a first step towards answering the question of genomic origin, the 
relationship of the induction of ViPK to the life cycle of the virus 
was examined. Studies were done to see if the characteristics of 
appearance*of ViPK were consistent with those for virally coded 
enzymes.
Experiments were performed to see whether infection of BHK cells with 
another member of the herpesvirus family, HSV-1, caused the induction 
of a protein kinase similar to the ViPK induced by PRV. The 
rationale of this was to examine the two enzyme activities for 
possible structural or functional differences which might suggest 
that the enzymes were distinct entities. Such differences would be 
consistent with the two enzymes being encoded by viral DNA.
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Induction of ViPK by infection with PRV or HSV-1
Because of the number of protein kinases in crude cellular extracts, 
it was necessary to fractionate these extracts by anion-exchange 
chromatography to identify and assay ViPK. This fractionation is 
shown in Fig. 1.1(A) for uninfected cells and in Fig. 1.1(B) for 
cells infected with PRV where, as observed by Katan et al. (1985), an 
additional peak of protein kinase activity was found. This enzyme 
was found to elute at a higher ionic strength (approximately 220mM on 
DEAE-cellulose) than the other protamine kinases. These other 
enzymes were identified as protein kinase C, which eluted at 50-80mM 
KC1, and the so-called protein kinase M, its presumed proteolytic 
derivative. This latter activity eluted at approximately 150mM KC1 
(Fig. 1.1). It has been shown previously that viral infection does 
not influence the yield or relative proportions of these latter 
enzymes (Katan et al. 1985). When cells were infected with HSV-1 
rather than PRV, a new protamine kinase activity was also observed. 
This routinely eluted at a somewhat lower ionic strength than the 
enzyme found in cells infected with PRV, and was sometimes 
incompletely resolved from the kinase M activity (Fig. 1.1D). This 
different chromatographic behaviour was the first indication that the 
enzymes induced by PRV and HSV-1 were different.
Correlation of induction of ViPK with viral infection 
Infection of cells with herpesviruses results in the controlled 
sequential appearance of virus-induced mRNA and proteins (Honess and 
Roizman, 1974; 1975). Experiments were performed to see if it was
possible to correlate the appearance of ViPK with the immediate-early 
(a), early (8) or late (y) viral proteins; and whether
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factors affecting the induction of yirally coded proteins had similar 
effects on the induction of ViPK.
The time at which ViPK appeared in cells infected with PRV or HSV-1 
was examined (Fig. 1.2A and B). There was a steady increase in 
activity during the growth cycle of the virus, and this roughly 
paralleled that of the early ($) protein, viral DNA polymerase, 
and preceeded the release of virus from the cells (Fig. 1.2A).
The amount of ViPK detected depended on the multiplicity of infection 
with either PRV or HSV-1 at multiplicities of up to 20 p.f.u./cell 
(Fig. 1.3). A decreased yield with PRV was obtained at high 
multiplicities, but this was similar to effects observed for other 
enzymes induced by HSV-1 (Perera, 1970). These findings were 
consistent with the possibility that the enzymes induced by PRV and 
HSV-1 were products of early viral genes.
Initial characterization of the catalytic and physical properties of 
ViPKs
In view of the slight differences observed in elution from 
DEAE-cellulose and DEAE-Sephacel chromedia it was necessary to 
determine the extent to which these enzymes had similar catalytic 
properties. In addition to their preference for protamine as an 
artificial substrate, two features were initially observed which 
argued their similarity. Firstly they were both active at 
concentrations of KC1 up to 1M, at least (Fig. 1.4); and secondly 
they were both able to phosphorylate ribosomal protein S7 on 40S 
ribosomal subunits in vitro (Fig. 1.5), a characteristic of ViPK 
previously reported for the enzyme from cells infected with PRV 
(Katan et al., 1985). Other protein kinases (notably protein
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kinase C) do not phosphorylate this protein (Parker et al., 1985).
This characteristic was useful in subsequent experiments for 
confirming a particular enzyme was ViPK. The preparation of ViPK 
from cells infected with HSV-1 was also capable of phosphorylating 
ribosomal protein S6 at low ionic strength (Fig. 1.5), whereas the 
enzyme induced by PRV could only phosphorylate this protein at high 
ionic strength. However the ability of the HSV-1 enzyme preparation 
to phosphorylate ribosomal protein S6 at low ionic strength may be a 
consequence of cross contamination with protein kinase M rather than 
an intrinsic difference from the enzyme isolated from cells infected 
with PRV.
The different chromatographic properties observed on DEAE-Sephacel of 
the ViPKs from cells infected with the different viruses (Fig. 1.1) 
could indicate that the two enzymes are distinct, or it might merely 
be an artefact caused by non-specific association of an identical 
cellular protein kinase with different viral proteins. To 
investigate this further, preparations of ViPK isolated by 
DEAE-Sephacel chromatography of extracts of cells infected with PRV 
or HSV-1 were mixed and subjected to re-chromatography on the high 
performance Mono Q anion exchange column as described in Methods, 
Section 3.6. This resolved the mixture into two peaks of activity 
(Fig. 1.6). Separate chromatography of the two enzymes revealed that 
the first peak represented ViPK from cells infected with HSV-1 and 
the second from cells infected with PRV. This order of elution is 
similar to that from DEAE-cellulose and DEAE-Sephacel. Further 
evidence that the first peak of activity was HSV-1 ViPK was its 
ability to phosphorylate both ribosomal proteins S6 and S7 at 
moderate ionic strength, as had been found for cruder preparations of
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ViPK from cells infected with HSV-1 (Fig. 1.5). Under the same 
conditions the second peak of activity only catalysed the 
phosphorylation of ribosomal protein S7 (inset Fig. 1.6). Because 
the enzymes from the two sources showed apparently genuine 
differences in behaviour in anion-exchange chromatography they were 
subjected separately to another type of fractionation , gel-permeation 
chromatography on Sephacryl S-200 (Fig. 1.7). It was found that the 
apparent relative molecular mass (approximately 200,000) for ViPK 
from cells infected with HSV-1 was much greater than that 
(approximately 90,000) from cells infected with PRV. The fact that 
the chromatography was conducted at 0.5M KC1 would argue against the 
differences being due to non-specific aggregation, but would rather 
imply that two distinct enzymes were involved.
One possible trivial explanation of the different physical properties 
of the ViPK preparations was partial proteolytic cleavage of one of 
the enzymes during extraction from the cells and subsequent 
chromatography. However, when isolation was performed in the 
presence of protease inhibitors (2mM EGTA, 40pg/ml PMSF,
100yg/ml leupeptin) no difference in the position of elution 
from DEAE-Sephacel was observed. Specific intracellular partial 
proteolysis could not, however be excluded at this stage.
Requirement for viral gene expression in the induction of ViPK
Experiments were performed to investigate what role, if any, the 
viral genome played in the induction of ViPK in cells infected with 
HSV-1 or PRV. If ViPK were virally coded or if it required for its 
induction, activation by a virally specified protein; disruption of 
viral gene expression would be expected to affect the appearance of 
ViPK in infected cells.
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It was found that the induction of ViPK was prevented if the virus
was inactivated by ultra-violet light (Fig. 1.8). The result of this
experiment is consistent with there being a need for viral gene 
expression for the induction of ViPK. Inactivation of the virus by
ultra-violet light however, has some limitations. The dose of
ultra-violet radiation necessary to inactivate viral DNA may also 
inactivate proteins of the virion. Thus it could not be completely 
excluded from this experiment that induction of the enzyme only 
requires interaction of virion proteins with the host cell (cf. Kemp 
et al., 1986).
In the case of HSV-1 a less equivocal approach was possible because 
of the availability of temperature-sensitive mutants. The mutant, 
tsK (Preston, 1979) was used, in which a mutation in the 175,000 
molecular weight immediate early protein, a4, prevents the 
synthesis of mRNA for the early and late proteins at the restrictive 
temperature (Watson and Clements, 1980). It was found that ViPK was 
induced at the permissive temperature (31°C) but not at the 
restrictive temperature (38.5°C), even though the enzyme was induced 
by infection with the parent virus at the latter temperature 
(Fig. 1.9). It should be noted that the amount of kinase detected in 
this experiment was less than in other experiments because
Q
circumstances dictated the use of only 5 x 10 cells (rather than the 
5 x 10^  cells of the experiment illustrated in Fig. 1.1). The DNA 
polymerase activity of a portion of the post-ribosomal supernatants 
was also determined in each case, and the results confirmed that 
there was no escape into the synthesis of early viral proteins at the 
restrictive temperature (38.5°C) (Fig. 1.10).
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Therefore the appearance of ViPK in cells infected with PRV or HSV-1 
both required and correlated with the expression of the viral genome. 
However, although viral gene expression was required, a necessary 
condition if ViPK were to be a viral enzyme, the results did not 
exclude the possibility of a newly synthesised viral protein 
activating or stimulating the synthesis of a cellular protein kinase.
1.2 Relation of the protein kinase induced by HSV-1 to the US3 gene
As already mentioned in the Introduction, strong evidence that 
a-herpesviruses do indeed encode a protein kinase came from the 
finding that the amino-acid sequences of the predicted products of 
the US3 gene of HSV-1 and the US2 gene of VZV contain most of the 
sequence motifs of protein kinases. It was now pertinent to 
investigate whether the knowledge of the structure of the gene 
product of US3 could be used to relate it to ViPK.
Two different strategies were followed for this investigation. One 
entailed using a mutant virus with a deleted US3 gene. The other 
involved the use of an antiserum raised against the predicted US3 
gene product.
1. Studies with a Mutant Virus with a Specific Deletion in the US3 
Gene
To determine whether the protein kinase induced by HSV-1 was 
encoded by the open reading frame US3, experiments were 
performed with a mutant virus with a genetically engineered 
deletion in the US3 gene. This mutant was generated by Richard 
Longnecker (University of Chicago), and the construction and
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restoration of the deletion (the latter being conducted during 
a collaboration between RL and the author of this thesis) is 
described briefly below.
Construction and Properties of the HSV-1 Mutants
Four mutants, R7035, R7040, R7041 and R7050 were constructed, 
starting with HSV-1(F)A305 which is a TK" strain derived 
by recombination replacement of the wild-type thymidine kinase 
(TK) gene with a fragment from which 700 bp within the domain
of the TK gene had been deleted (Post and Roizman, 1981).
(i) R7035 contains a chimeric TK gene inserted into the US3
gene of HSV-1(F)A305. It was constructed by 
co-transfection of HSV-1(F)A305 intact TK" viral
DNA with a DNA fragment in which a chimeric TK gene
replaced a small Ncol fragment within the coding region
for US3 (Fig. 1.11, lines 3,8). The chimeric TK gene was 
constructed by fusion of the promoter-regulatory domain 
of the a27 gene to the transcribed non-coding and 
coding sequences of the TK gene. Analysis of 
plaque-purified progeny selected for TK activity verified 
the site of insertion of the chimeric TK gene.
(Longnecker and Roizman, 1987).
(ii) R7040 is a TK" derivative of R7035 containing a deletion 
in the US3 gene. It was constructed by co-transfection 
of intact R7035 viral DNA with plasmid pRB3696 DNA. The 
HSV-1(F) DNA fragment cloned in plasmid pRB3696 
contained a deletion within the US3 coding region from 
the Pst I site located at the predicted amino acid 69 of
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the 5* end of US3 to the Bam HI site located at amino 
acid 357 of US3 (Fig. 1.11, line 9) (Longnecker and 
Roizman, 1987; McGeoch et al., 1985). As a result of the 
deletion, the US3 coding sequences downstream of 
the deletion have been frameshifted (Fig. 1.11, line 9). 
The domains of the coding sequence deleted from the open 
reading frame included the motifs common to protein 
kinases cited in the Introduction and located in 
positions shown in Fig. 1.11, line 10 A and B. Plasmid 
pRB3696 was then co-transfected with intact R7035 DNA 
into rabbit skin cells. TK" progeny was selected in 143 
TK" cells in the presence of bromodeoxyuridine and the 
plaque purified R7040 DNA was shown to lack the sequences 
deleted from pRB3696 DNA (Longnecker and Roizman, 1986; 
1987).
(iii) R7041 is a US3 deletion strain identical,jto R7040 except 
that the 700 bp deletion in the TK gene was restored by 
co-transfection of intact R7040 DNA and Bam HI Q DNA 
cloned as pRB103 into rabbit skin cells. The progeny of 
the transfection were plated on 143 TK" cells and TK+ 
progeny was selected, plaque purified and tested for the 
presence of an intact Bam HI Q fragment (Fig. 1.11 D, 
line 3) with restriction endonucleases (Longnecker and 
Roizman, 1986; 1987). R7041 would be expected to differ
from the wild-type HSV-1(F) solely with respect to the 
deletion in the US3 open reading frame (Fig. 1.11, 
line 5.)
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(iv) Recombinant R7050 is a derivative of R7035 in which the 
US3 gene has been rescued. It was constructed by 
co-transfecting on rabbit skin cells intact R7035 DNA 
with a cloned HSV-1(F) Sac I fragment (pRB3446) 
containing the entire US3 coding region and flanking DNA. 
The progeny of the transfection was plated on 143 TK" 
cells and TK" virus was selected, plaque purified, and 
tested for the presence of an intact Bam HI N DNA 
fragment containing an intact US3 open reading frame.
(v) Recombinant R7051 is a derivative of R7041 in which the 
US3 gene has been rescued. It was constructed by 
co-transfecting on rabbit skin cells intact R7041 DNA 
with an excess of cloned HSV-1(F) Sac I fragment 
(pRB3446) containing the entire US3 coding region and 
flanking DNA. Plaques from the progeny of the 
transfection were selected and viral DNA was isolated 
from these and tested for the presence of an intact Bam 
HI fragment containing an intact US3 open reading frame.
To test whether the HSV-1 induced protein kinase was encoded by 
the open-reading frame US3, BHK (TK+), BHK (TK") and Vero (TK") 
cells were infected with the specially constructed viral 
mutants. Cellular cytoplasmic extracts were then prepared and 
fractionated by anion-exchange chromatography, modified to 
improve the resolution of ViPK from the other protein kinases 
in the extract (Methods, Section 3.1B). Because of the 
instability of the protein kinase C peak of activity in BHK 
cells, which eluted at 0.1M KC1 (Fig. 1.12), Vero
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cells, in which this enzyme activity proved more stable, were 
used for the major experiments. HSV-1(F) could induce ViPK 
well in these cells and highly reproducible relative yields of 
protein kinases C and M obtained.
The results of infection with the mutant viral constructs are 
shown in Fig. 1.13 C and D. It can be seen that the elution 
profile of the protein kinases from extracts of Vero cells 
infected with the US3 deletion strain R7041 (Fig. 1.11) lacks 
the protein kinase activity eluting at 0.22M KC1 in the 
extracts of cells infected with wild-type virus. The profile 
obtained with this mutant is almost identical to that of the 
mock-infected cells (Fig. 1.13). Similar differences 
in the elution patterns were obtained in two independent 
experiments with cytoplasmic extracts of infected Vero cells 
and in two experiments with cellular cytoplasmic extracts of 
infected BHK cells (Fig. 1.12 A and B).
It was necessary to establish that the lack of the 
virus-induced protein kinase activity in cells infected with 
these viral mutants is due to the lack of a functional US3 
gene, and not to a fortuitous mutation introduced into the 
domain of the TK gene during its rescue, and concurrently in 
the genes which partially overlap the TK gene. The US3 open 
reading frame of recombinant virus R7035 was therefore repaired 
and this repaired recombinant virus designated R7050 (Fig. 
1.11). Infection of cells with R7050 resulted in the 
re-appearance of the protein kinase activity induced by the 
wild-type virus (Fig. 1.13 D).
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The rescue of R7035 to R7050, although a persuasive result, 
required further controls. It was necessary to demonstrate 
that R7035, like R7041, did not induce viral kinase activity. 
Further a more direct control would be a rescued strain 
generated from R7041 in a single step. This latter strain, 
R7051, was constructed by Dr. Richard Longnecker, as already 
noted above. Strain R7051 and R7035, together with HSV-1(F) 
and R7041, were used in further experiments to infect BHK cells 
(Fig. 1.12 B). It can be seen that R7035 did not induce the 
viral protein kinase whereas the strain R7051, directly rescued 
from R7041, did. In this experiment there was loss of protein 
kinase C in the case of R7041. However, the inability of R7041 
to induce viral protein kinase had already been demonstrated in 
BHK and Vero cells under conditions when there was no loss of 
protein kinase C (Fig. 1.12 A and 1.13). To control for the 
possibility that the inability of R7041 to induce the protein 
kinase reflected poor growth of this strain, two additional 
experiments were done. The results of the first, summarized in 
Table 1.1, shows that similar yields of virus were obtained 
from duplicate Vero roller bottle cultures I8h after infection 
with R7041, R7050 and HSV-1(F) under conditions similar to 
those used for the preparation of extracts tested for protein 
kinase activity. In the second experiment, samples of the 
cytoplasmic cellular extracts previously used for the 
determination of the protein kinase activity were tested for 
the presence of glycoprotein B. In these experiments, 
identical amounts of total protein from the cell extracts were
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electrophoretically separated in denaturing polyacrylamide 
gels, transferred to nitrocellulose and reacted with monoclonal 
antibody H1163, specific for HSV-1(F) glycoprotein B (all as 
described in Methods, Section 4.3(H)). The results shown in 
Fig. 1.14 indicate that the cell extracts of R7041, R7050 and 
HSV-1(F) contained similar amounts of glycoprotein B, and 
confirm that the infection with the viral mutants was as good 
as that with the wild-type.
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2. Studies with an Antiserum raised against a Synthetic
Oligopeptide from the predicted product of the HSV-1 Gene US3
Experiments were performed with an antiserum raised by Margaret 
Frame (Virology Dept., University of Glasgow) against an 
oligopeptide in the US3 gene. The peptide used was: 
NH2-Tyr-Cys-Leu-Pro-Leu-Phe-Gln-Gln-Lys-C00H 
which represents the 8 carboxyl amino acids (474-481) together 
with an additional tyrosine residue (not specified by the US3 
sequence) at the N-terminus, to allow coupling to bovine serum 
albumin. Rabbits were immunised with the peptide-serum albumin 
conjugate and the anti-serum albumin antibodies were removed 
from the immune sera generated by adsorption with serum 
albumin. The resulting antiserum was designated anti-US3 
serum.
This antiserum was used in immunoblotting experiments to detect 
the protein product of the US3 gene. Proteins extracted from 
BHK cells infected with 20 p.f.u./cell HSV-1(G) for I8h and 
labelled with 100viCi/ml[^^S] methionine were electro- 
phoretically separated on a 10% SDS-polyacrylamide gel and 
transferred to nitrocellulose strips all as described in 
Methods, Section 4.1 and 4.3. Antigens immobilised on the 
nitrocellulose were detected by the antibody and [^**1] protein A
s
(Methods, Section 4.3(i)).
The product of the US3 gene was detected as a 68,000 molecular 
weight protein (Fig. 1.15, lanes 2 and 3). It can be seen that 
the anti-US3 serum also weakly immunoblotted a lower molecular
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weight species of 50,000 molecular weight (Fig. 1.15, lane 2). 
This may be related to the 68,000 molecular weight polypeptide, 
perhaps as a cleavage product of this. No reaction was seen 
when the antiserum was blotted against an extract from 
mock-infected cells. To determine whether or not the 68,000 
molecular weight protein recognised by the anti-US3 serum was 
the protein kinase induced by HSV-1, the enzyme was purified 
from cellular cytoplasmic extracts of BHK cells infected for 
I8h with HSV-1(G) at a multiplicity of infection of 10 
p.f.u./cell as described in Methods, Sections 1.3 and 2.3.
This entailed successive chromatography cn DEAE-cellulose, TSK 
phenyl-5PW, threonine-sepharose and protamine-agarose. This is 
described in Methods, Sections 3.1C-3.4 and illustrated in 
Results, Section II.
Although the final preparation of the protein kinase was not 
homogeneous, it contained only two major bands when analysed by 
polyacrylamide gel electrophoresis under denaturing conditions 
(Results, Section II, Fig. 2.8). The anti-US3 serum was used 
in immunoblotting experiments with material from various stages 
of the purification and with a purified preparation of protein 
kinase C as a control. After the threonine-sepharose stage of 
the purification a 68,000 molecular weight protein was detected 
by the anti-US3 serum at a low level. (Fig. 1.16 lanes 5 and 
6). After the protamine-agarose stage the amount of the 68,000 
molecular weight species detected was increased considerably 
(Fig. 1.16, lanes 2 and 3). The US3-antiserum showed no 
reaction with homogeneous protein kinase C, another protein 
kinase capable of phosphorylating protamine (Fig. 1.16, lanes 8
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and 9). A number of unrelated anti-peptide sera, including 
that shown in Fig. 1.16 against the immediate-early polypeptide 
product of gene aO(1E 110) of HSV-1 (Perry et al., 1986) were 
used and showed no reaction with any of the protein kinase 
preparations. These served as controls against the possibility 
that a component of the anti-US3 serum, other than the US3 
antibodies, might be binding non-specifically or specifically 
to the 68,000 molecular weight protein. Although there may not 
appear to be much difference in intensity of the reaction of 
crude extracts and enzyme purified to the protamine-agarose 
stage, it should be pointed out that approximately 2000 times 
more crude extract protein than protamine-agarose purified 
protein was loaded on the gel (Fig. 1.15). Thus the amount of 
the 68,000 molecular weight US3 product detected in the 
purified material after affinity chromatography on 
protamine-agarose correlated well with the increase in the 
specific activity of the viral kinase (Results, Section II, 
Table 2.2(A)).
Further evidence consistent with the 68,000 molecular weight 
polypeptide detected by immunoblotting being a protein kinase 
was obtained from autophosphorylation of the preparation (Fig. 
1.16). This is discussed in more detail in Results, Section II, 
where the purification of the protein kinase is presented. 
However, at this juncture what is pertinent to mention is the 
fact that autophosphorylation resulted in the labelling of a 
protein of Mr 68,000, the same value obtained for the 
immunoblotting.
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Considered together, all the results presented in Section I 
provide overwhelming evidence that the ViPK is the product of 
the HSV-1 US3 gene. This will be argued in detail in the 
discussion. However, it would appear justified, from this 
point in the thesis onwards, to refer to the protein kinase as 
the protein kinase specified by the particular herpesvirus, 
namely HSV-1 PK and PRV PK.
Page 121
Page 122
Fig. 1.1 DEAE-Sephacel Column Chromatography of Protein Kinases from BHK
Cells Infected with Herpesviruses
Mock-infected BHK cells (A,C), or (B) cells infected for 8h 
with PRV, or (D) for I8h with HSV-1(G), were processed as 
described in Methods, Section 2.3, and their post-ribosomal 
supernatants were subjected to anion-exchange chromatography on 
DEAE-Sephacel as described in Methods, Section 3.1.
The protein kinase activity (»-•) of a 40jjl aliquot of each 
column fraction was assayed with protamine as a substrate 
employing the standard protein kinase assay conditions 
described in Methods, Section 4.1 A.
The KC1 concentration (— ) of the column fractions was also 
determined from conductivity measurements.
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Fig. 1.2 Temporal Relationship of Appearance of ViPK to other Events
During the Infection of BHK Cells with the Two 
Alpha-Herpesviruses PRV and HSV-1
BHK cells were infected (A) with PRV, or (B) with HSV-1(G), as 
described in Methods, Sections 1.2 and 1.3, and the 
post-ribosomal supernatants isolated at the times indicated.
The major portions of these were subjected to chromatography on 
DEAE-Sephacel as in Fig. 1.1, and a 40pl aliquot of each 
column fraction assayed for protein kinase activity. The total 
ViPK activity («-«) was estimated and expressed as a percentage 
of the maximum value, as was the DNA polymerase activity (o-o) 
assayed on a small: portion of the original post-ribosomal 
supernatant.
(The initial DNA polymerase activity is that of the host 
enzyme). The number of p.f.u. of virus in the growth medium 
was also determined^— ■).
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Fig. 1.3 Effect of Multiplicity of Infection with PRV or HSV-1 on the
Yield of ViPK
BHK cells were infected for 8h with PRV with input 
multiplicities of 1, 5, 20, 40 and 100 p.f.u./cell, or for I8h 
with HSV-1(G) at input multiplicities of 1, 5 and 20 p.f.u./ 
cell. Post-ribosomal supernatants were prepared from each 
condition as described in Methods, Section 2.3.
These were subjected to DEAE-Sephacel chromatography and column 
fractions were assayed for protein kinase activity. The total 
PRV ViPK (•-•) and HSV-1 ViPK (o-o) activity was estimated in 
each condition.
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Fig. 1.4 Effect of KC1 on the Activity of PRV ViPK and HSV-1 ViPK
Partially purified ViPK preparations (40pl) obtained by 
chromatography on DEAE-Sephacel (Fig. 1.1) were used to 
phosphorylate protamine at various concentrations of KC1 at 
10mM MgCl2. The enzyme prepared from cells infected with PRV 
(#-») was compared with that obtained from cells infected with 
HSV-1(G) (■-■).
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Fig. 1.5 Phosphorylation of Ribosomal Proteins by ViPK from BHK Cells
Infected with Herpesviruses
Partially purified ViPK preparations obtained by chromatography 
on DEAE-Sephacel (Fig. 1.1) were used to phosphorylate BHK 40S 
ribosomal subunits in vitro at 150mM KC1 and these were 
subjected to SDS-polyacrylamide gel electrophoresis, all as 
described in Methods, Sections 5.1C and 4.1 A.
An autoradiograph of the dried gel is presented.
(A) ViPK from BHK cells infected with PRV.
(B) ViPK from BHK cells infected with HSV-1(G).
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Fig. 1.6 Resolution of ViPK Activities by High Performance
Anion-Exchange Chromatography on Mono Q
Equal activities of ViPK, partially purified from BHK cells 
infected with PRV or HSV-1(G) by chromatography of 
post-ribosomal supernatants on DEAE-Sephacel, were combined and 
subjected to chromatography on Mono Q (Methods, Section 3.6). 
Fractions, the WaCl concentrations of which are indicated 
(— ), were assayed for protein kinase activity («-#).
Standard assay conditions were used, i.e. 40pl aliquots of 
the column fractions were used to phosphorylate protamine 
sulphate as described in Methods, Section 5.1 A.
The absorbance at 280nm (— ) is also shown. The inset shows 
the result of phosphorylation of 40S ribosomal subunits by the 
ViPK peaks 1 and 2, performed as described in Methods, Section 
5.1C at 50mM KC1 and 80mM NaCl and 10mM MgCl2-
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Fig. 1.7 Gel-Permeation Chromatography on Sephacryl S-200
Preparations of ViPK, partially purified by DEAE-Sephacel 
anion-exchange chromatography from BHK cells infected with PRV 
(•-•) or HSV-1(G) (o-o), were concentrated. These preparations 
(each containing approximately 1mg of protein) were separately 
subjected to chromatography on sephacryl S-200 in a buffer 
containing 500mM KC1, 1mM EDTA, 10mM 2-mercaptoethanol, 20mM 
Tris-HCl (pH7.6) as described in Methods, Section 3.8.
Aliquots (40ul) of the column fractions were assayed for 
protein kinase activity using protamine as substrate.
The positions of elution of proteins of known relative 
molecular mass (Mr) are indicated and the inset shows a 
semilogarithmic plot of Mr X 10“  ^against Kav 
[(Ve-V0)/(VfV0)], where Ve is the elution volume, V0 the void 
volume and Vt the column volume.
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Fig. 1.8 Effect of Irradiation with Ultra-Violet Light on the Ability of
PRV to Cause the Induction of ViPK in BHK Cells
BHK Cells were infected for 8h with 20 p.f.u./cell PRV (A), or
with an equivalent amount of virus that had been subjected to
p
5kJ/m ultra-violet radiation (B), as described in Methods, 
Sections 1.2 and 1.12.
The post-ribosomal supernatants were isolated, subjected to 
chromatography on DEAE-Sephacel and fractions, the KC1 
concentrations of which are indicated (— ), were assayed for 
protein kinase activity (•-•).
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Fig. 1.9 Induction of ViPK in BHK Cells Infected with the tsK Mutant of
HSV-1(G)
BHK cells were infected with tsK (10 p.f.u./cell) at either 
31°C (A), or 38.5°C (B), or with the parent wild-type virus at 
38.5°C (C), and harvested I8h later. The post-ribosomal 
supernatants were isolated, subjected to chromatography on 
DEAE-Sephacel using a somewhat shallower gradient than 
elsewhere (Fig. 1.1).
40]il aliquots of the column fractions were assayed for 
protein kinase activity with the substrate protamine (•-•). 
(Methods, Section 5.1A). The KC1 concentrations of the 
fractions are indicated (— ).
ViPK is indicted by the arrows, eluting at approximately 220mM 
KC1.
Pr
ot
ei
n 
ki
na
se
 
ac
ti
vi
ty
 
(c
.p
.m
. 
x 
10
~3
4
2
0
4
2
0
ViPK
4
'v
2
0
400
300
200
100
0
400
300
200
100
0
400
300
200
100
0
Fraction number
K
C
l(m
M
) 
KC
l 
(m
M)
 
KC
I 
(m
M)
Page 140
Fig. 1.10 DNA Polymerase Activity in BHK Cells Infected with the tsK
Mutant of HSV-1(G) at either 31°C or 38.5°C, or with the 
Parent Wild-Type Virus at 38.5°C.
Time courses of appearance of viral DMA polymerase were 
performed over a 60 minute incubation period.
The early or 8 viral protein, DNA polymerase, was assayed 
(Methods, Section 1.13) in a sample of the post-ribosomal 
supernatant prepared from cells infected for I8h with the 
various viruses at the appropriate temperatures.
(«-®) tsK at the permissive temperature (31°C)
(A-A) tsK at the restrictive temperature (38.5°C)
(■-■) HSV-1(G) at the restrictive temperature (38.5°C)
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Fig. 1.11 Schematic Representations in the DNA Sequence Arrangements in
HSV-1(F) and the HSV-1(F) Recombinants R7035, R7040, R7041 and 
R7050
Panel A: The boxes in lines 1-5 represent the terminal
sequences that are repeated internally and divide the HSV-1(F) 
genome into the long (L) and short (S) components.
Line 1: Sequence arrangement in the HSV-1(F) genome. TK and
US3 indicate the locations of the thymidine kinase gene and of 
US3 open reading frame, respectively.
Lines 2-5: Sequence arrangement of the various viral
recombinants. The genotype of each of the viral recombinants 
is indicated.
Panel B: Lines 6 and 7 show the two species of mRNA that are
encoded by the US3 open reading frame (McGeoch et al., 1985; 
McGeoch and Davison, 1986). The boxes indicate the translated 
portion of the mRNA.
Line 8: Pertinent restriction endonuclease sites located
within the US3 coding region (Ps = Pst I, Nc = Nco I, and 
Ba = Bam HI). The Nco I sites indicate the insertion site of 
the a27-TK. The sequences intervening between the Pst I 
site and Bam HI site were deleted in the R7040 and R7041 viral 
genomes. As a result of the deletion the protein encoded by 
the US3 mRNA is out of frame downstream (3*) to the Bam HI 
site. Numbers in lines 7 and 8 correspond to the predicted 
amino acid number in the predicted translation product of the 
US3 open reading frame.
Line 10: The short line designated as A indicates the position
of the motifs thought to constitute the nucleotide binding 
site. The longer line designated as B indicates the position 
of the domain containing the other motifs shared by known 
protein kinases (Hunter and Cooper; 1985, McGeoch and Davison; 
1986) .
Panel C: Shows the structure of plasmid inserts containing
intact and deleted versions of the US3 gene of HSV-1(F).
Panel D: Shows a restriction endonuclease map of the HSV-1(F)
genome showing the position of the Bam HI Q and N fragments.
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Fig. 1.12A DEAE-Cellulose Chromatography of Protein Kinases from
Cytoplasmic Extracts of BHK Cells Infected with Different 
Strains of HSV-1(F)
BHK cells (15 roller bottles containing a total of 
approximately 3 x 10^  cells) were infected with either HSV-1(F) 
or R7041 at 10 p.f.u./cell, and harvested 17h after infection 
all as described in Methods, Section 1.3. A cellular 
cytoplasmic extract was prepared for each condition and 
subjected to DEAE-cellulose chromatography (Methods, Section 
3.1B). The column was eluted with a linear gradient of KC1 
(— ). 80pl aliquots of each column fraction was assayed 
for protein kinase activity using protamine as a substrate 
all as described in Methods, Section (5.1A): (•-•) (HSV-1(F)
and (o-o) R7041. Arrow indicates the protein kinase activity 
found only in cells infected with HSV-1(F).
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Fig. 1.12B DEAE-Cellulose Chromatography of Protein Kinases from
Cytoplasmic Extracts of BHK Cells Infected with Different 
Strains of HSV-1(F)
BHK cells (15 roller bottles containing a total of 
approximately 3 x 10^  cells) were infected with either 
HSV-KF), R7041, R7035 or R7051, with a total of 5.5 x 1010 
p.f.u. virus/condition, and harvested 17h after infection. A 
cellular cytoplasmic extract was prepared for each condition 
and subjected to DEAE-cellulose chromatography on a 5 x 1.6 cm 
(ht x diameter) column at a flow rate of 60ml/hr, 5 ml 
fractions being collected. The column was eluted with a linear 
gradient of KC1.
80)il aliquots of each column fraction were assayed for 
protein kinase activity using protamine as a substrate (•-•) 
(Methods, Section (5.1A)).
The arrows indicate the protein kinase activity found only in 
cells infected with wild-type F or the rescued US3 R7051 mutant 
virus of HSV-KF).
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Fig. 1.13 DEAE-Cellulose Chromatography of Protein Kinases from
Cytoplasmic Extracts of Vero Cells Infected with Different 
Strains of HSV-1(F)
Vero cells (15 roller bottles containing a total of 
approximately 3 x 10^  cells) were infected with either 
HSV-KF), R7041, R7050, or mock-infected at 10-15 p.f.u./cell, 
and harvested 17h after infection, all as described in Methods, 
Section 1.3.
A cellular cytoplasmic extract of Vero cells was prepared for 
each condition and subjected to DEAE-cellulose chromatography 
by adsorbing the extract onto DE-52 and eluted with a gradient
of KC1 (--). 80pl aliquots of each column fraction was
assayed for protein kinase activity using protamine as a 
substrate (•-•), all as described in Methods, Sections 2.3,
3.1B and 5.1A. The elution profiles illustrated are:
A. Mock-infected
B. HSV-KF)
C. R7041
D. R7050
The structures of the recombinants are shown in Fig. 1.11.
The arrows indicate the protein kinase activity found only in 
cells infected with wild-type F or the rescued US3 R7050 mutant 
virus of HSV-KF).
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Fig. 1.14 Titration of the Glycoprotein B Synthesised in Vero Cells Mock-
Infected or Infected with the. Wild-Type Parent Strain HSV-KF) 
and the Recombinant Viruses R7041 and R7050 
Mock-infected or infected cell proteins were solubilized, 
dissolved in sample buffer and subjected to polyacrylamide gel 
electrophoresis under denaturing conditions as described in 
Methods, Section 4.1 A.
The separated proteins were then electrically transferred to 
nitrocellulose, and reacted with monoclonal antibody H1163 to 
glycoprotein B in an immunoperoxidase-coupled reaction, as 
described in Methods, Section 4.3(ii).
Protein concentrations were determined by the method of 
Bradford (1976) and the amount loaded in each lane is indicated 
in the figure.
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Fig. 1.15 Idenbificabion of HSV-1 US^ Gene Product bv Immunoblofcbing
Extracts of BHK cells infected with HSV-1 at a multiplicity of
20 p.f.u./cell for I8h and labelled with [^S]methionine were
prepared (Methods, Sections 1.3 and 2.1). The proteins were
solubilised, dissolved in sample buffer and separated on a W
SDS polyacrylamide gel as described in Methods* Section 4.1A. d-)
-Pro/v\ ukr\\aJoeAled cells 
The separated proteins^were blotted onto nitrocellulose
(650/ig protein per strip) probed with anti-US3 serum (A/US3)
at 1:2 dilution (lane 2), 1:10 dilution (lane 3)» and normal
rabbit serum (NRS) at a 1:2 dilution (lane 4), all as described
in Methods, Section 4.3* Lane 1 shows the blotted i n f e c t e d ( < s b e / / e
cell polypeptide profile. The molecular weights of known viral
polypeptides are shown on the left-hand side.
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Fig. 1.16 Detection of the US3 Gene Product in Purified Preparations of
HSV-1 PK
HSV-1 PK preparations after the threonine-sepharose (5)ig 
protein/strip) and after the protamine-agarose stage (1pg 
protein/strip) of the purification scheme (described in 
Methods, Section 3) were blotted and probed with anti-US3 serum 
at a 1:2 dilution (lanes 5 and 2), or a 1:10 dilution (lanes 6 
and 3); or with a 1:2 dilution (lanes 4 and 7) of control 
anti-oligo peptide serum against the viral immediate-early 
polypeptide IE 110, (a0) (C).
A purified protein kinase C preparation was included as an 
antigen control and probed with 1:2 and 1:10 dilutions of the 
anti-US3 antiserum (lanes 8 and 9), or the control antiserum 
(lane 10). Lane 1 shown an infected cell polypeptide profile 
blotted from the same polyacrylamide gel of l&besll&cl CB-lls.
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RESULTS TABLE 1.1
Table 1.1 Titres of HSV-1(F) and Recombinant Viruses R7041 and R7050 
obtained in replicate Roller Bobble Cultures of Vero Cells.
Vero cells were harvested I8h after infection with 10-15 
p.f.u./cell of the appropriate virus and centrifuged for 10 min 
at 2000 rpm (500g) to sediment the cells and virus. The cells 
and virus were resuspended in growth medium, sonicated and the 
virus was titred on Vero cell monolayer cultures, as described 
in Methods, Section 1.9C.
Virus Titre (p.f.u. per ml x 10"^ )
HSV-1(F) 4.8
R7041 7.9
R7050 3.6
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II PURIFICATION AND SUBSTRATE-SPECIFICITY OF HSV-1 PK AND PRV PK
1 PURIFICATION
1.1 Complete purification of the pseudorabies virus protein kinase;
PRV PK
A partial purification of PRV PK has been described previously (Katan 
et al., 1985). This employed DEAE-cellulose, high performance 
gel-permeation and high performance anion-exchange chromatography, 
and resulted in a preparation with a specific activity of 
approximately 30 units/mg. Although this was a satisfactory method 
for resolving PRV PK from other known protein kinases in order to 
obtain an initial characterization, the specific activity it yielded 
fell far- short of the 1000-5000 units/mg of most homogeneous protein 
kinases (e.g. Beavo et al., 1974: Parker et al., 1984). To attempt
to achieve complete purification from the limited amounts of material 
provided by infected tissue culture cells it was necessary to devise 
an alternative strategy employing a relatively small number of more 
powerful steps. These latter were, in fact, suggested by the 
characteristics of partially purified preparations of the enzyme.
The exact details of the complete purification of PRV PK are 
presented in Methods, Section 3.
The first steps of the purification entailed the preparation of a 
cellular cytoplasmic extract (also referred to as a post-ribosomal 
supernatant), as previously described in Methods, Section 2.3, 
followed by anion-exchange chromatography (Fig. 2.1). This was 
followed by hydrophobic-interaction chromatography, a step suggested 
by the peculiar stability of the enzyme at high ionic strength and 
its activity in the presence of non-ionic detergent NP40 at 10%.
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Initially phenyl-sepharose CL-4B (Pharmacia) was used; but this was 
subsequently replaced by a rapid HPLC system employing a TSK 
phenyl-5PW column, the high capacity of which allows the material for 
one preparation to be subjected to chromatography in a single run 
(Fig. 2.2k). The next step, the threonine-sepharose affinity 
chromatography (Fig. 2.2B), was employed after it emerged that PRV PK 
could catalyse the transfer of phosphoryl groups to threonyl residues 
(Results, Section II, 2, Fig. 2.15). The final purification step, 
protamine-agarose chromatography (Fig. 2.2C), was also an affinity 
method. However, this capitalised on a different facet of the 
substrate specificity of the enzyme, its preference for a highly 
basic environment at the target seryl or threonyl residue. Table 2.1 
shows quantitive data for the purification. It can be seen that one 
of the most significant features of the purification was the high 
specific activity (1000 units/mg) achieved. The other salient 
feature was the single 38,000 Mr band stained with Coomassie 
Brilliant Blue, obtained when the preparation from the last stage of 
purification was subjected to gel-electrophoresis under denaturing 
conditions (Fig. 2.3). Although in some preparations silver staining 
revealed a slight contamination with the 55,000 Mr band from the 
threonine-sepharose stage, it seems most likely that the 38,000 Mr 
band (Fig. 2.3, lanes 5 and 6) corresponds to PRV PK.
The overall 446-fold purification given in Table 2.1 is almost 
certainly an underestimation, perhaps by a factor of 10. This is 
because, although accurate estimations of PRV PK in the crude 
post-ribosomal supernatant fraction could not be done, because of the 
other contaminating kinases present at this stage, it seems unlikely 
that the DEAE-cellulose step would have not resulted in any increase
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in specific activity. The relatively good 23% overall recovery may, 
likewise, be a slight overestimation if there were incomplete 
recovery at the DEAE-cellulose stage.
To obtain a further perspective on the relationship of the 38,000 Mr 
band of Fig. 2.3 to the enzymic activity, the ability of PRV PK to 
undergo the so-called "autophosphorylation" reaction was 
investigated. This phenomenon appears to be a feature of many, if 
not all protein kinases (Introduction, Section 1.1), In the absence 
of added substrates the 38,000 Mr band in the most purified 
preparation of PRV PK did become phosphorylated (Fig. 2.4). The
38,000 Mr band was also the major phosphorylated protein when a 
preparation from the previous step was used, even though other 
stained bands predominated in this latter case. The results were 
completely consistent with the conclusion that the 38,000 Mr band was 
PRV PK.
The Mr 38,000 obtained for the stainable protein of purified PRV PK 
when subjected to gel-electrophoresis under denaturing conditions 
(Fig. 2.3) constrasted markedly with a value of 68,000 for that of 
the enzyme activity in a partially purified preparation obtained by 
gel-permeation chromatography and, consistent with this, a 
sed[mentation value on sucrose density gradient centrifugation 
similar to that of serum albumin (Katan et al., 1985). It was 
therefore necessary to re-examine the native Mr value using the most 
purified enzyme preparation. A Superose 12 high performance 
gel-exclusion column was used for this purpose (Methods,
Section 3.5A). All the enzyme activity eluted at a position which 
corresponded to a Mr of approximately 70,000, as did the protein
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(Fig. 2.5). Analysis of this latter by denaturing 
gel-electrophoresis again showed a Mr of 38,000 and an ability to 
undergo autophosphorylation (inset, Fig. 2.5). It therefore seems 
most likely that the native form of PRV PK comprises two identical 
subunits.
Another physical characteristic of PRV PK which was determined was 
its isoelectric point. The 01Farrell two-dimension electrophoresis 
system was employed (Methods, Section 4.1B) and autophosphorylated 
enzyme was used for ease of detection. The value obtained (Fig. 2.6) 
was approximately pH 4.9 for the phosphorylated form of the enzyme. 
That of the unphosphorylated form is presumably somewhat higher.
This rather low value is consistent with the relatively high 
concentration of KC1 required to elute PRV PK from DEAE-Sephacel 
(Fig. 1.1) and DEAE-cellulose (Fig. 2.1).
1.2 Partial purification of the Herpes Simplex Type-1 protein kinase, 
HSV-1 PK
HSV-1 PK was purified from cellular cytoplasmic extracts of BHK cells 
infected for I8h with HSV-1 at a multiplicity of infection of 10 
p.f.u./cell. The same chromatographic methods used for the 
purification of PRV PK were applied to purify HSV-1 PK, with and 
without the threonine-sepharose stage (Fig. 2.7). The combined 
separation techniques were not as effective for the purification of 
HSV-1 PK as they had been for PRV PK. This is not unreasonable, as 
HSV-1 PK eluted differently from DEAE-cellulose and at each stage of 
its purification the proteins present in the mixture would be 
different from those present during the purification of PRV PK.
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Although the final preparation of purified HSV-1 PK was not 
homogeneous, it nevertheless contained only two major bands of 
apparent molecular weights 68,000 and 61,000 when analysed by 
gel-electrophoresis under denaturing conditions (Fig. 2.8). Because 
the power of the chromatography methods employed has already been 
demonstrated for the purification of PRV PK, it is reasonable to 
consider that one of the two major bands may be HSV-1 PK, even though 
the highest specific activity obtained so far was only 200 units/mg. 
This is because both this final specific activity and the apparently 
modest 94-fold increase from the DEAE-cellulose stage (Table 2.2(A)) 
are almost certainly underestimates of the protein purification 
because of the poor overall recovery of activity compared with PRV 
PK. This can be attributed to a very v&rid hie initial specific 
activity: routinely five to ten-fold lower yields of HSV-1 PK were
obtained at the outset. Consistent with this interpretation was the 
fact that loss of activity was less (Table 2.2B) when the 
threonine-sepharose stage was omitted and the protamine-agarose 
column eluted with a linear gradient of KC1 (Fig. 2.7).
Further circumstancial evidence that the protein kinase was one of 
the two major components of the most purified preparation of HSV-1 PK 
was provided by autophosphorylation experiments. The most purified 
preparation of HSV-1 PK could autophosphorylate, and a single major 
phosphorylated species with Mr 68,000 was detected after analysis by 
gel-electrophoresis under denaturing conditions (Fig. 2.9). It can 
be seen that autophosphorylation could not be detected in the 
previous stage of the purification,where the protein complexity is
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much greater. It has already been mentioned that this 68,000 Mr 
protein corresponded to the polypeptide which reacted with the 
anti-US3 serum (Results, Section I and Fig. 1.16).
The isoelectric point of the autophosphorylated form of HSV-1 PK was 
also determined. A value of pH 5.6 (Fig. 2.10) was obtained, which 
was somewhat greater than the pH 4.9 previously found for PRV PK, but 
is consistent with the respective positions of elution of HSV-1 PK 
and PRV PK from DEAE-cellulose.
High performance gel-exclusion chromatography using a Superose 6 
column (Methods, Section 3.5B) revealed that HSV-1 PK eluted at 
approximately the same position as aldolase, a protein of Mr 158,000 
(Fig. 2.11). Because of the poor resolution of proteins above Mr
100,000 on this column, it was not possible to determine a more 
accurate molecular weight. However the result obtained suggested 
that HSV-1 PK was not a monomer but possesses a multimeric structure, 
most probably as a homodimer, which would be consistent with the 
indications for PRV PK.
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Fig. 2.1 Scheme for the Complete Purification of PRV PK and the Partial
Purification of HSV-1 PK
(A) The post-ribosomal supernatant from BHK cells
10(approximately 10 cells) was subjected to chromatography 
on a DEAE-cellulose column (Methods, Section 3.1C).
Column fractions were assayed for protein kinase activity 
with the substrate, protamine (•-©). The KC1 gradient
(--- ) was determined by conductivity measurements and the
absorbance of column fractions was measured at 280nm
(B) Fractions containing ViPK activity were pooled and 5-6 
such preparations were concentrated by Aquacide II and 
subjected to further purification by the schemes shown.
Pr
ot
ei
n 
ki
na
se
 
ac
ti
vi
ty
 
(c
ou
nt
s 
per
 m
in 
x1
0_
3)
«-
80-
60-
o .
2 0 -
100
Fraction number
Concentration 
by aquaelde\
High performance hydrophobic 
chromatography
Aff Ini ty chromatography 
threonine - sepharose
Aff lnl ty chromatography 
protamine - agarose
Partially 
purified 
HSV-l PK
High performance size exclusion 
chromatography
Purified PRV V I P K .
r 0.3
-0.25
-0.2
-0.15
- 0.1
-0.05
-0
[K
C1
1 
(M
)-
-
Page 166
Fig. 2.2 Chromatographic Purification of Pseudorabies Virus Protein
Kinase, PRV PK
1 nPost-ribosomal supernatant from approximately 10 cells 
infected with PRV (20 p.f.u./cell) was subjected to 
DEAE-cellulose chromatography and active fractions were 
combined.
4-5 such preparations were concentrated and then subjected to 
successive chromatography on (A) TSK phenyl-5PW, (B) 
threonine-sepharose, and (C) protamine-agarose, as described in 
Methods, Section 3.
Aliquots (40]il) of the fractions indicated were assayed for 
protein kinase activity using protamine as substrate (•-#).
The protein concentration or A280 fractions (---), as
indicated, and the concentration of the salt used to develop 
each particular column (--), are also presented.
The arrows in A indicate the multiple injections of sample.
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F ig . 2 .3  P o ly a c ry la m id e  G el A n a ly s is  o f  PRV PK a t  D i f f e r e n t  S tages o f
Purification
One-dimensional gel electrophoresis under denaturing conditions
was performed as described in Methods, Section 4.1 A on protein
from the different stages of purification listed in Table 2.1
lane 1 - post-ribosomal supernatant (25ug)
lane 2 - DEAE-cellulose stage (25]ig)
lane 3 - TSK phenyl-5PW stage (25ug)
lane 4 - threonine-sepharose stage (25ug)
lane 5 - protamine-agarose stage (5pg)
lane 6 - protamine-agarose stage (7pg)
The electrophoretic separation from which lane 6 is taken 
employed narrower wells and a thinner gel to facilitate 
visualisation. This was a different gel with greater 
electrical resistance, and the protein migrated a shorter 
distance compared with lane 5, but still at the 38,000 Mr 
position as determined from standard proteins.
Photographs of gels stained with Coomassie Brilliant Blue are 
presented, and the positions of migration of proteins of known 
Mr are indicated.
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F ig .  2 .4  A u to p h o sp h o ry la tio n  o f  PRV PK
Enzyme (c o n ta in in g  1 .5 ]ig  p ro te in  p u r i f ie d  to  e i t h e r :  1, 2 ,
the threonine-sepharose stage or, 3, 4, the protamine-agarose 
stage) was subjected to phosphorylation in the absence of 
exogenous substrate and prepared for gel electrophoresis, as 
described in Methods, Section 4.1 A and 5.2.
Polyacrylamide gel electrophoresis was performed under 
denaturing conditions, the gel stained with Silver (1, 3), 
dried, and subjected to autoradiography (2, 4), all as 
described in Methods, Sections 4.1 and 4.2B.
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Fig. 2.5 High-Performance Gel-Exclusion Chromatography of PRV PK on
Superose 12
Purified enzyme was concentrated and subjected to 
chromatography on Superose 12 as described in Methods, Section 
3.5A, and the protein kinase activity (o-o) of fractions
determined. The A28O (---) fractions is also indicated, the
increase after fraction 20 being non-protein in origin. The 
positions of elution of aldolase, serum albumin, ovalbumin and 
myoglobin are indicated by arrows surmounted by the Mr (x 10“ )^ 
of each individual protein. The inset shown the results of two 
separate gel electrophoretic analyses of aliquots of fractions 
13- 1 6 :
A. photograph of silver stained gel (80pl applied),
B. autoradiograph of gel lane of sample (lOOpl) subjected 
to autophosphorylation, the Mr of the band being indicated.
00 UD cr OJ o
•— •
(r o L x u i i u  J9d s tu n o o )  A ^ i a u o b  9Sbui>| u i s i o u db -
Fr
ac
ti
on
 
nu
mb
er
Page 174
Fig. 2.6 Determination of the Isoelectric Point of Phosphorylated PRV PK
Purified protein kinase (1pg) was subjected to 
autophosphorylation followed by two-dimensional polyacrylamide 
gel separation, as described in Methods, Sections 5.2 and 4.1B. 
The gel was dried and subjected to autoradiography. The scale 
above the autoradiograph indicates the pH gradient in the first 
(isoelectric focussing) dimension, as deduced from measurements 
of ampholines eluted into degassed water as described in 
Methods, Section 4.2.
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Fig. 2.7 Chromatographic Purification of HSV-1 PK
1 0Post-ribosomal supernatant from approximately 10 BHK cells 
infected with HSV-1 at 10 p.f.u./cell was subjected to 
DEAE-cellulose chromatography and active fractions were 
combined. 5-8 such preparations were concentrated and then 
subjected to successive chromatography on 1(A) TSK phenyl 5PW 
and 1(B) protamine-agarose or TSK phenyl-5PW followed by 2(A) 
threonine-sepharose and 2(B) protamine-agarose, as described in 
Methods, Section 3. Aliquots (40pl) of the fractions 
indicated were assayed for protein kinase activity (®-®). The
protein concentration or A28O fractions (---- ), as
indicated, arid the concentration of the salt used to develop 
each particular column (— ), are also presented. The arrows 
in 1(A) represent multiple injections of sample via a 5ml 
sample loop.
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F ig .  2 .8 P o lyacry lam id e  Gel A n a ly s is  o f  HSV-1 PK a t  D i f f e r e n t  S tages o f
Purification
One-dimensional gel electrophoresis under denaturing conditions 
was performed on protein from various stages of the 
purification of HSV-1 PK. A represents a gel showing the 
progression of the purification of HSV-1 PK with 
threonine-sepharose chromatography before protamine-agarose.
B represents a similar gel but with the threonine-sepharose 
chromatography performed after protamine-agarose.
Gel A
lane 1 post-ribosomal supernatant (50iig)
lane 2 DEAE-cellulose (25pg)
lane 3 TSK phenyl-5PW (25pg)
lane 4 threonine-sepharose (25ug)
lane 5 -protamine-agarose (5]ig)
The gel was stained with Coomassie Brilliant Blue, and the 
position of proteins of known molecular weights are indicated.
Autophosphorylation of 1pg protein obtained after the
threonine-sepharose stage, and 0.25ug of protein obtained 
after protamine-agarose, were incubated with [y^P]ATP in 
the absence of exogenous substrate according to Methods, 
Section 5.2, and subjected to electrophoresis on the same gel. 
The arrows indicate that the phosphorylated species 
corresponded to one of the major components in the purified 
fraction in lane 5.
Gel B
lane 1 post-ribosomal supernatant (50pg)
lane 2 DEAE-cellulose (25]ig)
lane 3 TSK Phenyl-5PW (25pg)
lane 4 protamine-agarose (5pg)
lane 5 threonine-sepharose (5ug)
P r o t e i n  p u r i f i c a t i o n  A u t o p h o s p h o r y l a t i o n
A.
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Fig. 2.9 Autophosphorylation of HSV-1 PK
The final partially-purified preparation of HSV-1 PK 
(0.25pg) was subjected to autophosphorylation, followed by 
one-dimensional polyacrylamide gel electrophoresis under 
denaturing conditions, as described in Methods, Sections 5.2 
and 4.1A.
The gel was fixed, dried and subjected to autoradiography. 
Positions of standard molecular weight marker proteins are 
indicated. The Arrow indicates the 68 kDa phosphorylated 
protein.
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Fig. 2.10 Determination of the Isoelectric Point of Phosphorylated
HSV-1 PK
Partially-purified HSV-1 PK from the protamine-agarose stage 
(0.5-1Ug) was subjected to autophosphorylation followed by 
two-dimensional O'Farrell polyacrylamide gel electrophoresis as 
described in Methods, Section 4.1B. The gel was dried and 
subjected to autoradiography. The horizontal scale above the 
autoradiograph indicates the pH gradient in the first 
(isoelectric focussing) dimension, and the vertical scale 
indicates the positions of migration of proteins of known Mr in 
the second dimensions.
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Fig. 2.11 High-Performance Gel-Exclusion Chromatography of HSV-1 PK on
Superose 6
A preparation of HSV-1 PK was purified by chromatography on 
DEAE-cellulose and then TSK Phenyl-5PW. The enzyme (0.5mg) was 
concentrated and subjected to chromatography of Superose 6 as 
described in Methods, Section 3.5B.
40pl aliquots of the column fractions were assayed for 
protein kinase activity (®-©) using protamine as the substrate. 
The A28O (--- ) fractions is also indicated.
The positions of elution of the standard proteins, aldolase 
(158,000), serum albumin (68,000), ovalbumin (43,000) and 
chymotrypsinogen (25,000) are indicated by arrows surmounted by 
the Mr (x10~3) of each individual protein.
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TABLE 2.1 PURIFICATION OF PSEUDORABIES VIRUS PROTEIN KINASE
The protein kinase was purified and assayed as described in Materials 
and Methods.
Purification
step
Volume
(ml)
Protein
(mg)
Enzyme 
activity 
% (units)
Recovery
{%)
Specific 
activity 
units/mg)
Purifi­
cation
(fold)
1. Post-ribosomal 
supernatant 80 393 - - - -
2. DEAE-cellulose 37 98 238 (100) 2.4 (1)
3. TSK Phenyl-5PW 20 5.1 192 81 37.7 16
4. Threonine- 
sepharose 17.5 0.875 146 61 167 70
5. Protamine- 
agarose 5 0.050 54 23 1070 446
* 1 unit PRV PK incorporates 1nmol phosphate/min into protamine under 
standard assay conditions
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TABLE 2.2 (A) PARTIAL PURIFICATION OF HERPES SIMPLEX-1 VIRUS PROTEIN KINASE
Purification
step
Enzyme
activity
(units*)
Recovery
(50
Specific
activity
(units/mg)
Purification
(-fold)
1. Post-ribosomal 
supernatant
- - - -
2. DEAE-cellulose 29 (100) 0.33 (1)
3. TSK phenyl-5PW 5 37 1.3 4
4. Threonine- 
sepharose
3 22 14 42
5. Protamine- 
agarose
0.7 5 31 94
* 1 unit HSV-1 PK incorporates 1 nmol phosphate/min into protamine under 
standard assay conditions.
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TABLE 2.2 (B) PARTIAL PURIFICATION OF HERPES SIMPLEX-1 VIRUS PROTEIN KINASE
Purification
step
Enzyme
activity
(units*)
Recovery 
{%) 1
Specific
activity
(units/mg)
Purification
(-fold)
1. Post-ribosomal 
supernatant
- - - -
2. DEAE-cellulose 726 100 11 (1)
3. TSK phenyl-5PW 239 34 77 7
4. Protamine- 
agarose
113 16 187 17
* 1 unit HSV-1 PK incorporates 1 nmol phosphate/min into protamine under 
standard assay conditions.
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2 THE SUBSTRATE-SPECIFICITY OF THE PROTEIN KINASES SPECIFIED BY THE
ALPHA-HERPESVIRUSES
Synthetic peptides synthesised by Prof. F. Marchiori were used to 
investigate the site specificity of highly purified PRV PK and HSV-1 
PK in experiments performed by the author in the laboratory of Prof. 
L.A. Pinna (University of Padua, Italy). PRV PK and HSV-1 PK were 
purified as described in the previous section except that the 
threonine-sepharose stage was not included. (This work was initiated 
before the final purification of PRV PK). Nevertheless the PRV PK 
was purified 1000-fold at least, had a specific activity of 
approximately 200 units per mg, and exhibited two major stained bands 
on polyacrylamide gel-electrophoresis under denaturing conditions.
The HSV-1 PK was of similar purity (Fig. 2.8).
The conditions for the assay of protein kinase activity with the 
synthetic peptide substrates are described in Methods,
Section 5.1(B), and in the individual figure legends.
The peptides used in this study are referred to by a logical 
nomenclature to provide unambiguous reference to definite fragments 
of naturally occurring polypeptides. In this nomenclature, such 
peptides were designated by the initials of the parent protein 
followed, in parenthesis, by the original sequence numbers of the 
first and last residues of the peptide. Where a modified derivative 
was synthesised in which a new amino acid residue has been substituted 
for one of the original ones, this is also indicated. Thus,
1-1(32-37) indicates the hexapeptide RRPTPA, corresponding to 
fragment 32-37 of protein phosphatase inhibitor-1, and its derivative 
with Pro^ replaced by an Ala termed Ala^ 1-1(32-37).
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2.1 The site-specificity of PRV PK
Because of the preference of PRV PK for protamine over histones 
(Katan et_al., 1985), many of the peptide substrates used in this 
study were based in whole or in part on three potential phosphorylation 
sites within the protamines, thynnine and galline: TH(1-12),
PRRRRRSSRPVR; TH(13-33), RRRRYRRSTVARRRRRVRRRR and GA(52-65), 
RRRRYGSRRRRRRY. Others were similarly based on preferred sites for 
the cyclic AMP-dependent protein kinase in protein phosphatase 
inhibitor-1 and pyruvate kinase (Type L): 1-1(30-37), RRRRPTPA, and
PK(8-13), RRASVA.
The results of these studies allowed the following main conclusions 
regarding the site specificity of PRV PK.
(i) In order to be able to act as positive determinants for
substrates of PRV PK, basic residues must apparently be on the 
N-terminal side of the amino acid residue that is the target of 
phosphorylation.
This is indicated by the results in Fig 2.12 and Table 2.3 (in 
which the peptides were assayed at a concentration of 50pM 
and 1mM respectively). Thus, TH(1-12) is the best substrate 
for the viral protein kinase among those tested, and the 
conclusion that this is due to the five N-terminal Arg residues 
may be drawn from the inability of the peptide lacking these, 
TH(7-12), to serve as a substrate for PRV PK. It is true that 
TH(7-12) has only two Arg residues on the C-terminal side of 
the Ser residues; however GA(57-65) with six C-terminal Arg 
residues is also not a substrate for PRV PK even though
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GA(52-65), with four additional N-terminal Arg residues is 
(Fig. 2.12, Table 2.3). Other peptides that reinforce this 
conclusion are TH(12-23) and 1-1(30-37), which can act as 
substrates, and TH(18-33), which cannot.
(ii) At least two basic N-terminal residues are required, and 
additional basic residues had a further positive modulating 
effect. This is evident from Table 2.3 from a comparison of 
Val^ 1-1(33-37) and Val^ 1-1(32-37), containing one and two 
Arg residues, respectively; and 1-1(32-37) and 1-1(30-37), 
containing two and four Arg residues, respectively. In Table 
2.4, it can be seen that the peptides with the lowest Km values 
contain between four and six Arg residues on the N-terminal 
side of the amino acid residues which become phosphorylated.
(iii) Both Thr and Ser can be phosphorylated (Fig 2.15) but Tyr most 
probably cannot.
It was not previously known whether Thr residues could be 
phosphorylated by PRV PK, as salmine, the protamine used to 
assay the protein kinases routinely, lacks Thr. The 
phosphorylation by PRV PK of 1-1 peptides made it clear that 
Thr could act as a phosphate acceptor. Comparison of the 
phosphorylation of PK(8—13) and Thr^ PK(8-13) indicated that 
Thr was not such a good phosphate acceptor as Ser; the 
difference in Vmax between these peptides was considerable 
(Table 2.4). Although directly comparable peptides in which a 
Tyr residue replaced a Ser residue were not available, it 
seemed most unlikely that the viral kinases could phosphorylate
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Tyr residues. Thus after incubation with viral kinase no 
phosphotyrosine was detected in TH(12-23), GA(52-65)
(Table 2.3), or in the peptide RRRRY, all of which have a Tyr 
residue flanked on its N-terminal side by multiple Arg 
residues. Nor did the viral kinase phosphorylate angiotensin II 
(DRVYIHPF), a good artificial substrate for many tyrosine 
kinases (Casnellie et_al., 1982; Hunter, 1982; Swarup et al.; 
1983; House et al., 1984).
(iv) The N-terminal Arg residues that are positive modulators of the 
ability of sites to serve as substrates for PRV PK may need to 
be displaced from the target Ser or Thr residue for optimal 
effect.
This is illustrated by the results of Table 2.5 for the 
phosphorylation of thynnine peptides containing adjacent Ser
and Thr residues. In TH(12-23), which has a long run of Arg
20 21residues on its N-terminal side, Ser is preferred to Thr ,
consistent with the results for PK(8-13) mentioned above.
However in TH(18-23), a truncated form of the peptide with
only two Arg residues on the N-terminal side of the SerThr
20sequence, the phosphorylation of Ser markedly decreased
21relative to that of Thr . The simplest interpretation of this 
result is that an Arg has a much greater positive modulating 
influence on the phosphorylation of a target amino acid when 
located three, rather than one or two, positions to its 
N-terminal side. It should also be pointed out that GA(52-65) 
is a tolerably good substrate for PRV PK although it lacks 
basic residues in both positions -1 and -2.
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(v) Other amino acids, on both the N-terminal and C-terminal sides 
of the phosphate acceptor, exerted a modulating influence on 
substrates for PRV PK.
Although more extensive studies are required, there were 
indications that hydrophobic amino acids in the position 
immediately adjacent to the target residue on its N-terminal 
side cause a decrease in phosphorylation by PRV PK. Thus the 
replacement of a Ser residue by an Ala residue in this 
position, illustrated in the comparison of the peptides 
TH(18-23) and Thr^ PK(8-13), caused a decrease of approximately 
50% in the phosphorylation of the Thr residue. (This was 
calculated from the relative rates of phosphorylation of the 
two peptides given in Table 2.3; 26% and 7% maximum, the
former figure was then adjusted to 14% because of the 
contribution of Ser to the phosphorylation of TH(18-23) as 
indicated in Table 2.5). A Pro residue adjacent to the target 
residue exerted a marked effect, depending on whether it was 
N-terminal or C-terminal. When it was on the N-terminal side 
phosphorylation was enhanced, as illustrated by comparison of 
Thr11 PK(8-13) or TH(18-23) with Val36 1-1(32-37), in which 
an Ala or Ser residue, respectively, was replaced by a Pro 
residue (Table 2.3). When a Pro residue is on the C-terminal 
side phosphorylation was decreased, as illustrated by 
comparison of Thr^ PK(8-13) with Ala3^(32-37), in which a 
Val residue was replaced by a Pro residue (Table 2.3). This 
behaviour recalls that of the cyclic AMP-dependent protein 
kinase (Chessa et al., 1983). When two additional Arg were
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present on the N-terminal side of the target residue, the 
negative modulating effect of Pro in 1-1(32-37) was relieved 
(Fig. 2.16).
Other amino acid residues on the C-terminal side of the target 
residue appeared capable of negative modulation of the 
phosphorylation of peptides by the viral kinase (Table 2.3). 
These included acidic residues, illustrated by the effect of a 
Glu residue as a replacement for Val in Glu^ TH(18-23). One 
might also be tempted to conclude from a comparison of 
TH(18-23) and TH (18-33) that Arg residues on the C-terminal 
side of the target could exert a similar effect. However the 
fact that GA(52-65), with six such Arg residues, could still 
be phosphorylated quite well, and TH(1-12), with two such 
residues, was an extremely good substrate (Tables 2.3 and 2.4), 
suggested that any effect of a single Arg residue on the 
C-terminal side of the target may be quite small.
(vi) Basic residues other than Arg were much inferior as positive 
determinants for substrates of PRV PK. It can be seen from 
Table 2.3 that the replacement of the Arg residues in 
TH(18-23) by Lys residues resulted in an 80% decrease in the 
rate of phosphorylation. The replacement of Arg residues by 
Orn residues in this and several other peptides (Table 2.3) 
caused an even more striking decrease in the ability of these 
to serve as substrates for PRV PK.
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Although these studies were done with an enzyme preparation 
that was not homogeneous, their main features were subsequently 
confirmed with the homogeneous enzyme. Thus homogeneous PRV PK 
was equally active at 0.15M, 0.5M and 1.0M KC1. Synthetic 
peptides lacking serine but containing threonine could still 
serve as substrates for the enzyme. The relative substrate 
preference remained consistent with that already presented.
Also the results with the synthetic peptides were consistent 
whether assays were performed at 150mM or 500mM KC1.
2.2 The site-speeificity of HSV-1 PK
More limited studies were also performed with HSV-1 PK. The results 
of some of these are shown in Table 2.6, from which it can be seen 
that the site specificity of the HSV-1 enzyme was broadly similar to
that of PRV PK. Thus, there was a similar preference for Arg
residues on the N-terminal side of the target residue, a similar 
ability for Thr residues as well as Ser residues to act as phosphoryl 
acceptors and a similar influence of Pro and Glu on the 
site-specificity of the viral kinase. HSV-1 PK and PRV PK also had 
similar apparent Km and Vmax values for the protamine, salmine 
(Fig 2.13 and Fig 2.14).
2.3 Comparison of the site-specificity of herpesvirus protein kinases and 
other protein kinases
Because most of the peptides used in this study had previously been 
used as model substrates for the cyclic AMP-dependent protein kinase
(Meggio et al., 1981; Chessa et al., 1983) and protein kinase C
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(Ferrari et al., 1985), it was possible to make a direct comparison 
of the structural requirements of these enzymes with those of the 
viral enzymes.
Although both viral enzymes and protein kinase C prefer very basic 
peptides as substrates, their site-specificities may be distinguished 
by the fact that protein kinase C can readily phosphorylate peptides
like GA(57-65), with Arg on their C-terminal side, whereas the viral
kinases cannot. Furthermore unlike the viral kinases, protein kinase 
C will employ substrates in which Orn replaced Arg. Other
differences than these must exist to explain why the viral kinases,
unlike protein kinase C, could not phosphorylate Ser3-* in the 
sequence RRKASGPP in bovine histone H1 (Iwasa et al;, 1980).
There were several apparent similarities between the viral kinases 
and the cyclic AMP-dependent protein kinases. Both required basic 
residues on the N-terminal side of the phosphorylated residue and in 
both cases Arg could not be replaced by Orn (Meggio et al., 1981).
An acidic group on the C-terminal side of potential target residues 
exerted a negative influence in both cases and both enzymes responded 
similarly to the insertion of a Pro residue immediately adjacent to 
the target residue on the N-terminal or C-terminal side.
Nevertheless the difference between the site-specificities of these 
two types of enzyme was very clear when the relative Km values of some 
of their common substrates were compared (Table 2.7), Of these, 
PK(8-13), with only two Arg residues on the N-terminal side of the 
target residue, was the peptide with the lowest Km for the cyclic 
AMP-dependent protein kinase, but the one with the highest Km for PRV 
PK. The converse was true for the peptides TH(1—12) and TH(12-23),
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with five and six Arg residues, respectively. Furthermore the much 
higher Km of the cyclic AMP-dependent protein kinase for TH(18-23) 
compared with PK(8-13), recalled the well-established importance of 
an N-terminal hydrophobic residue for this enzyme, a feature that 
appeared if anything to have a negative modulating influence on the 
substrates for the viral kinase.
A further point of difference was that Thr residues could substitute
for Ser residues much more effectively in the case of the viral
kinase than in the cyclic AMP-dependent protein kinase. This is
illustrated in Table 2.5 in which are compared the relative extents
of phosphorylation by the two types of enzymes of Thr in
TH(18-23). It has previously been shown that substitution of Thr 
1 1for Ser in PK(8-13) caused a dramatic rise in Km for the cyclic 
AMP-dependent protein kinase, in addition to a decrease in Vmax 
(Chessa et al., 1983). However with the viral protein kinase the Km 
is unaffected, only the Vmax being decreased (Table 2.4).
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Fig. 2.12 Rates of Phosphorylation of Salmine and Synthetic Peptides by
PRV PK
Peptide substrates employed were:-
PEPTIDE 
(•) TH(1-12)
(o) Salmine 
(■) TH(12-23)
(□) GA(52-65)
(A) PK(8-13)
Thr11PK(8-13)
TH(7-12)
TH(18-23)
TH(18-J3) 
Val36I-1(32-37) 
GA(57-65)
STRUCTURE
PRRRRRSSRPVR
PRRRRSSSRPVRRRRRPRVSRRRRRRGGRRRR
RRRRYRRSTVA
RRRRYGSRRRRRRY
RRASVA
RRATVA
SSRPVR
RRSTVA
RRSTVARRRRRYRRRR
RRPTVA
GSRRRRRRY
The peptides were used at a final concentration of 50|iM and 
phosphorylated according to Methods, Section 5.1B.
The reactions were stopped by addition of 2% ice-cold 
trichloroacetic acid after incubation for 0 min, 5 min, 15 min, 
and 30 min at 30°C.
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Fig. 2.13 The Apparent Km of PRV PK for Salmine and Peptide TH(1-12)
A preparation of purified PRV PK was assayed in standard 
reaction mixtures (Methods, Section 5.1B) containing 
concentrations of salmine (•-•) or TH(1-12) (o-o) from
2-80pM. The initial velocity was measured from the values 
obtained by terminating the reaction after 0, 2, 10, 15 and 
30 min at each of the concentrations tested. The apparent Km 
was calculated from the double reciprocal plot fitted to the 
Michaelis-Menten equation.
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Fig. 2.14 The Apparent Km of HSV-1 PK for Salmine
A preparation of purified HSV-1 PK was assayed in a standard 
reaction mixture containing salmine in the concentration range 
2-80yM. The initial velocity was measured from the values 
obtained by terminating the reaction after 0, 2, 5, 10, 15 and 
30 min, at each of the concentrations tested.
The apparent Km was calculated from the double reciprocal plot 
fitted to the Michaelis-Menten equation.
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Fig. 2.15 The Phosphorylation of Both Seryl and Threonyl Residues in
Synthetic Peptides by PRV PK
Autoradiograms of analyses of [^2P]phosphoamino acids in 
synthetic peptides. (A) TH(18-23), RRSTVA, and (B) TH(12-23), 
RRRRYRRSTVA. Both peptides were phosphorylated by PRV PK for 
1h with a supplement of an additional 0.05 units of enzyme 
after 30 mins. The phosphorylated peptide was precipitated on 
P81 paper to separate it from ATP. The phosphopeptide was then 
eluted from the paper and subjected to acid hydrolysis followed 
by high voltage paper electrophoresis, all as described 
previously in Methods, Sections 6, 7 and 8.
(A) Peptide TH(18-23), RRSTVA
Separation of [^2P]Ser and [^ 2P]Thr are illustrated.
(B) Peptide TH(12-23), RRRRYRRSTVA
The autoradiogram was scanned and the relative proportions 
of [ ^ 2 P ] S e r  and [^ 2P]Thr are illustrated. The number of 
counts of radioactivity incorporated are also indicated.
A- 3 2 p - s e r
- 3 2 p - t h r
P e p t i d e :  TH ( 18-23) R R S J V A
©
m
B+
Fig. 2.16 The Effect of Proline Residues on both N-terminal and
C-terminal Sides of the Phosphate Acceptor 
Purified preparations of PRV PK were assayed with peptide 
substrates Va136 1-1(32-37), RRPTVA; 1-1(32-37), RRPTPA; 
and 1-1(30-37), RRRRPTPA, at concentrations in the range of 
0.1-2.5mM, as described in Methods, Section 5.1B.
Incubation was for 15 min each case.
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Table 2.3 Rates of Phosphorylation of Synthetic Peptides by Pseudorabies
Virus Protein Kinase (PRV PK)
Peptides were at a concentration of 1mM and the initial rates 
of their phosphorylation were determined by incubation for 
10 min at 30°C with 0.05 units of PRV PK, as described in 
Methods, Section 5.1B.
Ser and Thr residues are underlined and basic residues are 
indicated in bold type. The standard one-letter code for 
amino acids if employed, with 0 representing ornithine.
\
Peptide Structure Rate of phosphorylation
(% of that with TH(1-12))
TH (1—12) PRRRRRSSRPVR 100
0rn2-5'9'12TH(1-12) POOOOOSSOPVO <1
TH(7—12) SSRPVR <1
TH(18-23) RRSTVA 26
Lys18Lys19TH(18-23) KKSJVA 5
0rn18Lysl9TH(18-23) OKSTVA <1
0rn18-19TH(18-23) OOSJVA <1
TH(12-23) RRRRYRRSTVA 26
TH(18-33) RRSJVARRRRRVRRRR <1
G1 u22TH(18-23) RRSJEA <1
PK(8-13) RRASVA 25
Thrl1PK(8-13) RRATVA 7
Val36I-1(32-37) RRPJVA 33
Val36I-1(33-37) RPIVA <1
Ala34I-1j (32-37) RRATPA <1
1-1(32-37) RRPTPA <1
1-1(30-37) RRRRPTPA 24
Val39Ala40I-1(32-40) RRPTPATVA <1
Ser35I-1(32-37) RRPSPA <1
GA(52-65) RRRRYGSRRRRRRY 18
0rn52"55'59~64GA(52-65) OOOOYGSOOOOOOY <1
GA(57-65) GSRRRRRRY <1
Table 2.4 Kinetic Constants for Pseudorabies Virus Protein Kinase (PRV
PK) with Synthetic Peptide Substrates
The concentrations of peptides were varied in the appropriate 
ranges these being from 2-80pM to 0.1-4mM, 0.05 units of 
PRV PK being used in each assay.
Apparent Km and Vmax values were calculated from double 
reciprocal plots fitted to the Michaelis-Menton Equation and 
are tabulated in the figure.
The structures of the peptides are indicated by the standard 
one-letter code.
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Table 2.5 Phosphorylation of Seryl and Threonyl Residues of Thynnine
Peptides by PRV PK and Cyclic AMP-dependent Protein Kinase 
The peptides were used at a concentration of 1mM and the 
reaction time was 60 min. 0.05 units of enzyme were used in 
each case and the reaction mixture was supplemented by a 
further 0.05 units after 30 min.
The sequences of the peptides TH(12-23) and TH(18-23) are 
RRRRYRRSTVA and RRSTVA, respectively.
After the phosphorylation of each peptide by the appropriate 
enzyme, the mixture was hydrolysed, phosphoserine and 
phosphothreonine were separated by high-voltage paper 
electrophoresis on Whatman 3MM filter paper. The areas 
corresponding to [^P]Ser and [^^P]Thr were cut out and their 
radioactivity determined by scintillation spectrometry, all as 
described in Methods, Sections 7 and 8.
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Table 2.6 Rates of Phosphorylation of Synthetic Peptides with Herpes
Simplex Virus Type-1 Protein Kinase (HSV-1 PK)
Peptides were at a concentration of 1mM and the initial rates 
of their phosphorylation were determined by incubation of the 
peptide with 0.05 units of enzyme for 30 min at 30°C (Methods, 
Section 5.1B). Ser and Thr residues are underlined and basic 
residues are indicated in bold type. The standard one-letter 
code for amino acids is used.
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Table 2.7 Comparison of the Kinetic Constants of PRV PK and of Cyclic
AMP-Dependent Protein Kinase for Phosphorylation of Synthetic 
Peptide Substrates
The concentration of peptides was either in the range of 
2-80pM or 0.1-4mM. Assays were performed as described in 
Methods, Section 5.1B, the duration of each incubation at 30°C 
was 10 min. Apparent Km and Vmax values were calculated from 
double reciprocal plots fitted to the Michaelis-Menton and are 
tabulated in the figure. 0.05 units of the appropriate enzyme 
were used in each case.
The structure of the peptides are indicated by the standard 
one-letter code for amino acids.
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Fig. 2.17 The Phosphorylation in vivo of Proteins of Vero cells infected
with HSV-1(F) and Recombinant virus R7041
p
25cm plaque dishes of Vero cells were either mock-infected or 
infected with HSV-1(F) or R7041 at a multiplicity of 10-15 
p.f.u./cell. 13h after the infection the cells were washed 
with 199V medium with the phosphate content reduced to 1/10th 
its usual concentration (Materials, Section 3.3B); Methods 
Section 1.3). 1h later the cells were labelled with 250pCi 
and harvested 3h later (as described in Methods 
Section 2). Approximately 25pg of protein from the 
cytoplasm was subjected to electrophoresis under denaturing 
conditions on an 11.5% polyacrylamide gel cross-linked with 
DATD.
Replicate dishes were prepared and cells were labelled with 
[3^S]Met 3h after infection for 1-2h with 100-200]iCi 
[3^S]Met, and then harvested. Cytoplasmic and nuclear extracts 
were prepared and loaded on the same gel as markers.
[3^S]Met-labelled cytoplasmic proteins from cells 
infected with HSV-1(F).
[ ■ ^ S ] M e t - l a b e l l e d  cytoplasmic proteins from cells 
infected with R7041.
[ 3 ^ S ] M e t - l a b e l l e d  nuclear proteins from cells infected 
with HSV-1(F).
[ 3 ^ S ] M e t - l a b e l l e d  nuclear proteins from cells infected 
with R7041.
[3^P]labelled cytoplasmic proteins from mock-infected 
cells.
{ 3 ^ P ] l a b e l l e d  cytoplasmic proteins from cells infected 
with HSV-1(F).
[■^^P]labelled cytoplasmic proteins from cells infected 
with R7041.
Known herpesvirus proteins are indicated on the left hand side 
of the gel (ICP).
lane 1 
lane 2 
lane 3 
lane 4 
lane 5 
lane 6 
lane 7
I CP
4 —
5 —
6
8 —
1 1  —  
15 —
19/20 —
24
25 —  
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DISCUSSION
1 THE GENETIC ORIGIN OF THE PROTEIN KINASE INDUCED IN CELLS INFECTED
WITH HERPESVIRUSES
The results presented in Section I clearly establish that the new 
protein kinase present in cells infected with HSV-1 is specified by 
the virus, and encoded by D M  sequences within the domain of the open 
reading frame, US3. This conclusion is drawn from consideration of 
several lines of evidence, both indirect and direct.
At the outset, it was shown that the appearance of the protein kinase 
in cells infected with either HSV-1 or PRV both required and 
correlated with the expression of the.viral genome (Figs. 1.2, 1.3, 
1.8 and 1.9). However, the appearance in infected cells of new 
proteins dependent on viral gene expression does not necessarily 
indicate that the proteins are viral. Cellular proteins are also 
found among those newly detectable after viral infection, and some of 
these proteins are dependent for their induction on the expression of 
the viral genome (Latchman and Preston, 1987). These include stress 
proteins (Notarianni and Preston, 1982), the promoters of which 
appear to be activated in a similar manner to those of a-genes; 
and the proteins induced by interferon (Friedman et al., 1984), the 
production of the latter probably requiring the generation of 
overlapping viral RNA transcripts.
Comparison of the SDS-polyacrylamide gel mobilities of similar 
proteins from cells infected with different strains of HSV has 
frequently been used to provide an indication whether these are of 
viral origin. To employ this approach for PRV PK and HSV-1 PK, 
homogeneous preparations of both enzymes would have been needed.
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Initially, therefore, a modification of this strategy was used, 
involving comparison of the chromatographic behaviour of the enzyme 
activities induced in cells infected with these different 
herpesviruses. The results of these experiments showed that the 
protein kinase activity induced in cells infected with HSV-1 differed 
in chromatographic behaviour from that induced in cells infected with 
PRV. Such differences were found for chromatography on 
DEAE-cellulose (DE-52), DEAE-Sephacel, Mono Q and Sephacryl S-200 
(Figs. 1.1, 1.6 and 1.7), and were consistent with the enzymes being 
encoded by the viral genome.
Nevertheless, because of their indirect nature, the experiments just 
mentioned were still open to possible objections. For example, the 
different chromatographic behaviour might have been due to 
interaction of a single host protein kinase with different viral 
proteins. Alternatively different patterns of specific intracellular 
partial proteolysis might have generated the two apparently different 
enzyme activities from a single inactive cellular enzyme. A strong 
interaction with a viral protein, resisting dissociation at 0.5M KC1, 
does not seem very likely, but there has been one report suggesting 
the existence of a possible herpesvirus protease (Dierich et al., 
1979).
The publication of the sequence of gene US3 of HSV-1 (McGeoch et al., 
1985), and the identification in it of motifs conserved in eukaryotic 
protein kinases (Fig. 17) (McGeoch and Davison, 1986), allowed for 
more direct approaches to the question of the genomic origin of this 
enzyme. In one of these approaches cells were infected with a mutant 
of HSV-1(F) (R7041) containing a deletion in the US3 gene, and no 
protein kinase activity was detectable (Fig. 1.12 and Fig. 1.13).
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Moreover the protein kinase activity was regained when cells were 
infected with strains (R7050 and R7051) in which the US3 gene was 
restored (Fig. 1.12B and Fig. 1.13.).
Although this provided very strong evidence in favour of the protein 
kinase being the product of the HSV-1 US3 gene, there remained the 
possibility that the protein kinase was not the product of the US3 
gene, but a cellular enzyme phosphorylated and activated by the 
latter. Such a cascade type of activation is exemplified in many 
instances in intermediary metabolism, the best characterized being 
that initiated by activation of the cyclic AMP-dependent protein 
kinase (e.g. Krebs, 1985). One genetic means of rejecting this 
possibility of a cascade system is by using a temperature-sensitive 
mutant of the gene in question whereby one can determine whether the 
putative gene product is also temperature-sensitive. This approach 
was used successfully in the case of the tyrosine kinase encoded by 
the src gene of Rous sarcoma virus (Collett and Erikson, 1978). In 
the present work, a different approach was used. The fact that the 
antiserum to a synthetic oligopeptide corresponding to the 
carboxy-terminal eight amino acids of the US3 gene-product 
cross-reacted with a component in purified preparations of HSV-1 PK 
(Fig. 1.16) provided the necessary direct correlation between gene 
and protein, and effectively eliminated the cascade possibility.
If the results with the antiserum were considered in isolation one 
could perhaps argue for the possibility of a chance cross-reaction, 
or criticise the lack of homogeneity of the most purified preparation 
of HSV-1 (even though the autophosphorylation results are very 
persuasive). However, when the results of both the genetic deletion 
and immunochemical approaches are considered together, the objections 
to either alone lose their force. Thus, although a correlation of
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the amino acid sequence of the purified protein with that predicted 
from the nucleotide sequences is required for ultimate proof, the 
evidence that the protein kinases are virally coded would seem to be 
as strong as that for almost any of the other enzymes thought to be 
encoded by HSV-1. If this conclusion is accepted, a corollary of
these results is that the US3 gene of HSV-1 does indeed encode a
protein kinase. This point may appear trivial in view of the highly 
conserved motifs that the predicted protein from the US3 gene 
sequence shares with other protein kinases. However, the predicted 
product of the US3 gene of HSV-1 and of the corresponding gene of VZV 
deviate from the protein kinase consensus sequences in two major 
respects. These both involve the important nucleotide binding site 
of the enzyme, which in all protein kinases previously identified 
contains the hexapeptide sequence GlyXaaGlyXaaXaaYaa (where Yaa is 
Gly or Ala or Ser) followed 11-28 amino acids later by AlaXaaLys 
(Hunter and Cooper, 1985). In the predicted US3 gene product 
however, the corresponding sequences are ThrXaaGlyXaaXaaGly and 
IleXaaGly (McGeoch et al., 1985).
It is intriguing that such otherwise highly conserved features of
protein kinases are not found in the viral enzymes, and one wonders 
whether this has any functional significance. It would be 
interesting to use site-directed mutagenesis to convert the sequence 
of the HSV-1 PK to that of the consensus and see what effect this had 
on its catalytic activity.
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2 IMPLICATIONS OF THE PURIFICATION OF THE VIRAL PROTEIN KINASES
The complete characterisation of any enzyme requires its purification 
to homogeneity. In the case of PRV PK this has been achieved 
(Results, Section II, 1). The evidence that PRV PK has been 
completely purified is as follows:
A single 38kDa protein is the only band visible by staining, with 
Coomassie Blue or silver, a polyacrylamide gel after electrophoresis 
under denaturing conditions. That this 38kDa band is the protein 
kinase is argued by two independent results. The specific activity 
is in the same range (1000-5000 units/mg) as other homogeneous 
protein kinases, for example protein kinase C (Parker et al., 1984) 
and cyclic AMP-dependent protein kinase (Reimann and Beham, 1983).
One imagines that this similarity in specific activity reflects a 
similar catalytic mechanism with an upper limit on its efficiency.
The single 38kDa protein observed under denaturing conditions was 
also the sole species phosphorylated when the purified enzyme 
preparation was incubated with [y^P]ATP, a result indicative of 
autophosphorylation of a pure protein kinase.
The purification of PRV PK has already shown its value. It has 
allowed unequivocal studies on catalytic and structural properties 
(see below) as well as important comparisons with other homogeneous 
protein kinases, including the partially pure HSV-1 PK. For the 
future the purification has opened other avenues. The fact that 
PRV PK can be obtained in quantities of 40-50]ig per preparation 
should allow microsequencing to be performed. This will ultimately 
allow comparison of partial amino acid sequences of tryptic peptides 
of PRV PK with the amino acid sequence predicted by the nucleotide 
sequence of the PRV PK gene, when this is known. Microsequencing 
will also be essential to identify the phosphopeptides, and thus the
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amino acids which are phosphorylated during the autophosphorylation 
reaction. This is of potential importance as it has been shown that 
some tyrosine protein kinases can regulate their own activities by 
autophosphorylation (Hunter, 1987).
The purification of HSV-1 PK was not complete despite the adoption of 
a similar strategy to that employed successfully with PRV PK. The 
purification was made more difficult because lower initial yields of 
HSV-1 PK were routinely obtained, as compared with PRV PK. This may 
be partly due to the lower initial input multiplicity of infection 
(10 p.f.u./cell) for HSV-1, in contrast to the 20 p.f.u./cell used in 
the PRV infection (Fig. .1.3). This seems unlikely to be the complete 
explanation. The HSV-1 PK may simply be more labile during the 
preparation procedure than PRV PK; or the low yield of HSV-1 PK may 
reflect a lower expression of the HSV-1 US3 gene. It is not 
inconceivable that this viral protein kinase need only be present in 
small quantities in the infected cell, and that the PRV PK is 
produced in excess of requirement. Such a situation would not be 
unprecedented as, by definition, the non-rate-limiting cellular 
enzymes of a metabolic pathway are present in excess. Thus a lower 
extent of expression from a weaker promoter in HSV-1 might still 
supply an adequate amount of enzyme. Eventually it should be 
possible to test the strengths of the PRV and HSV-1 US3 promoters by 
the construction of chimeric genes.
The best preparation of partially purified HSV-1 PK had a specific 
activity of 200 units/mg, and two major components of apparent 
molecular weights 68,000 and 61,000 were visible on an SDS 
polyacrylamide gel stained with Coomassie Brilliant Blue. As argued 
in the Results, Section II, 1, one of these components probably 
corresponds to HSV-1 PK, and the enzyme is thus probably almost pure.
It was essential to purify HSV-1 PK substantially from the 
cytoplasmic extract in order to correlate the intensity of the signal 
when the protein was probed with anti-US3 serum, with the 
purification of the protein kinase activity. The degree of purity 
achieved proved adequate for this purpose, and, furthermore, allowed 
certain conclusions regarding the structural and functional 
properties of the enzyme to be drawn with a fair degree of 
confidence.
The clearest conclusion regarding the structure of the viral protein 
kinases can be drawn for PRV PK. The discrepancy between that Mr 
obtained for PRV PK under denaturing conditions and the native Mr 
suggests a multimeric structure. The Mr value for the homogeneous 
enzyme obtained from SDS polyacrylamide gels was 38,000, this 
representing the Mr under denaturing conditions. Several techniques 
were used to determine the Mr of the enzyme under native conditions. 
Sucrose density gradient centrifugation and chromatography on three 
types of gel filtration chromedia, TSK 3000, G150 (Katan et al,
1985), and Superose 12 (Fig. 2.5), all gave values of approximately 
68,000. Sephacryl S-200 gave a somewhat larger value of 90,000 (Fig.
1.7); but this anomalous value was rejected. As the native Mr of
68,000 is quite close to twice the denatured molecular weight (i.e. 
76,000) it is most likely that the native form of PRV PK is a 
homodimer.
The Mr obtained for HSV-1 PK from immunological identification after 
SDS polyacrylamide gel electrophoresis was 68,000. The native Mr was 
also investigated using two types of gel exclusion chromatography.
The first was Sephacryl S-200, which yielded a value of 200,000 (Fig.
1.7), and the second was Superose 6, which gave an estimation of Mr
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in the range between that of aldolase (158,000) and catalase 
(240,000) (Fig. 2.11). The poor resolution of this column for 
proteins with an Mr above 100,000 meant that it was not possible to 
determine an accurate value for HSV-1 PK. The Mr obtained from 
chromatography on Sephacryl S-200, by corollary with that for PRV PK, 
is probably too high. A dimer of HSV-1 PK would be expected to have 
a native Mr of 136,000, whereas the anticipated value for a trimer 
would be 204,000. In view of the apparent dimeric nature of PRV PK, 
and the fact that homotrimeric structures are rare because this 
symmetry is unfavourable, it is tentatively concluded that HSV-1 PK 
is probably also a homodimer.
The Mr of 68,000 for the US3 protein is considerably higher than the
53,000 predicted from the DNA sequence. However discrepancies of this 
order of magnitude have frequently been found between estimates of 
molecular weights of HSV proteins from polyacrylamide gels and the 
molecular weights indicated by the nucleotide sequence (Perry et al, 
1986; McGeoch et al, 1985).
PRV PK would appear to be considerably smaller than HSV-1 PK, as judged 
by a comparison of the Mr values (38,000 v 68,000) obtained by SDS 
polyacrylamide gel electrophoresis. This may reflect difficulty in 
relating apparent Mr on SDS gel electrophoresis to actual size, as 
indicated above. The most likely cause of this discrepancy in the 
present instance is charged residues on the proteins; and the 
magnitude of this effect could differ for PRV PK and HSV-1 PK. 
Nevertheless it is likely that PRV PK is considerably smaller than 
HSV-1 PK. There is no reason to regard this as unlikely if the 
VZV PK is considered. This is predicted to be 44kDa in size, some
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smaller than the 53kDa HSV-1 PK. When both the VZV US2 and HSV-1 US3 
gene sequences are analysed, the C terminal (catalytic) region in 
each is approximately the same size: in HSV-1 it contains 287 amino 
acids, corresponding to approximately 32kDa of protein, and in VZV it 
contains 297 amino acids corresponding , to! ‘approximately 33kDa of 
protein. On the other hand the N-terminal regions differ 
substantially: in HSV-1 US3 it contains 194 amino acids 
(approximately 22kDa of protein), whereas in VZV it is considerably 
smaller, containing only 96 amino acids (approximately 10kDa of 
protein) (Fig. 16). Hence PRV PK might have a catalytic domain of a 
similar size to HSV-1 PK, but only a very short N-terminal sequence, 
perhaps even shorter than that in VZV PK. Such a short N-terminal 
domain has a precedent in the catalytic subunit of the cyclic 
AMP-dependent protein kinase. This protein kinase is also quite 
small (approximately 40.5kDa) and has only 45 amino acids in its 
N-terminal domain.
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3 THE SUBSTRATE-SPECIFICITY OF THE VIRAL PROTEIN KINASES
The site-specificities of several protein kinases have been shown by 
analysis of residues phosphorylated in vivo to depend largely on the 
amino acid sequence around the target residue. Utilization of 
synthetic peptides mimicking phosphorylation sites made it possible 
to define the substrate specificity of several protein kinases in 
vitro. Examples of kinases, the substrate specificity of which has 
been investigated using this approach, are shown in Table 12.
This strategy was adopted for PRV PK and HSV-1 PK. At the outset 
there were three main objectives in performing these studies. The 
first was to allow further comparison of these enzymes with other 
known protein kinases; the second was to provide a basis from which 
the amino acid sequences of herpesvirus proteins might be examined to 
identify potential substrates for these enzymes; and the third was 
to provide a basis from which to design a specific inhibitor of these 
protein kinases.
The results presented in Results, Section II 2, show that the 
herpesvirus protein kinases can catalyse the phosphorylation of both 
seryl and threonyl residues in peptides that contain several arginyl 
residues on the amino-terminal side of the target residue. At least 
two arginine residues are required, and the best substrates examined 
contained four to six such residues.
Although the results described in Section II 2, do not completely 
define the determinants of site-specificity for the viral protein 
kinases they are useful in several different ways. Thus they 
demonstrated clearly that HSV-1 PK and PRV PK are catalytically 
similar to one another, but distinct from other known protein
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kinases. For example these enzymes differ from protein kinase C in 
being unable to phosphorylate peptides in which multiple arginine 
residues are on the carboxy-terminal side of the target residue, or 
to phosphorylate peptides in which the arginyl residues are replaced 
by ornithyl residues. Although the viral kinases and the cyclic 
AMP-dependent protein kinases have several peptide substrates in 
common, their relative preferences for these (as indicated by Km 
values) were found to be very different (Results, Section II 2,
Table 2.7). The information now available (Table 12) regarding the 
site specificity of protein kinases clearly distinguishes the viral 
kinases from other protein kinases besides the cyclic AMP-dependent 
protein kinases and protein kinase C. These include the cyclic 
GMP-dependent protein kinase (Glass et al., 1982), myosin light chain 
kinase and histone H4 kinase (Eckols et al., 1983). This in turn 
suggests that the function of the viral protein kinases is different 
from these other protein kinases.
A second way in which the information regarding substrate-specificity 
is useful is in relation to the prediction of possible substrates for 
these enzymes. Before discussing this it should be stressed, 
however, that the total three-dimensional structure of the true 
physiological substrate could alter the minimum requirement for 
phosphorylation of the target serine or threonine. Thus proteins 
capable of being phosphorylated by the viral protein kinases in vitro 
may not display all the necessary determinants outlined in Results, 
Section II 2. This point is illustrated by a consideration of protein 
kinase C (Woodgett et al., 1986), which can phosphorylate substrates 
which do not have long runs of basic residues on the N and C terminal 
sides of the target residues, even though the best peptide substrates
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for this enzyme in vitro have these characteristics. In the case of 
the viral protein kinases, although peptides with long runs of 
arginine residues on the N-terminal side of the target are the best 
substrates for the enzymes in vitro it is possible that the 
physiological substrate of the enzymes contains fewer arginine 
residues on the N-terminal side of the target, the three-dimensional 
configuration providing additional determinants for good interaction 
with the enzyme.
Bearing these reservations in mind an attempt will be made to use the 
results of the studies on site-specificity to assess possible 
substrates. The fact that HSV-1 PK is encoded by open reading frame 
US3 (Results, Section I) raises the possibility that its substrate 
might also be encoded in the Us region of the herpesvirus genome, as 
functionally related proteins have been found to be clustered at 
several locations of the genome of HSV-1 (eg the proteins for DNA 
synthesis (Quinn and McGeoch, 1985; Gibson et al., 1984)).
As the whole sequence of the HSV-1 Us region is known (McGeoch 
et al., 1985) it was possible to scan the amino acid sequences of 
the predicted gene products of the Us region to determine possible 
phosphorylation sites for HSV-1 PK. Two potentially favourable sites 
for HSV-1 PK were identified in genes US7 and US9 of HSV-1 (Table 
D1). If these sites are functionally important one would expect them 
to be conserved in VZV, which also has a protein kinase gene at a 
corresponding region of its genome. The genes in VZV corresponding 
to US7 and US9 of HSV-1 are US3 and US1, respectively; but when these 
were examined it was found that the potentially favourable 
phosphorylation sites had not been conserved (Table D1).
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It is possible that the multiple arginine residues on the N-terminal 
side of possible target residues in the predicted products of the US7 
and US9 genes of HSV-1 arose fortuitously because of the very high 
(68$) GC content of the DNA of this virus; and the fact that 
arginyl residues are encoded by the CGN codon family. This feature 
is not shared by VZV (46$ GC), the genome of which should therefore 
be more amenable to analysis for potential viral substrates for the 
protein kinases.
As analysis of the Us region of HSV-1 and VZV did not reveal a 
conserved putative phosphorylation site for the viral protein 
kinases, the possibility of another viral substrate was examined, 
particular attention being paid to known phosphoproteins. As the 
whole of the HSV-1 genome sequence was not yet available the 
published VZV sequence (Davison and Scott, 1986) was analysed, this 
having the additional advantage of a lower GC content as already 
mentioned above. Table D2 shows the best potential sites in the 
genome of VZV for phosphorylation by the a-herpesvirus protein 
kinase. The equivalent HSV-1 gene, if any, was identified by 
reference to Table 1 of Davison and Scott (1986). It can be seen 
that only for gene 4 is there an equivalent in HSV-1 a27.
Inspection of the sequence of a27 (Frame and McGeoch, personal 
communication) revealed partial conservation of this potential 
phosphorylation site, and, as a27 is phosphorylated in vivo (Pereira 
et al., 1977; Hay and Hay, 1980) this protein might be regarded as a 
possible substrate. However as PRV has only a single immediate-early 
gene, the equivalent of a4, it is doubtful whether a functional 
homologue of a27 exists in PRV, excluding it from being the
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substrate of PRV PK. Other VZV genes predicted to encode the 
proteins, the HSV equivalent of which are known phosphoproteins, did 
not contain such sites. These included the large subunit of the 
ribonucleotide reductase (gene 19), D M  polymerase (gene 28), the 
major D M  binding protein (gene 29), immediate-early protein a4 
(gene 67, 71) and the exonuclease (gene 48). It is likely that 
cellular protein kinases, such as the ubiquitous casein kinase II, 
are responsible for the phosphorylation of these viral proteins 
(Stevely et al., 1985; Jakubowicz and Leader, 1987b). Indeed typical 
casein kinase II sites have been found with specific acidic 
determinants around possible phosphorylation sites of many of these 
viral proteins. Examples are: HSV-1 US9, oiO, a4, a22 and 
ICP 39.3. Putative sites for casein kinase I, another cellular 
protein kinase, have been tentatively identified in ICP31, the major 
65kDa tegument protein, D M  polymerase and ICP8.
It could be argued that analysis of possible phosphorylation sites by 
comparison between the proteins of HSV-1 and VZV is invalid as the 
protein kinases of the two viruses might have different substrate 
specificites. Although it is not yet possible to exclude this 
experimentally, the unique nature of the protein kinase gene at a 
similar position in the genomes of these viruses makes this as 
unlikely as the putative thymidine kinase and ribonucleotide 
reductase genes in VZV having different substrates from the 
corresponding genes in HSV-1.
Even if HSV-1 PK is responsible for catalysing the phosphorylation of 
sites on some of the known indispensible viral phosphoproteins, this 
phosphorylation is obviously not necessary for their function, as the 
mutant of HSV-1(F) with the protein kinase gene deleted is viable in
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tissue culture cells. Thus such proteins could not be physiological 
important targets of the enzyme. In fact initial experiments (Fig. 
2.17) have failed to detect any major differences between the 
^^P-labelling in vivo of viral phosphoproteins of cells infected with 
wild type HSV-1(F) and those infected with R7041. Therefore the 
possibility of a cellular substrate for this enzyme now deserves 
strong consideration.
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TABLE D1
ANALYSIS OF THE Us REGION OF HSV-1 FOR POTENTIAL PHOSPHORYLATION SITES 
CONSERVED IN VZV
HSV-1 gene
Potential 
phosphorylat ion 
sequence
Equivalent 
VZV gene
Potential 
phosphorylation 
sequence (if present)
US1 KRKRPSRPLSS
RRSVRQAQ
RRSSARWT
RS2 (63)
usi - - -
US3 RRRSRDEIG
RYRSRAA
US2 (66) RRSGTHP
US4 RRGRRTHPSVR - -
US5 - - -
US6 - - -
US7 RRYRRSRRPIY
KSRRRSSR
SRRRSSRTP
US3 (67)
US8 RRVSVGEDV US4 (68) -
US9 RRRRRTRCVGM US1 (65) -
US10 - RS3 (64)
US11 - - -
US 12 - - -
References: McGeoch et al., 1985
Davison and Scott, 1986 
McGeoch and Davison, 1986
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TABLE D2
ANALYSIS OF THE VZV GENOME FOR POTENTIAL PHOSPHORYLATION SITES FOR THE 
VIRAL PROTEIN KINASES
VZV gene
Potential
phosphorylation
site
HSV-1 gene
Potential
phosphorylation
site
4 RRSSRSYNTQ
RRRRPTTP
0.21 RRRAPRT
9 VRRKTTPSY - -
33 RRRRVSP - -
38 RRRKKS - -
52 RRKYKSTF - -
References: Davison and Scott, 1986
McGeoch et al., 1986
McGeoch and Frame (personal communication)
Page 238
4 POSSIBLE FUNCTIONS OF THE PROTEIN KINASE CODED BY a-HERPESVIRUS
The absence of a suitably conserved potential target for the viral 
protein kinases in the VZV and HSV genomes suggest a host protein as 
the most likely substrate. This is also suggested by the viability 
of the deletion mutant of HSV-1(F) (R7041). Clearly the 
phosphorylation cannot be necessary for essential viral functions, 
such as the adsorption of the virus to the surface of the cell, the 
regulation of the temporal expression of different classes of viral 
genes, the transport of proteins to the nucleus or the assembly of 
the virion. If this is true, the viral proteins involved in these 
processes are likewise excluded as physiologically important
substrates.
*
It is also unlikely that HSV-1 PK plays a role in the latency and 
reactivation of the virus. This conclusion emerges from some 
preliminary experiments performed in the laboratory of B. Roizman. 
The recombinant virus R7041,,lacking a functional US3 gene, is still 
able to establish latency in experimental animals (B. Meigner, R. 
Longnecker and B. Roizman, personal communication).
Although potential host functions of the viral protein kinase can 
only be guessed at present, it seems worth discussing a number of 
general possibilities. One possibility is that the viral protein 
kinase may function in the shut-off of host cell protein synthesis. 
Phosphorylation is known to inhibit protein synthesis in certain 
circumstances. For example, eIF-2 can be phosphorylated by a highly 
specific protein kinase, preventing it recycling after a round of 
initiation (Pain, 1986). However the viral protein kinase cannot 
phosphorylate eIF-2 in vitro (Katan et_al., 1985), and it is 
difficult to see how phosphorylation of any of the known initiation
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factors could cause inhibition of host cell protein synthesis, while 
maintaining a high level of viral protein synthesis. Indeed studies 
of the inhibition of host-cell protein synthesis by HSV-1 indicate 
that the early phase of inhibition does not require viral gene 
expression (Fenwick and Clark, 1982) and that the viral genes 
responsible for the late phase of inhibition do not map in the Us 
region (Daksis and Chan, 1987).
Another possible role for the protein might be in transcription. 
Activation of viral RNA synthesis would clearly be an indispensible 
function, and the viability of the deletion mutant.R7041 effectively 
eliminates this from consideration. However the possibility that the 
protein kinase may inhibit host cell RNA synthesis or cause 
degradation of host mRNAs remains to be tested. In the context of 
current knowledge, the most attractive possibility at present is that 
the enzyme plays a role in viral DNA replication. This could either
be by facilitating viral DNA synthesis or by preventing host cell DNA
1 '
synthesis. It is striking that most of the other enzymes encoded by
• \
a-herpesviruses : are involved in DNA replication. Examples
are: Alkaline exonuclease, DNA polymerase, DNA binding protein, 
ribonucleotide reductase, thymidine kinase and dUTPase. Most of 
these enzymes perform functions very similar to host enzymes, and it 
is thus conceivable that the viral protein kinase has a cellular 
homologue, as yet undiscovered. It is pertinent in this regard to 
point out that several yeast genes that have been shown to encode 
protein kinases control progression through the cell cycle (Patterson 
et al., 1986; Reed el at., 1985). It is tempting to speculate that 
the viral protein kinase may function in a similar manner to one of 
these host enzymes, perhaps preventing the entry of the host cell
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into S phase, thus preventing competition of the host cell with the 
virus for precursors of DNA.
The fact that these considerations are still speculative should not 
detract from the results presented here. The HSV-1 protein kinase 
is the first and only eukaryotic protein kinase shown to be an 
authentic product of a viral gene. The protein kinases of acute 
transforming retroviruses such as Rous sarcoma virus, are of course, 
the products of recently transduced cellular genes. It is obvious 
that the protein kinase gene of a-herpesviruses would not have 
been conserved had it not conveyed a selective advantage to the virus 
that contained it. It is reasonable to expect that the use of mutant 
viruses lacking a functional protein kinase gene will eventually 
allow us to discover the nature of this selective advantage and to 
identify the substrate and function of this intriguing viral 
enzyme.
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